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ABSTRACT  
Steroids are endogenous compounds derived from cholesterol which can be divided into five 
families comprising of estrogens, androgens, progestins, mineralocorticoids and 
glucucorticoids. Most circulating steroids are conjugated to a hydrophilic moiety (e.g. 
glucuronide and sulfate) or bound to carrier proteins (e.g. sex hormone binding globulin and 
albumin) with a small proportion in a non-protein bound form. The production of steroids is 
regulated by the pituitary gonadotropins i.e. luteinizing hormone (LH) and follicle 
stimulating hormone (FSH) that mediate their bioactivity by binding to cognate G protein-
coupled receptors expressed on the surface of specific target cells in the gonads – Leydig 
cells for LH and Sertoli cells for FSH. Steroids exert biological activities by binding to their 
specific intracellular receptors in both reproductive and non-reproductive target tissues. 
Accurate measurement of reproductive hormones is vital to evaluate neonatal disorders of 
sexual differentiation, pubertal status, gonadal function, and hormonal doping in sports. 
Steroids from biological fluids, notably serum and urine, can be measured using 
immunoassays and gas chromatography mass spectrometry (GC-MS); however, these 
traditional assays have significant limitations. The advent of liquid chromatography tandem 
mass spectrometry (LC-MS/MS) coupled with soft ionization (e.g. atmospheric pressure 
photo ionization: APPI) method has expanded the scope for measurement of small molecules 
from biological matrices with higher accuracy, specificity, sensitivity and requires less 
sample preparation. The overall aim of this study is to develop and validate LC-MS/MS 
methods to measure steroids from biological samples for clinical research studies.   
The first part of this thesis was to develop methodologies and analysis of androgens i.e. 
testosterone (T) and nandrolone (N) from dried blood spot (DBS) samples using LC-MS/MS. 
Conventionally T esters are used as replacement therapy for T deficient men and is usually 
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administered by intramuscular (im) injections to produce long-acting depots which is more 
convenient in sustaining T release for weeks to months and thereby assists in maintaining 
long-term adherence to treatment. However, administration of androgen esters via deep im 
injections into the gluteal muscle requires medical personnel (to give the injection at the right 
site) and yet the injectate is often deposited into subcutaneous (sc) fat due to the thick sc fat 
layer in most men. IM injections are also associated with local pain and discomfort, injection 
site infection or bleeding and may not be suitable for patients with bleeding disorders or 
using anti-coagulants. Thus, the aim of this clinical study was to investigate the feasibility 
and pharmacology of sc injection (at a single abdominal site) of nandrolone decanoate (ND), 
as a typical androgen ester in an oil vehicle, in healthy men and to collect whole blood 
samples from finger pricks onto filter cards at home for 21 days to investigate the 
pharmacokinetics of single sc injection of ND and its pharmacodynamic effects on 
endogenous T. A LC-MS/MS method was developed to enable measurement of serum T and 
N from the whole blood spot. This bypassed using a subsample to avoid non-homogenous 
distribution of blood and hematocrit effect on the filter paper. The assay had lower limits of 
quantitation of 50 (T) and 156 (N) pg/mL, respectively using 50 μL of blood. In the clinical 
study, daily serum N peaked 2.50 ± 0.25 (SEM) ng/mL at a median (range) of 6 (4-13) days 
causing a reduction in serum T from 3.50 ± 0.57 ng/mL at baseline to a nadir of 0.38 ± 0.13 
(SEM) ng/mL (89 ± 3% suppression) at a median (range) of 8 (5-16) days. This study 
demonstrates that (a) DBS sampling with LC-MS/MS steroid assays achieves frequent time 
sampling in the community without requiring clinic visits, venesection or frozen serum 
storage and (b) an androgen ester in oil vehicle can be delivered effectively by sc injection 
avoiding the need for medically supervised deep im injections. 
The second part of this thesis evaluated the measurement of urinary LH immunoreactivity 
using immunofluorometric (IF) and immunochemiluminometric (ICL) LH assays after 
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prolonged frozen storage. These commercially available LH immunoassays are developed 
and validated for human blood samples but not urine thus LH assays intended for use with 
urine samples needs thorough validation. LH was measured in serial urine samples following 
administration of a single injection of one of two doses of recombinant human chorionic 
hormone (rhCG) with assays run at the end of study (2008) and again after 4 years of frozen 
(-20 °C) storage where samples were stored without adding preservatives. The ICL assay 
showed quantitatively reproducible LH measurements after prolonged -20 °C storage. 
However, the IF immunoassay gave consistently lower LH levels relative to ICL (2008) with 
a further proportionate reduction after 4 years of sample storage (2012). Yet, both the assays 
displayed similar patterns of the time-course of urine LH measurement both before and after 
4 years of frozen storage. We found that both immunoassays are suitable for urinary LH 
measurements with ICL assay being more robust for quantitative urinary LH measurement 
such as for anti-doping purpose whereas the IF could be applicable for research studies where 
urine LH levels are compared within-study but not in absolute terms. 
Urinary hormone concentrations are often adjusted to correct for hydration status. The third 
part of this thesis investigated whether first morning void urine hormones in growing 
adolescents require adjustments for urine dilution/concentration and, if so, whether urinary 
creatinine or specific gravity (SG) are better adjustments. The study population was 
adolescents aged 10.1 to 14.3 years initially who provided fasting morning blood samples at 0 
and 12 months (n=343) and first morning urine every three months (n=644). LC-MS/MS 
method was developed and validated to measure unconjugated T, estradiol (E2), 
dihydrotestostorone (DHT) and dehydroepiandrosterone (DHEA) in human urine. In 
addition, urine LH was measured using the previously validated ICL assay. Unadjusted, 
creatinine and SG-adjusted hormonal concentrations were compared by Deming regression 
and Bland-Altman analysis and grouped according to self-rated Tanner stage or chronological 
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age. Correlations of paired serum and urinary hormonal concentration of unadjusted and 
creatinine and SG adjusted were also compared. Fasting first morning void hormone 
concentrations correlated well and were unbiased between unadjusted or adjusted by either 
creatinine or SG. Urine creatinine concentration increases with Tanner stages, age and male 
gender whereas, urine SG was not influenced by Tanner stage, age or gender. Adjustment by 
creatinine or SG of urinary LH, E2, T, DHT and DHEA concentrations did not improve 
correlation with paired serum concentrations. The study demonstrates that urine steroid and 
LH concentrations in first morning void samples of adolescents are not significantly 
influenced by hydration status and may not require adjustments; however, if desired, both 
creatinine and SG adjustments are equally suitable. 
The final part of this thesis aimed to describe the longitudinal relationships of within-
individual hormone and anthropometric changes during puberty. Temporal changes in urine 
and serum hormones over 12 months to standard measures of pubertal development were 
assessed. A community sample of 104 adolescents (57 female) was studied over 12 months 
with annual anthropometric assessment, blood sampling and self-rated Tanner staging and 
urine collected every 3 months. Serum and urine sex steroids (T, E2) were measured by the 
developed and validated LC-MS/MS method and LH by ICL assay. A high proportion (92%) 
of scheduled samples were obtained with low attrition rate of 6.7% over the 12 months. The 
study demonstrated that the urine hormone measurements correlated cross-sectionally and 
longitudinally with age, anthropometry and Tanner stage. This study successfully developed 
a feasible and valid sampling methodology and measurements for puberty hormones in urine, 
which allows a sufficiently intensive sampling frequency to monitor individual pubertal 
progression in adolescents. 
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Chapter 1 Literature Review 
1.1 Steroid hormones 
1.1.1 Structure and classification  
Steroids can be classified into five families depending on its structural and biological basis. 
These comprise estrogens, androgens, progestins, mineralocorticoids and glucocorticoids. 
Vitamin D, bile acids and thyroid hormones also have close structural resemblance to the 
steroid family of molecules. Steroids are lipophilic compounds derived from cholesterol, a 
sterol which is made up of three hexagonal carbon rings (A, B and C) and a pentagonal 
carbon ring (D) to which a side chain is attached (Figure 1.1). This four-membered 
hydrocarbon core has two important methyl groups are attached at position 18 (attached to 
C13) and 19 (attached to C10). The carbon rings fused in a trans orientation to form a planar 
structure. The orientation of the substituent groups on the steroid skeleton is either above (β) 
or below (α) the plane. According to the chemical structure, steroids are divided into cholane, 
cholestane, androstane, estrane and pregnane. Cholanes (bile acids) and cholestanes (vitamin 
D and cholesterol) are known as sterols with long and branched hydrocarbon side chains 
attached to D ring. Partial cleavage of the cholestane, C27 sterol side chain (ring-D) produces 
pregnane C21 series steroids (progestins and corticosteroids), whereas the total cleavage of 
the side chain yields androstane C19 series steroids (androgens). Finally, removal of the 
methyl group between the A- and B-rings results in production of estrane C18 series steroids 
(estrogens). The structures of the three classes of steroids are shown in Figure 1.2. Various 
functional groups such as hydroxy, keto and methyl-groups are located at different positions 
of the carbon backbone in all series depending on the compound.  
Each steroid has common alike structure and stereochemistry. However, each class of 
steroids displays distinct physiologic activities depending on the family of nuclear 
transcription factors the molecules activate via its cognate (steroid hormone receptor) 
                                                                                                                                                                   Chapter 1 
 
           6 
 
(Strauss 2014). Progestagens, androgens and estrogens are classified as sex steroids whereas 
corticosteroids and mineralocorticoids are adrenal steroids (Figure 1.2). The ovary, testis, 
adrenal cortex and placenta are the endocrine organs that specialize in steroid hormone 
production. The ovaries secrete estrogens and progestagens, the testis produces mainly 
androgens and the adrenal produces both corticosteroids (mineralo- and glucucorticoids) and 
sex steroid precursors. During pregnancy, the placenta produces progestagens and estrogens.  
 
 
 
Figure 1.1 Cholesterol structure 
The rings are identified with capital letters and carbon atoms are numbered. The bold and 
cross-hatched wedges represents the bonds extending above and below the plane, 
respectively. 
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Figure 1.2 Classification of steroids according to basic backbone structure (androstane, estrane and pregnane) and example of steroid 
classes: sex steroids (androgen, estradiol and progesterone), corticosteroids and mineralocorticoid. 
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1.1.2 Physiological action 
The production of steroids occurs in the mitochondria and smooth endoplasmic reticulum of 
cells in the adrenal cortex, the gonads or the placenta. Steroids are hydrophobic molecules 
that can penetrate biological membrane of lipophilic cells and are not stored in intracellular 
vesicles like peptide hormones. They are then transported rapidly in the bloodstream to reach 
targeted cells where the steroids bind to its specific receptor, which acts as transcriptional 
activators of steroid-responsive genes. Besides genomic response which may take between a 
few hours to days to manifest, steroids also regulate non-genomic responses (or ‘rapid 
actions’) that occurs within seconds to an hour (Norman et al. 2004). The pathway of steroid 
hormone biological responses is shown in the schematic diagram below (Figure 1.3).  
In biological fluid, small proportion of steroids circulate in unbound form (2-3%) and 
the remaining are in conjugated form with a hydrophilic moiety such as glucuronide or 
sulfate or they are bound to 50-60 kd carrier protein glycoproteins, such as sex hormone 
binding globulin (SHBG), corticosteroid binding globulin (CBG) as well as albumin (Dunn et 
al. 1981). Albeit the steroid binding proteins circulate at low concentration compared to 
albumin, they have higher binding affinity to certain steroids. SHBG and CBG have high 
binding affinity towards sex steroids (testosterone and estradiol) and corticosteroids, 
respectively (Kicman 2010). The binding of steroids to the circulating binding proteins serves 
as a reservoir of the hormone, protects the steroids from rapid inactivation or urinary/biliary 
excretion and ensures ubiquitous distribution of the steroids (Kronenberg et al. 2011). 
According to the free hormone hypothesis, the free steroids are physiologically available to 
bind to their target cell, whereas the steroids bound to the carrier proteins are believed to have 
different and limited physiological activity (Mendel 1989). Contrary to this latter concept, 
recent studies have found that the cell membrane endocytic receptors, also known as the 
megalin receptor, expressed in the reproductive tissues mediates cellular uptake of circulating 
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protein-bound sex steroids. Once transported into the cells, lysosomes degrades the carrier 
protein bound and releases the steroids allowing it to bind to its receptor that further induces 
steroid responsive-genes (Hammes et al. 2005). SHBG bound androgens and estrogens are 
involved in the development and maturation of reproductive organs (Hammes et al. 2005, 
Kahn et al. 2008). 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
A. In the genomic pathway, binding of steroids to the nuclear receptors (present either in the 
nucleus, in the cytoplasm complexed to chaperones or in between the cytoplasm and nucleus) 
leads to up- or down regulation of gene transcriptional responses regulating protein synthesis 
within minutes to days. B. Non-genomic biological responses of steroid involves occupancy of 
steroids to the plasma membrane of the cell, which in turn activates direct biological responses by 
intracellular signaling molecules such as mitogen activated protein (MAP) kinase, protein kinase A 
(PKA), cyclic adenosine monophophate (cAMP), and opening of calcium channels or indirect 
biological responses through genomic pathway [adapted from (Norman et al. 2004, Vogeser and 
Parhofer 2007)].  
 
 
 
 
A B 
Figure 1.3 Genomic (A) and non-genomic (B) pathways of steroid hormones 
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1.2 Steroid metabolism 
1.2.1 Steroidogenesis (Biosynthesis of steroids)  
The synthesis of steroids specifically takes place in the adrenal cortex (zona fasciculata, 
reticularis and glomerulosa), testicular Leydig cells, ovarian granulosa and theca cells and the 
placental syntiotrophoblast cells (Miller and Bose 2011). Cholesterol is a starting point for 
biosynthesis of all steroids hormone, bile acids and vitamin D. The three sources of 
cholesterol are from dietary low density lipoprotein (LDL)-uptake, stored cholesterol and de 
novo synthesis. LDL is taken up by the steroidogenic cell via specific receptor-mediated 
endocytosis. Within the cell, stored lipoprotein cholesterol esters are then converted by the 
lysosomal acid lipase into free cholesterol which is the substrate for steroidogenesis (Brown 
et al. 1978, Gwynne and Strauss 1982). Excessive cholesterol uptake by the cell is either 
transferred out as an external lipoprotein or stored within the cell cytoplasm as lipid droplets 
upon cholesterol esterification catalyzed by the acyl-coenzyme A:cholesterol acyltransferase 
(ACAT). As required, the stored lipid droplets are hydrolized by acid lipase to release free 
cholesterol (Miller and Bose 2011). Cholesterol is also synthesized de novo by the smooth 
endoplasmic reticulum of the steroidogenic cells catalyzed by at least 17 enzymes. The 
cellular cholesterol synthesis and lipoprotein uptake by the steroidogenic cells is stimulated 
by the tropic peptide hormones (Miller and Bose 2011).    
The conversion of cholesterol to steroids is regulated by a series of enzyme reactions. 
The two main classes of enzymes involved in the steroids conversion pathway are the 
cytochrome P450 (CYPs) heme containing proteins and hydroxysteroid dehydrogenases 
(HSDs) (Miller and Auchus 2011, Payne and Hales 2004). The CYP enzymes includes type I 
or type II which is located in the mitochondria and endoplasmic reticulum, respectively. 
Whereas the HSD enzymes can be classified into aldo-keto reductase (AKR) and short-chain 
dehydrogenase/reductase (SDR) families (Miller and Auchus 2011). CYP enzymes mediate 
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hydroxylation, aromatization and carbon-carbon bond cleavage using molecular oxygen and 
nicotinamide adenine dinucleotide phosphate (NADPH) as a cofactor which irreversibly 
oxidize steroids (Miller 2005). In vitro, the HSD reactions are reversible directing reactions 
to either oxidation of hydroxysteroids or reduction of ketosteroids depending on conditions, 
for example, pH, cofactor and substrate availability. However in vivo, HSD enzymes 
catalyzes unidirectional reactions and are classified as dehydrogenases or reductases where 
pyridine nucleotide acts as cofactors (Agarwal and Auchus 2005).  
Steroidogenesis is first initiated from the conversion cholesterol (C27) to the first 
steroid pregnenolone (C21) via the action of CYP11A (cytochrome P450 side-chain cleavage 
enzyme: P450scc) (removes six carbon units) (Waterman and Simpson 1985) and 
steroidogenic acute regulatory protein (StAR) (Lin et al. 1995). CYP11A is expressed in all 
steroidogenic cells as a rate-limiting step at the start of steroidogenesis (Ishimura and Fujita 
1997, Oonk et al. 1990, Payne and Youngblood 1995, Pelletier et al. 2001, Strauss et al. 
1996). The StAR protein is responsible for transporting the hydrophobic cholesterol substrate 
from the outer to the inner mitochondrial membrane where this reaction takes place (Miller 
and Auchus 2011, Miller and Bose 2011). The CYP11A enzyme reaction introduces hydroxyl 
groups at C20 and C22 and cleaves the cholesterol side chain between these carbons (Payne 
and Hales 2004). After this rate limiting step, pregnenolone is transported out of the 
mitochondria into the endoplasmic reticulum where the remainder of steroidogenesis takes 
place. Pregnenolone further undergoes 17α-hydroxylation to produce 17α-
hydroxypregnenolone in a reaction catalyzed by CYP17 (P450c17). In the adrenal zona 
reticularis, ovarian theca cells and Leydig cells, the CYP17 enzyme also catalyzes cleavage 
of C17 and C20 (lyase) bond to produce dehydroepiandrosterone (DHEA, C19 steroid) 
(Payne and Hales 2004). The 3β-HSD type 2 converts 5-ene-3β-hydoxylated steroids (Δ5) to 
4-ene-3-oxo steroids (Δ4), resulting in conversion of DHEA to androstenedione in the gonad 
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and adrenal (Payne and Hales 2004). The 17β-HSD type 3 which is expressed exclusively in 
the testicular Leydig cells converts androstenedione to testosterone (Geissler et al. 1994).  
Whereas, the 17β-HSD type 5 which is the only form of 17β-HSD found the ovarian theca 
cells catalyzes the production of testosterone from androstenedione (Pelletier et al. 1999). 
Testosterone is converted to dihydrotestosterone (DHT) by the irreversible 5α-reductase type 
2 enzyme reaction in the prostate and external genitalia (Thigpen et al. 1993). Additionally, 
DHT can also be generated through the “backdoor pathway” bypassing DHEA, 
androstenedione and testosterone, as intermediates. This pathway involves the conversion of 
17-hydroxyprogesterone (17-OHP) to produce androstanediol which is an immediate 
precursor of DHT. The conversion involves 3α and 5α-reduction activity followed by 
sequential CYP17 and 17β-HSD type 3 enzyme activity. Finally, androstanediol can be back-
converted to DHT by 3α-oxidation reaction (Auchus 2004). Figure 1.4 outlines the classic 
and backdoor pathways involved in DHT biosynthesis. In humans, DHT generated by both 
pathways plays indispensible role in male fetal sexual development but role of the backdoor 
pathway in mature individuals remains unclear (Flück et al. 2011, Greaves et al. 2014).  
In the ovary, the androstenedione produced by the theca cells is later diffused into the 
granulosa cells, where the aromatase enzymes, CYP19 (P450arom) catalyses hydroxylations 
of androstenedione to produce estrone (C18 steroid with phenolic A ring). Estrone is later 
converted to estradiol by the 17β-HSD type 1 (Miller and Auchus 2011). The aromatase 
enzyme also converts testosterone to estradiol in brain, bone and adipose tissues but not liver 
(Perel and Killinger 1979, Sasano et al. 1997). In the adrenal zona fasciculata, the enzyme 
3β-HSD converts 17-hydroxypregnenolone to 17-OHP (Payne and Hales 2004). 
Consequently,  CYP11B1 (P450c11β1) and CYP21 (P450c21) enzymes converts 17-OHP to 
11-deoxycortisol and cortisol. The biosynthesis pathway of androgens, estrogens, 
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corticosteroids (minerolocorticoid and glucocorticoid) and progestogen metabolites are 
outlined in Figure 1.5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The classic and backdoor pathways involved in DHT biosynthesis are 
shown on the left and right, respectively. Adapted from (Flück et al. 
2011, Holčapek et al. 2010). 
 
The classic pathway requires the following protein and enzymes: StAR 
(steroidogenic acute regulatory protein), CYP11A (cytochrome P450 side-chain 
cleavage enzyme, P450scc), CYP17A1 (17α-hydroxylase/17,20-lyase, P450c17), 
HSD3B2 (3β-hydroxysteroid dehydrogenase, type 2), HSD3B2 (3β-hydroxysteroid 
dehydrogenase, type 2), HSD17B3 (17β-hydroxysteroid dehydrogenase, type 3) and 
5α reductase, type 2. 
Additional enzymes involved in the backdoor pathway includes: 5a-reductase, type 1 
(5a-reductase 1, 3a-reductase, type 3 and possibly 3a-reductase, type 1 and HSD17B6 
(17β-hydroxysteroid dehydrogenase, type 6).  
 
Steroid abbreviations: 17-OHP: 17-hydroxyprogesterone; 17OH-DHP: 17-hydroxy-
dihydroprogesterone (or 5a-pregnane-17a-ol-3,20-dione); 17OH-allo: 17-hydroxy-
allopregnanolone (or 5a-pregnan-3a,17a-diol-20-one); 5a-DHP: 5a-
dihydroprogesterone (or 5a-pregnane-3,20-dione), and 3a-OH-DHP: 
allopregnanolone (or 3a-hydroxy-dihydroprogesterone or 5a-pregnane-3a-ol-20-one).  
Figure 1.4 Classic and backdoor pathways of DHT synthesis. 
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1.2.2 Phase I metabolism 
 
Phase I metabolism involves converting active steroids into inactive metabolites that are 
substrates for phase II conjugation for eventual excretion in the urine and bile. The 
inactivation primarily occurs in the liver although there are also metabolic enzymes present in 
the steroid target tissues (Strauss 2014). The enzymes that are involved in the phase I steroid 
metabolism include 3α/3β-HSDs, 5β-reductase, 11β-HSDs, 17β-HSDs and 20α-HSDs that 
acts on C3, C5, C11, C17 and C20 positions of steroid, respectively (Rižner and Penning 
2014). However, most of the target tissues also express HSD isoforms that are capable of 
converting the inactive steroids metabolites back into active form (Bélanger et al. 2003). 
Thus, these enzymes acts as ‘switches’ that tightly regulate the receptor occupancy by the 
steroids and balance the synthesis and metabolism of the steroids (Penning 2011). In the liver, 
5α and 5β reductase converts circulating testosterone to form 5α-DHT and 5β-DHT, 
respectively. In the prostate and androgen target tissues, DHT is reduced by 3α-HSD, 3β-
HSD and 17β-HSD forming androsterone, 5α androstan-3α-17β-diol (3α-diol), 5α androstan-
3β-17β-diol (3β-diol), androstanedione and epiandrosterone (Bélanger et al. 2003, Dufort et 
al. 2001). Basically steroids with 3-keto- Δ4,5 structure may first be 5α-reduced and 
subsequently 3α-reduced to form stereoisomeric tetrahydrosteroids which are later conjugated 
in phase II metabolism and finally excreted in the urine (Jin and Penning 2001). However, the 
17β-HSD type 6 can catalyze oxidation of 3α-diol back to form 5α-DHT in the prostate 
(Penning 2011). In the kidney, the 11β-HSD type 2 catalyzes the oxidation of potent 
glucucorticoid, cortisol into its inactive counterpart cortisone to enable the less abundant 
aldosterone to occupy the mineralocorticoid receptors (Strauss 2014). Conversely in the liver, 
adipose tissue and skeletal muscle, the inactive cortisone is reduced back to the inactive 
moiety cortisol by 11β-HSD type 1 (Strauss 2014). In breast tissues, 17β-HSD type 1 
converts estrone to estradiol whereas 17β-HSD type 2 and type 4 inactivates estradiol by 
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catalyzing the reverse reaction. Progesterone is converted by 20α(3α-)-HSD to a weaker 
progestin metabolite, 20α-hydroxyprogesterone whereas 17β-HSD type 2 directs the reverse 
reaction (Rižner and Penning 2014). Figure 1.6 illustrates the HSD enzymes involved in the 
activation and inactivation of androgens, glucucorticoid, estrogens and progestins. 
 
 
Figure 1.5 Biosynthetic pathway and steroidogenic enzymes involved in the pathway. 
 
 
 
 
 
 
The pathway is divided into colour zones to depict the different classes 
of steroids; androgen (green), estrogen (blue), glucocorticoid (yellow), 
mineralocorticoid (orange) and progestogens metabolites (white) 
[adapted from (Ja ntti et al. 2010)].   
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Figure 1.6 Androgens (5α-DHT and testosterone), glucocorticoid (cortisol), estradiol 
(estrogen) and progestin (progesterone) phase I metabolism by hydroxysteroid 
dehydrogenase enzyme (aldo-keto reductase; AKRs and short-chain dehydrogenase; 
SDRs). 
 
 
 
The enzymes act in pairs to regulate the steroid occupancy towards the specific 
receptor at target tissues. The steroids are activated and deactivated by the 
specific enzymes to form potent steroids weak steroids, respectively which the 
latter is readily available for phase II metabolism. Adapted from (Penning 
2011). 
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1.2.3 Phase II metabolism (conjugate formation) 
 
Steroid hydroxyl metabolites from phase I metabolism further undergo conjugation reactions 
to form hydrophilic conjugates with lower affinity for cognate receptor and plasma proteins 
compared to their parent steroid (Andrew 2001, Tukey and Strassburg 2000). This metabolic 
pathway is catalyzed by enzymes which inactivate steroidal biological activity and increases 
the polarity of the steroids to aid their excretion (urine and bile). Phase II metabolism 
involves conjugation of steroids with glucuronides or sulfates which are the most abundant 
conjugated derivatives. Other cholesterol metabolite conjugates involved in phase II 
metabolism includes N-acetylglucosamine (GlcNAc), amino acids, glucose and galactose 
(Goto et al. 2005, Marschall et al. 1989, Vessey 1978, Wietholtz et al. 1991). Only small 
amount of steroids are excreted in unconjugated form in urine (e.g. less than 3% of urinary 
androgens secreted in free form) (Dehennin and Matsumoto 1993). Generally steroid 
conjugates are regarded inactive, however there are conjugated steroids that remain in 
circulation (e.g. DHEA sulfate) or stored locally in tissues (e.g. estrone sulfate) serving as a 
reservoir for back conversion to its active hormones or as steroid hormone precursor, 
reactions catalyzed by sulfatase enzyme (Andrew 2001, Hobkirk 1985, Reed et al. 1996, Zhu 
and Conney 1998).    
Glucuronidation: This is a major route of steroid elimination. This reaction involves covalent 
linkage (conjugation) of glucuronic acid moiety (glycosyl group) derived from uridine 
diphosphate-glucuronic acid (UDPGA) co-substrate to lipophilic substrates that commonly 
contains hydroxyl, carboxyl or nitrogen group. This mechanism is catalyzed by an 
endoplasmic reticulum membrane enzyme, uridine diphosphate (UDP)-
glucuronosyltransferases (UGTs) (Figure 1.7) (Court 2014, King et al. 2000, Tukey and 
Strassburg 2000). The co-substrate UDPGA is formed in the cytosol from the oxidation of 
UDP-glucose catalyzed by the UDP-glucose dehydrogenase (Zamek-Gliszczynski et al. 
                                                                                                                                                                   Chapter 1 
   18 
 
2006). The human genome encodes 19 UGT enzymes which are most abundant in the liver, 
although some are also expressed in other tissues such as the intestine, kidney, mammary 
gland and prostate (Gaganis et al. 2007, Mackenzie et al. 2005, Ohno and Nakajin 2009). The 
distribution of the enzyme varies in  tissues according to age, gender, hormonal status, 
genetic factors and environmental exposure (Ritter 2000). Based on the homology of primary 
structure, UGTs can be divided into four families: UGT1, UGT2, UGT3 and UGT8 
(Mackenzie et al. 1997). UGT1 and UGT2 are the two main enzyme families involved in 
steroid glucuronidation comprising of three subfamilies: UGT1A, UGT2A and UGT2B 
(Barbier and Bélanger 2003, Hum et al. 1999, Mackenzie et al. 1992). The UGT1 isoforms 
have specificity for bilirubin, amines and phenolic compounds as substrate, whereas the 
UGT2 targets the elimination of steroids, bile acids and opioids (You 2004). Metabolism of 
most estrogens and androgens are catalysed by subfamily UGT1A and UGT2B, respectively. 
All of the UGT1A isoforms members specificity (with exception to UGT1A6) are mainly 
directed towards C18 steroid substrates such as estradiol, estrone (UGT1A1; UGT1A10), 2-
hydroxyestrone (UGT1A3) and 4-hydroxyestrone (UGT1A9) (Albert et al. 1999, Basu et al. 
2004, Cheng et al. 1998, Mojarrabi et al. 1996, Strassburg et al. 1998). In humans, there are 
seven UGT2B isoforms isolated namely UGT2B4, UGT2B7, UGT2B10, UGT2B11, 
UGT2B15, UGT2B17 and UGT2B28 with broad overlapping substrate specificities (Girard 
et al. 2003, Riedy et al. 2000). All of the UGT2B isoforms are involved in the 
glucuronidation of steroids with exception to UGT2B10 and UGT2B11 (Turgeon et al. 2001). 
The UGTB4 catalyzes the conjugation of 3α-diol, estriol and hydroxyestrone (Lévesque et al. 
1999). Whereas, UGT2B7 is involved in conjugation of different classes of steroids which 
includes the 5α-reduced metabolites of cortisol, progestins and androgens (Girard et al. 
2003). UGT2B7, UGT2B15 and UGT2B17 enzymes catalyzes glucuronidation of major 
circulating C19 steroid metabolites at 17β-hydroxy position (e.g. DHT, testosterone and 3α-
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diol). The UGT2B7 and UGT2B17 enzymes (but not UGT2B15) also catalyzes the C19 
steroid metabolites at 3α hydroxy position (e.g. androsterone) (Beaulieu et al. 1996, Chen et 
al. 1993, Turgeon et al. 2001). The UGT2B28 type 1 catalyzes the conjugation of 3α-diol, 
estradiol, androstane and testosterone (Lévesque et al. 2001). Androsterone glucuronide 
circulates 20 times higher compared to 3α-diol glucuronide concentration in the circulation 
and both the glucuronide forms are indicators of androgen metabolism in peripheral tissues 
(Bélanger et al. 1986, Horton and Lobo 1986). Table 1.1 summarizes glucuronidation of 
various steroids by UGT conjugating enzymes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UGT 
isoform 
Steroid substrate 
1A1 Estradiol, estrone 
1A3 2-hydroxyestrone, estrone 
1A4 16α-OHP 
1A7 Estriol, 2-hydroxyestradiol 
1A8 2-methoxyestradiol, 4-hydroxyestrone, 16,17-epiestriol 
1A9 4-hydroxyestrone, 11α-OHP 
1A10 Estradiol, estrone, estriol, 2-hydroxyestradiol, 4-hydroxyestrone, androsterone 
2B4 3α-diol, estriol, hydroxyestrone 
2B7 
Cortisol, progestins, DHT, testosterone, androsterone, 3α-diol, estradiol, estriol, 
11α-OHP 
2B15 DHT, testosterone, 3α-diol, 16α-OHP 
2B17 DHT, testosterone, androsterone, 3α-diol, 16α-OHP 
2B28 Estradiol, androsterone, testosterone, 3α-diol 
 
Abbreviations: OHP: hydroxyprogesterone; 3α-diol: 5α androstan-3α-17β-diol; DHT: 
dihydrotestosterone 
References are given in text. 
Table 1.1 List of steroid substrates metabolized by UGT enzymes. 
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Sulfation: Sulfate conjugation (also called sulphonation) is another important conjugation 
reaction that modulate the pharmacological activity of steroids. This reaction is catalysed by 
cytosolic sulphotransferases (SULTs) that attaches a sulfonate group (SO3
-
) from an enzyme 
cofactor, 3’ phosphoadenosine-5’-phosphosulfate (PAPS) to an acceptor group (O-, N- or S-) 
(Figure 1.7) (Mulder et al. 1990). The formation of PAPS involves two reactions: first the 
conjugation of the cytosolic inorganic sulphate with adenosine monophosphate catalyzed by 
ATP sulfurylase to form adenosine 5’-phosphosulfate (APS)  followed by the 
phosphorylation  of APS by the APS kinase to form PAPS (Zamek-Gliszczynski et al. 2006). 
The sulfation and glucuronidation reaction have overlapping substrates, with the sulfation 
reaction occuring at low substrate concentration due to its high affinity, whereas at high 
substrate concentration, the activation of the glucuronidation reaction occurs as the SULT 
enzymes saturates or its cofactor PAPS are exhausted (Pang et al. 1994, Zamek-Gliszczynski 
et al. 2006). The SULT enzymes display unique tissue distribution with varying degree of 
activity. SULT enzymes for steroid metabolism are located in the cytosol, mainly in cells of 
the liver and gastrointestinal tract, although they are also found in the brain, kidney, lung, 
prostate and placenta (Coughtrie 2002). Four families of SULTs namely, SULT1, SULT2, 
SULT4 and SULT6 have been identified in human with at least 13 distinct members 
(Gamage et al. 2006, Li et al. 2008). The SULT1 members (or known as phenol SULT), are 
involved in sulfation of various estrogens such as estrone and 17β-estradiol (SULT1A1 and 
SULT1E1) (Falany 1997, Falany et al. 1994, Pasqualini 2009). Whereas SULT2 members (or 
known as hydroxysteroid SULT) are divided into SULT2A1, SULT2B1a and SULT2B1b. 
SULT2A1 also referred as DHEA sulfotransferase catalyses a broad range of steroids 
including the 3α, 3β, and 17β-hydroxyl groups as well as 3-phenolic hydroxyl estrogens 
(Falany 1997, Falany et al. 1994). SULT2B1a and SULT2B1b sulfonates pregnenolone, DHT 
and DHEA. However, SULT2B1b has higher cholesterol sulfation activity compared to 
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pregnenolone (Meloche and Falany 2001, Strauss 2014). Table 1.2 listed the sulfate isoforms 
involved in steroid metabolism.   
 
Table 1.2 List of steroid substrates metabolized by sulfate isoforms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SULT isoform  Steroid substrate 
1A1 Estradiol, estrone, 2-hydroxyestradiol, 4-hydroxyestradiol, 4-hydroxyestrone  
1E1 Estradiol, estrone, DHEA, pregnenolone and androstenediol 
2A1 
DHEA, testosterone, androsterone, epiandrosterone, androstenediol, pregnenolone, 
etiocholanolone, estrone and estradiol  
2B1a Pregnenolone, DHT, epiandrosterone, DHEA, androstenediol  
2B1b Pregnenolone, DHT and DHEA 
Abbreviations: DHT: dihydrotestosterone; DHEA: dehydroepiandrosterone 
References are given in text. 
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+ PAP 
UGT 
Testosterone 
SULT 
PA
PS
Testosterone sulfate 
+ UDP  
+ H2O 
Testosterone glucuronide 
UDP
GA 
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Glucuronidation and sulfation reactions catalyzed by UDP-glucuronosyltransferases (UGTs) 
and sulphotransferases (SULTs). 
 
Figure 1.7 Phase II metabolism of testosterone. 
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1.3 Gonadotropin structure and regulation  
The pituitary luteinizing hormone (LH), follicle-stimulating hormone (FSH) and placental 
human chorionic hormone (hCG) are gonadotropins that, together with thyroid stimulating 
hormone (TSH), comprise the glycoprotein hormone family (Pierce and Parsons 1981). The 
glycoprotein hormones are large proteins with a molecular mass of 30 – 40 kDa. They are 
heterodimers featuring a common α-subunit with a specific β-subunit that confers biological 
specificity by binding to their specific G protein-coupled receptors. Although the subunits 
(mainly α) exist in “free” form in the pituitary or circulation, they are biologically inactive. 
Thus, both subunits must be combined as α/β heterodimers and form a strong and specific 
noncovalent interaction complex that enables hormonal activation (Pierce and Parsons 1981). 
The α-subunit contains 92 amino acid residues whereas the LHβ, FSHβ and hCGβ have 121, 
110 and 145 amino acids residues respectively (Stenman et al. 1997, Themmen and 
Huhtaniemi 2000). Each glycoprotein has specific oligosaccharide structure bound on the β-
subunit that determines its physiological specificity and differentiates the members of the 
glycoprotein hormones (Robinson et al. 2007, Ulloa-Aguirre et al. 2001). However, more 
than 85% of the first 114 amino acids sequence of LH and hCG β-subunit are significantly 
similar which is potentially responsible for the similar biologic activity of their respective 
dimers (Garcia-Campayo et al. 1997). Figure 1.8 illustrates the specific location of the 
oligosaccharide glycosylation of the four glycoprotein hormones. The α-subunit consists of 
two N-linked oligosaccharides, positioned at asparagine (Asn)-52 and Asn-78. Study on the 
mutagenesis of hCGα oligosaccharides revealed that they have distinct functions; the Asn-52 
is involved in the formation of intact glycoprotein dimer whereas the Asn-78 is important for 
the protein stability (Fares 2006, Matzuk and Boime 1988). Studies have also reported 
disruption in the glycoprotein secretion with the absence of the β-subunit N-linked 
oligosaccharides (Lash et al. 1992, Matzuk and Boime 1988). The carbohydrate portion is 
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also involved in the folding, assembly and clearance of the gonadotropin (Thotakura and 
Blithe 1995).  
 
 
 
 
 
 
 
 
 
 
 
 
 
The hCG is distinct from the other glycoprotein due to the O-linked glycosylation to a 
carboxyl terminal peptide (CTP) extension of the hCGβ subunit (Figure 1.8) which prolong 
the half-life and enhance the in vivo bioactivity of the hormone (Fares 2006, Kalyan and Bahl 
1983, Matzuk et al. 1990). Studies have shown insertion of CTP domain of the hCGβ subunit 
into other glycoproteins β-subunit (e.g. FSH and TSH) resulting in increase of the CTP-
 
The horizontal bar and the branched-like structures represent the amino acids and the N-
linked oligosaccharides, respectively. The subunits contains one (LHβ and TSHβ) or two 
(the common α-subunit, FSHβ and hCGβ) N-glycosidically linked oligosaccharides attached 
to the amino acids residues (locations of the oligosaccharides attachment to the amino 
acids are indicated with the numbers). Additionally, the hCGβ-subunit consists of four O-
glycosidically linked oligosaccharides in the carboxyl terminal extension (adapted from 
(Ulloa-Aguirre et al. 2001). 
Figure 1.8 Location of glycosylation sites in the human 
glycoprotein hormone α and β-subunits. 
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modified hormones’ half-life which proved to be beneficial for therapeutic purposes 
(Bouloux et al. 2001, Fares et al. 1992, Joshi et al. 1995). For in vitro fertilization, CTP-
modified FSH is used to induce the development of ovarian follicle maturation with only a 
single dose due to its long half-life in contrast to multiple doses using recombinant human 
FSH analog (Balen et al. 2004).  
The oligosaccharide contains side chains that terminate with sialic acid, galactose, 
fucose as well as sulfated N-acetylgalactosamine (only in LH). These complex carbohydrate 
side chains influences the glycoprotein hormones’ bioactivity and clearance rates by the liver 
and kidney (Ulloa-Aguirre et al. 2001). The glycoprotein hormones with highly sialylated or 
more acidic oligosaccharides (e.g. FSH and hCG) have longer plasma half-life but reduced in 
potency and lower receptor binding activity in vitro compared to the galactose and sulfated or 
more basic oligosaccharides (e.g. LH) which are cleared rapidly from the plasma by specific 
hepatic receptors (Fiete and Baenziger 1997, Fiete et al. 1991, Ulloa-Aguirre and Timossi 
2000). The glycosylation patterns of the glycoprotein hormones are variable depending on 
various physiological changes that occur according to age and sex (Ulloa-Aguirre et al. 
2001). Studies have shown that the secretion of gonadotropin glycosylated variants with low 
sialic acid or sulfate content during the preovulatory phase of the menstrual cycle compared 
to the early, mid-follicular and luteal phases which are believed to be influenced by high 
estrogen secretion (Birken et al. 2007, Padmanabhan et al. 1988, Wide and Bakos 1993). In 
males and postmenopausal women, the gonadotropins circulate in more acidic/sialylated 
isoforms (Veldhuis et al. 1989, Wide 1985, Wide 1989). Other examples include the release 
of the less sialyted FSH isoforms which are more biologically active during the mid-puberty 
in boys compared to other stages of puberty (Campo et al. 2007).  Due to the heterogeneity of 
the gonadotropin carbohydrate side-chains (microheterogeniety), many assays fail to either 
detect or differentiate between these isoforms. For example, throughout pregnancy the hCG 
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isoforms changes and a common hCG immunoassay employing monoclonal antibodies was 
unable to detect certain hCG isoforms produced during the early stages of pregnancy (Birken 
et al. 2001, Kovalevskaya et al. 1999).  
The cross-linked disulfide bond existing between the subunits stabilizes the 
glycoprotein structure and is responsible in maintaining the three-dimensional structure to the 
subunits which is important in maintaining the biological activity of the dimeric structure 
(Ulloa-Aguirre and Timossi 2000). Figure 1.9 illustrates the known crystal structures of hCG 
and human FSH.   
  
 
 
 
 
 
 
 
 
 
The gonadotropin-releasing hormone (GnRH) (previously known as luteinizing 
releasing hormone), regulates the release of LH and FSH. GnRH is a decapeptide hormone 
synthesized by the cell body of the hypothalamic neurons that projects axon to the median 
The α-subunit (yellow) and the β-subunit (hCG in green; hFSH in blue) have similar folding forming highly 
elongated molecules. Both the subunits intertwined with a 20 amino acid residue region of the β-subunit 
known as seatbelt (white region) wraps around and latched a portion of the α-subunit. The two 
gonadotropins exhibit differences in the conformation at the C-terminal portions of the seatbelt. As for 
the LH and TSH, no structures are yet available. However, it is believed that the conformation of LH and 
TSH are closely related to the known structures. Adapted from (Ascoli and Narayan 2014) 
 
Figure 1.9 Crystal structure of human chorionic gonadotropin (hCG; 
left) and human follicle-stimulating hormone (hFSH; right). 
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eminence of the brain. Regardless of the developmental stage, the secretion of GnRH from 
their terminals into the pituitary-portal blood supply is in a pulsatile or episodic manner. This 
pattern of release is absolutely critical as continuous release of GnRH causes desensitization 
of the GnRH receptors which further supresses the release of LH and FSH by the 
gonadotrope cells (Belchetz et al. 1978). Additionally the ratios of the LH and FSH released 
are also infuenced by the GnRH pulse frequency. High GnRH frequencies leads to higher LH 
secretion but lower FSH secretion, thus the LH/FSH ratio is high. However, the ratio 
decreases with the lowering of GnRH frequencies, due to increase in FSH and lower LH 
secretion (Wildt et al. 1981). Thus the GnRH pulse frequency and amplitude plays a pivotal 
role in the regulation of episodic release of LH and FSH into the general circulatory system. 
These gonadotropins binds to the glycoprotein hormone receptors to regulate hormonal and 
reproductive function of the gonads. The gonadotropin receptors are characterized by the 
large N-terminal extracellular domain that determines the recognition and binding affinity of 
their appropriate hormones (Braun et al. 1991). Both LH and hCG mediates their bioactivity 
through a single LH/CG receptor which is expressed in Leydig, theca, granulosa and luteal 
cells whereas FSH binds to its specific follicle stimulating hormone receptors expressed in 
the granulosa and Sertoli cells (Caltabiano et al. 2008, Pierce and Parsons 1981).  
In males, the placental hCG plays an important role to stimulate fetal steroidogenesis 
and Leydig cell growth and differentiation after the initial gonadotropin-independent phase 
(Huhtaniemi et al. 1977). hCG also circulates at very low concentrations in men (produced by 
testes) and nonpregnant women which increases around menopause (produced by the ovaries) 
(Handelsman 2006, Stenman et al. 1997). Meanwhile, the circulating concentration of LH 
stimulates the activity of steroidogenic enzymes including CYP11A and CYP17α-
hydroxylase in the testicular Leydig cells for the production of testosterone (Wu et al. 2007). 
LH is also responsible in maintaining high intratesticular testosterone levels required for 
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spermatogenesis. Testosterone binds to the androgen receptors (ARs) expressed in the 
somatic cell in the testes (Sertoli, Leydig and peritubular) but not germ cells to initiate 
spermatogenesis (Verhoeven et al. 2010). The FSH is also involved in the initiation and 
maintenance of spermatogenesis but is not essential to spermatogenesis (Singh et al. 1995). 
Studies on transgenic FSH mice revealed that both the FSH and testosterone binds to their 
specific receptors expressed in Sertoli cells in order to initiate and maintain spermatogenesis 
(Allan and Handelsman 2005).  
In females, LH regulates ovarian steroid synthesis. LH stimulates the thecal cells and 
the luteinized granulosa cells of the corpus luteum to produce androgen and precursors as 
well as progesterone, respectively. The androgen precursors then move to the neighboring 
granulosa cells where they are aromatized into corresponding estrogens under the control of 
FSH (Themmen and Huhtaniemi 2000). LH is also involved in regulating cholesterol 
availability for steroidogenesis and stimulates the activity of CYP11A to catalyze formation 
of pregnenolone from cholesterol. LH stimulates the gene expression and production of 
enzymes involved in steroidogenesis (Kaiser 2011). Mid-cycle peak of LH terminates 
preovulatory follicle growth and triggers ovulation and stimulates the corpus luteum to 
synthesize progesterone in the second half of the ovulatory cycle (Themmen and Huhtaniemi 
2000). In the ovary, granulosa cells express FSH receptors and are the only target cells of the 
FSH action. FSH is required for granulosa cell differentiation, modulates LH receptor 
expression in granulosa cells and regulates the estrogen production (Richards and Pangas 
2010). FSH is also important for follicular recruitment, selection and growth (Zeleznik and 
Pohl 2006).    
Taken together, the regulation of gonadotropins secretion is under positive control of 
the hypothalamic GnRH. The gonadotropins in turn regulate the gonadal secretion of 
androgen, estrogen and progesterone that exert their effects by binding to their specific 
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receptors. These are expressed in both reproductive and nonreproductive target tissues 
including the reproductive tract and genitalia, breast, fat, bone, muscle, liver and kidney. The 
sex steroid hormone receptors are also expressed in the central nervous system and pituitary 
gland to enable steroid feedback regulatory mechanisms by the hypothalamic-pituitary-
gonadal (HPG) axis. The gonadal steroids and peptide (inhibin) exert negative and 
stimulatory (positive) effects on the gonadotropin regulation and release, either directly at the 
level of pituitary gonadotrophs by the modulating the genes encoding LHβ and FSHβ or 
indirectly at the hypothalamus level to modulate patterned GnRH secretion.   
1.4 Steroid hormone production and action 
1.4.1 Androgens 
Androgens are produced by the gonads and androgen precursors by the adrenal glands in 
response to LH and adrenocorticotropin (ACTH), respectively, in both sexes. Testosterone 
and DHT are the two major and most potent androgens, both of which have a 17β-hydroxyl 
group and 3-oxo group (Figure 1.10). DHEA, dehydroepiandrosterone sulphate (DHEAS) 
and androstenedione are steroids with minimal androgenic activities but are pro-androgens 
(Mo et al. 2006). Testosterone is the most abundant androgen in mammalian males whereas 
the other weaker androgen precursors circulate at the same concentration in male and female. 
Testosterone is primarily produced by the testicular Leydig cells in men (approximately 
95%), the thecal and stroma cells of the ovaries in women (25% through direct secretion and 
25% through peripheral conversion of androgen precursors) and at a lesser amount in the 
adrenal zona reticularis and peripheral tissues (liver, skin and adipose) from conversion of 
androstenedione (Kicman 2008, Palacios 2007). Daily production of testosterone in 
eugonadal men is approximately 3-7 mg per day whereas only 0.1-0.3 mg is produced in 
women (Burger 2002, Kicman 2010). Approximately half of the circulating testosterone in 
women is produced peripherally by androstenedione conversion (Bardin and Lipsett 1967).   
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As described previously, circulating testosterone also acts as a pro-hormone at the 
target tissues when converted into DHT by 5α-reductase and into estradiol by aromatase 
(Figure 1.5) (Kicman 2008). Approximately 50% of the DHT production in men originates 
from this peripheral conversion and the remaining is secreted by the testes (Hammond et al. 
1977, Saez et al. 1972). Although testosterone circulates at 10-fold higher concentration than 
DHT, the potency of DHT is approximately 3-10 fold greater than testosterone (Barbier and 
Bélanger 2008, Wright et al. 1996). Testosterone and DHT binds to the same AR under 
physiological conditions. However, DHT binds with a higher affinity than testosterone 
resulting in activation of target genes even at lower concentrations compared to testosterone 
(Kicman 2008, Wright et al. 1996). Despite binding to the same AR, testosterone and DHT 
have different physiological roles in males. During sexual differentiation, testosterone 
stimulates the urogenital sinus and Wolfian duct development that leads to formation of 
internal male genitalia (epididymis, seminal vesicle and vas deferens) (Themmen and 
Huhtaniemi 2000). Postnatally, testosterone maintains spermatogenesis, maturation of sexual 
characteristics, and plays a role in masculization and libido. During embryogenesis, DHT is 
responsible for development of urogenital sinus (the male external genitalia, urethra and 
prostate) (Marchetti and Barth 2013). During puberty, DHT is involved in the development of 
phallus and prostate, and the appearance of virilizing features such as body and facial hair. In 
adults, DHT is also associated with modulation of prostatic function, and is believed together 
with other androgens to be involved in the homeostasis between cell proliferation and cell 
apoptosis (Carson III and Rittmaster 2003, Isaacs 1984).  
  Androstenedione and DHEA are major androgen precursors. The adrenal glands 
and gonads produces large amount of androstenedione. DHEA and its sulfated analog 
(DHEAS) are primarily produced by the adrenal cortex and lesser amount by the gonadal 
tissues (Labrie et al. 1995). DHEA and DHEAS are also known as neurosteroids, whereby 
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the production of these steroids occurs locally by the neurons and glia of the brain (Lazaridis 
et al. 2011). These steroids are postulated to regulate brain function. For example, the DHEA 
acts on γ-aminobutyric acid type A (GABA) receptors as an agonist whereas DHEAS acts on 
the same receptor as an antagonist (Park-Chung et al. 1999). DHEAS circulates in the 
bloodstream at a higher concentration (250-500 times) compared to its unconjugated form 
and is the most abundant androgen in human circulating 20 times higher than other steroid 
hormone (Ebeling and Koivisto 1994, Kroboth et al. 1999, Labrie et al. 1997). The enzyme 
steroid sulfatase acts on DHEAS to produce DHEA and further converted into other 
androgenic and estrogenic compounds in reproductive (endometrium, ovary, prostate, testis) 
and non-reproductive tissues (bone, breast, skin and brain) (Reed et al. 2005). During 
gestation, the sulfatase enzyme is highly expressed in the placental syncytiotrophoblast 
regulating the production of estrogen in the placenta from the sulfated DHEA produced by 
the fetal adrenal (Salido et al. 1990).  
 
 
 
 
 
 
 
 
 
Figure 1.10 Chemical structure of four main androgenic steroids: 
testosterone, dihydrotestosterone, dehydroepiandrosterone and 
androstenedione. 
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1.4.2 Estrogens  
 
The only naturally occurring estrogen is estradiol (or 17β estradiol) with one pro-estrogen 
(estrone) and phase I metabolite estriol (Figure 1.11). Typically estradiol and estrone 
circulate at higher concentration compared to estriol (Wiren 2007). Aromatase is expressed 
primarily in the ovarian granulosa cells (premenopausal women) and placental 
syncytiotrophoblast (pregnant women) to catalyze the synthesis of estrogen from androgens. 
Testosterone is aromatized into the potent estrogen, estradiol whereas the adrenal precursor 
androstenedione and DHEA are converted into the weaker pro-estrogen, estrone (Nawata et 
al. 1995). The aromatase enzyme is also expressed in the peripheral tissues (adipose and skin) 
which are the primary site for estrogen formation from C19 steroids precursor in both men 
and postmenopausal women (Simpson and Davis 2001, Simpson et al. 1994). The aromatase 
enzyme is also expressed in the muscle, brain, testicular Sertoli and Leydig cells and the 
osteoblast (Frieden et al. 1968, Longcope et al. 1978, Roselli et al. 1987, Saez et al. 1972, 
Sasano et al. 1997). Approximately 80% of the daily estradiol production in eugonadal men is 
produced peripherally from testosterone and the remainder is secreted directly by the testes 
(Baird et al. 1965). Estradiol has high affinity for estrogen receptors (ER) compared to the 
other pro-estrogens, hence known as the only potent bioactive estrogen (Jones 1992). In 
premenopausal women, the circulating level of estradiol is between 68 and 107 pg/mL across 
the menstrual cycle with higher levels during ovulation and is reduced in postmenopausal 
women to less than 5 pg/mL (Rothman et al. 2011). Although the levels of estradiol decrease 
dramatically in postmenopausal women, its metabolite estrone produced from the conversion 
of androstenedione in the adipose tissue remains unchanged (Ruggiero and Likis 2002). In 
men, the mean concentration of estradiol is about 20-30 pg/mL and its daily blood production 
rate is approximately 30-40 µg (Vermeulen et al. 2002). 
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Although throughout adulthood, men have plasma estradiol levels equivalent to 
postmenopausal women, estrogen action plays a pivotal role in the regulation of LH 
feedback. Recent studies have shown that testosterone and estradiol act independently on the 
LH regulation presumably via AR and ERα (Pitteloud et al. 2008). Studies have reported that 
estrogens act in the regulation of LH through the aromatization of testosterone at the pituitary 
level but testosterone does not require aromatization at the hypothalamic level to regulate LH 
secretion (Hayes et al. 2000, Pitteloud et al. 2008, Rochira et al. 2005). The role of estradiol 
on negative feedback regulation was demonstrated through studies conducted in normal or 
GnRH-deficient men where administration of aromatase inhibitor resulted in elevated of LH 
(Finkelstein et al. 1991, Marynick et al. 1979). In female, during the menstrual cycle, the 
concentration of estradiol regulates the negative or positive feedback action on 
gonadotropins. The serum estradiol levels gradually increase with the progression of 
follicular phase which resulted in inhibition of the gonadotropins secretion via the negative 
feedback. As the serum estradiol begins to rise rapidly during the late follicular phase, the 
positive feedback action leads to a preovulatory surge of LH and FSH. Thus estrogens play 
an important role in the gonadotropin regulation for ovulation (Ulloa-Aguirre and Timossi 
2000). Estrogens are also involved in the bone maturation, mineralization, prevention of 
osteoporosis and maintenance of cardiovascular health in both men and women (De Ronde et 
al. 2003, Grumbach and Auchus 1999). During puberty, estrogens are responsible in the 
development of secondary sex characteristics in females which includes breast development 
by stimulating alveolar growth, subcutaneous adipose tissue distribution, typical female body 
proportion and estrogen dependent changes of the genital tract (external genitalia, uterus, 
vagina, fallopian tubes and ovaries) (Dösch et al. 2001).   
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Estradiol is the most potent estradiol in non-pregnant women predominately 
produced by the granulosa cells from androgens. Estrone is produced via 
conversion of androstenedione in the adipose tissue. Estriol, a phase 1 
metabolite of estradiol is produced peripherally and by the placenta during 
pregnancy.  
Figure 1.11 Structures of estrone, estradiol and estriol. 
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1.5 Puberty 
1.5.1 Hormonal changes in puberty 
Puberty is a biological event that results in physical and reproductive maturity. This process 
is coordinated by a complex cascade of neuroendocrine changes which initiates secondary 
sexual characteristics, maturation of the genitalia, increase in growth velocity and ends with 
the acquisition of reproductive capability and attainment of adult body habitus and height 
(Plant and Barker‐Gibb 2004, Styne and Grumbach 2011). The pubertal transition involves 
two independent but temporarily overlapping physiological processes namely, adrenarche and 
gonadarche. 
Adrenarche refers to substantial increase of adrenal androgens, firstly DHEAS 
followed by DHEA and androstenedione, in response to ACTH (Styne and Grumbach 2011). 
The stimulus for this adrenal androgen steroidogenesis is unclear. The event of adrenarche 
only occurs in human and higher primates (chimpanzee, gorilla). Thus studies on its 
development in lower animals model are regarded as uninformative (Dorn and Biro 2011). 
The maturation of the adrenal cortex occurs from the age of about 6 to 7 years onwards in 
girls and 7 to 8 years onwards in boys (Ducharme et al. 1976, Korth-Schutz et al. 1976). The 
increase of adrenal androgens production occurs between 1 to 2 years before the changes of 
other pubertal hormones (Rogol et al. 2002) with higher levels reported in girls than in boys 
(Apter et al. 1979, Courant et al. 2010). The rise of adrenal androgens continues during 
gonadarche, with higher DHEAS levels in males compared to females after the age of 15 (de 
Peretti and Forest 1978). Adrenal androgen continues to increase on until the third decade of 
life and thereafter DHEAS levels gradually decline in both sexes (Ibáñez et al. 2000).  
Adrenarche is associated with the appearance of sexual hair (pubarche), axillary hair, adult 
apocrine odor and appearance of acne in some individuals (Rogol et al. 2002).  
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Gonadarche refer to the reactivation of the HPG axis at the end of the prepubertal 
phase resulting in dramatic surge in gonadal steroid production and initiation of 
folliculogenesis and ovulation in female and spermatogenesis in male (Witchel and Plant 
2014). Gonadarche also leads to the final maturation of primary sex organs (ovaries and 
testis) and external signs of puberty. The stages of sexual development have been well 
defined by Tanner and Marshall as a predictable and ordered sequence of event (Marshall and 
Tanner 1969, Marshall and Tanner 1970). This clinical assessment of pubertal maturation 
known as Tanner staging remains the primary system used as the descriptive standards for 
assessing pubertal development. Other measures of puberty status includes Petersen Pubertal 
Development Scale (PDS) which is a self-report that focuses on physical changes in growth 
and development (Petersen et al. 1988). Morris and Udry (Morris and Udry 1980) also 
introduced self-report method along with line drawings of external physical changes. Other 
groups combined method of physical examinations for pubertal staging and pubertal hormone 
concentrations to define pubertal status. Tanner stages are divided into five anatomically 
defined stages which include pubic hair growth, development of breast in females and the 
development of phallus in male (Carel and Leger 2008). Figure 1.12 illustrates the Tanner 
stages of both girls and boys. Overall, girls usually enter and complete each stages of puberty 
before boys. The timing (onset) and tempo (rate) is affected by many factors including 
genetic factors although it even varies among individual from the same ethnicity and gender 
(Clark and Rogol 1996, Euling et al. 2008).  
In girls, the appearance of breast buds (thelarche) underneath the areola is the initial 
sign of gonadarche (Tanner stage 2) which occurs between the age of 8 and 13 years 
indicating increased ovarian estrogen production (Jenner et al. 1972). As puberty progresses, 
the areola size, erectility and colour changes. Estrogen action is also demonstrated by the 
production of vaginal secretion and the enlargement of labia minora and majora. The adrenal 
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and ovarian androgen secretion leads to the development of pubic hair. Approximately 2.5 
years after the appearance of breast buds, the first menstrual cycle (menarche) takes place 
(Marshall and Tanner 1969). The duration of pubertal development in girls and boys 
normally takes between 3-3.5 years to complete or in some cases occur earlier (within 2 
years) or later (5 years) (Dorn et al. 2006).  
In boys, the first sign of gonadarche is associated with the enlargement of the testes 
and a thinning and reddening of scrotum which occurs between the age of 9 and 13 years 
(Rogol 2002). The volume of testes increases from 1-2 mL (prepubertal) to 4 mL at the onset 
of puberty (Tanner stage 2) coincides with the increase of testicular androgen production 
(August et al. 1972). The testicular volume dramatically increases to about 10-fold by the end 
of pubertal development with the initiation of spermatogenesis and proliferation and 
differentiation of the Sertoli cells (Marshall 1975).  Adrenal and testicular androgen secretion 
reflects the manifestation of pubic and axillary hair and development of acne (Greiner and 
Kerrigan 2006). As stated above, the two main hormones that mediate the biological 
manifestations of puberty are estradiol and testosterone, in girls and boys, respectively. 
However, most studies in the past have utilized assay methodologies that are considered 
inaccurate to measure low levels of these hormones in early and mid-puberty (Ankarberg-
Lindgren and Norjavaara 2008, Moal et al. 2007, Taieb et al. 2003).  
Adrenarche and gonadarche are two separate maturational events (Sklar et al. 1980). 
This is evident as the increase in adrenal androgens occurs when HPG axis is still inactive 
before the initiation of gonadarche. However, absence of adrenarche does not prevent 
gonadarche and vice versa. Girls with Turner’s syndrome, despite the absence of functioning 
ovaries, have normal adrenarche (Saenger 1996) but does not result in reproductive 
maturation. This was also noted in patients with hypogonadotropic hypogonadism (Counts et 
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al. 1987). Additionally normal onset of gonadarche was noted in boys with primary adrenal 
insufficiency condition (Urban et al. 1980).  
 
 
 
 
 
 
 
 
 
Panel A demonstrates the development of breast and pubic hair in girls rated 
from stage 1 (preadolescent) to 5 (mature). The development of breast buds 
(stage 2) marks the onset of gonadarche. Adrenarche begins at stage 2. 
Panel B illustrates the genital development and pubic hair development in 
boys rating from stage 1 (preadolescent) to 5 (adult). Stage 2 genital 
development marks the onset of gonadarche, which is characterized by 
enlargement of the testis and scrotum accompanied by changes in scrotal 
skin texture and color (reddening). The onset of pubic hair growth begins in 
stage 2.  
Here the pubic hair and genital/breast development is illustrated 
simultaneously; however it should be scored separately as they do not 
necessarily take place at the same time. Adapted from (Carel and Leger 
2008).   
Figure 1.12 Pubertal rating according to Tanner stages. 
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1.5.2 Activation of hypothalamus-pituitary-gonadal axis during development 
In humans, the activation of the HPG axis first occurs in utero. The diffusely distributed 
network of hypothalamic neurons expressing gonadotropin releasing hormone-I (GnRH-I) 
gene known as GnRH pulse generator activates the release of fetal pituitary LH and FSH. The 
fetal pituitary contains detectable levels of gonadotropins at the 10
th
 week of gestation and 
the gonadotropins are detectable in fetal circulation by 12-14
th
 week of gestation in response 
to the decreasing placental estrogen (Seminara et al. 1998, Styne and Grumbach 2011, 
Witchel and Plant 2014). The fetal testes expresses LH/hCG receptors that activates the 
Leydig cell to synthesize testosterone important for male gonadal maturation in utero (Biro 
and Dorn 2005) whereas at this stage the ovary development of female fetuses remains 
quiescent (Witchel and Plant 2014). The fetal ovary apparently does not express 
gonadotropin receptors and appears to be independent of gonadotropins and gonadal function 
(Huhtaniemi et al. 1987, Themmen and Huhtaniemi 2000). The circulating gonadotropins 
concentrations are much higher in female compared to male fetus. It is postulated that the 
male fetus have early development of negative feedback by testosterone (Grumbach and 
Gluckman 1994). At the end of pregnancy, the fetal LH and FSH levels decline progressively 
and the GnRH pulses are inhibited with the increase of maternal and fetal estrogen levels and 
the development of negative feedback mechanism (Grumbach 2004, Nagata et al. 2006).  
In male neonates, within a couple of minutes after birth, LH secretion surges 
approximately 10 times greater than the cord blood concentration resulting in secretion of 
testosterone which lasts for about 12 hours (Corbier et al. 1990, De Zegher et al. 1992). 
However, this LH surge is absent in female neonates (Grumbach 2005). After the first few 
days of birth, as the placental sex steroids inhibition is removed, the HPG axis activity 
commences. The circulating levels of LH and FSH rise intermittently to adult values or even 
occasionally higher at 2-3 months age and then declines to prepubertal levels between 6 to 9 
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months of age in boys and 2 to 3 years of age in girls (Andersson et al. 1998, Kuiri-Hänninen 
et al. 2011, Wright et al. 1996). This period is known as the neonatal surge or minipuberty. 
After this period of postnatal gonadotropin surge, the GnRH pulse generator becomes 
quiescent until its reactivation before onset of puberty. However, studies utilizing sensitive 
assays have shown that gonadotropins are released at low levels in pulsatile pattern primarily 
at night in prepubertal children with greater amplitude of FSH than LH pulses (Albertsson-
Wikland et al. 1997, Apter et al. 1989, Wu et al. 1991). Low levels of gonadal steroids 
circulate during this childhood period (Rogol 2010).      
Puberty represents the final step in the maturational process of the HPG axis. The 
onset of puberty is referred as (re)activation of the previously quiescent neuroendocrine 
reproductive axis which is reflected by increase in GnRH secretion (Ojeda and Skinner 2006, 
Plant and Skinner 2006). During this period, the reactivation of GnRH secretion transforms 
from low-level irregular pattern to a regular and pulsatile pattern which is detectable even 
prior to the exhibition of pubertal external signs (Harris and Levine 2003, Watanabe and 
Terasawa 1989). Marked increase in the amplitude and frequency of GnRH secretion 
enhanced the release of gonadotropin. At early progression of puberty, the pulses occur 
predominantly at night resulting in augmented LH secretion which in turn stimulates early 
morning release of gonadal steroids. Once again the gonadal steroid is able to inhibit GnRH 
secretion that cause decline in the gonadotropin and gonadal steroid levels throughout the 
day. As puberty progresses the gonadotropin pulses occurs both during the night and day as 
the negative feedback sensitivity of the hypothalamus decreases resulting in a more stable 
elevation of gonadal steroids hormones (Grumbach 2004, Grumbach 2005). At each pubertal 
stage, overnight LH values are approximately the same in both the genders but girls have 
higher FSH values (Manasco et al. 1997).  
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The specific neural and molecular mechanism that regulates the activation of the 
GnRH neuron during the initiation of puberty is not fully understood. However, previous 
studies have associated neurotransmitter and neuropeptide such as glutamate (Plant et al. 
1989), γ-amino butyric acid (GABA) (Keen et al. 1999), neurokinin B (Topaloglu et al. 
2008), leptin (Cheung et al. 2001), neuropeptide Y (El Majdoubi et al. 2000) and glial cell 
regulatory system (Grumbach 2004) with activation of GnRH neurons at puberty. In the last 
decade, neuropeptide kisspeptin has emerged as an important regulator of GnRH neurons in a 
number of mammalian species which led to the perception that kisspeptin signaling controls 
the timing of puberty (Terasawa et al. 2013). The involvement of kisspeptin in regulating 
reproductive axis was first reported by two independent groups in 2003. Their studies have 
shown that mutation or deletion of kisspeptin receptor, Gpr54 (G-protein receptor 54) 
recently renamed as Kiss1 receptor (Kiss1R) in humans and mice resulted in striking deficits 
in reproductive function, including failure to initiate puberty and infertility (de Roux et al. 
2003, Seminara et al. 2003). In the following years, many studies have emerged unraveling 
the role of kisspeptin in regulation of puberty and fertility. Exogenous treatment of kisspeptin 
accelerates the age of puberty in prepubertal rats by early activation of gonadotropic axis 
(Matsui et al. 2004). Studies also demonstrated increase in LH and FSH levels in adult 
rodents and primates (including human) with administration of kisspeptin (Dhillo et al. 2005, 
Kinoshita et al. 2005). This suggests that the secretion of kisspeptin is necessary not only for 
puberty to occur, but required for the maintenance of reproductive function. The increase in 
kisspeptin expression in the hypothalamic region immediately before the onset of puberty 
further elucidates the role of this neuropeptide in the maturation of the reproductive axis 
(Navarro et al. 2004, Silveira et al. 2010). Kisspeptin plays a critical role in the control of 
reproductive axis at different stages of life including postnatal, pubertal development and 
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adulthood. Figure 1.13 illustrates a model demonstrating the role of kisspeptin signaling in 
controlling the timing of puberty in primates.   
 
 
Figure 1.13 A proposed model for the control of the timing of puberty in primates. 
 
 
 
 
 
 
 
 
During infancy (left panel), the robust activity of GnRH pulse generator leads to the 
intermittent release of kisspeptin in the ME, that causes corresponding pattern of GnRH 
release in the portal circulation. This further leads to the secretion of LH and FSH by the AP.  
During the developmental progression from infancy to juvenile stage, a neurobiological brake 
results in inhibition of pulse generation by GnRH (reduce production of GnRH) and reduces the 
pulsatile release of kisspeptin into the ME (middle panel).  
Puberty is initiated when this neurological brake is release which then triggers reactivation of 
GnRH pulse generator and release of kisspeptin in the ME (right panel). However, the nature 
of the neurobiological brake during infancy and its release at the end of juvenile 
developmental phase is not well understood.  
The thickness of the arrows marked in blue (T, male) and gold (E2, female) indicates the degree 
of negative feedback by the gonadal steroids produced by the gonads (testis and ovaries) on 
LH secretion at the different developmental stages. Adapted from (Hu et al. 2005, Terasawa et 
al. 2013) 
Abbreviations: T: testosterone; E2: estradiol: AC: anterior commissure; AP: anterior pituitary 
gland; ARC: arcuate nucleus; OC: optic chiasm; ME: median eminence; MMB: mamillary body. 
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More recent genetic studies of familial central precocious puberty have linked 
another possible gene known as makorin ring finger 3 (MKRN3) with initiation of puberty 
(Abreu et al. 2013, Settas et al. 2014).  MKRN3 is a maternally imprinted gene that contains 
no introns and is located on chromosome 15q11.2 in Prader-Willi syndrome critical region. 
Mutations in MKRN3 gene has been associated with acceleration of puberty initiation leading 
to development of pubertal signs in both sexes which supports MKRN 3 role as a 
physiological inhibitor of hypothalamic activity during childhood (Abreu et al. 2013, Macedo 
et al. 2014, Schreiner et al. 2014). Studies have suggested that the MKRN 3 might function as 
a silencer of downstream genes that controls the activation of puberty such as kisspeptin 
(Hagen et al. 2015, Ojeda and Lomniczi 2014).  
1.5.3 Growth and skeletal maturation during puberty 
Puberty is accompanied by rapid sexually dimorphic changes in body composition, size and 
shape. Growth spurt is a major physical change that occurs during puberty which encompass 
15-20% of the final adult height (Juul 2001). During childhood, growth is relatively stable 
primarily depending on the dietary intake, hormonal balance (growth and thyroid hormone), 
general health and adequate psychosocial environment (Rogol 2010). Generally, in the first 
year of life, a child grows 25 cm and 12 to 13 cm the following year. After this age, the child 
growth is stable about 5 to 6 cm until puberty (Rogol et al. 2002). The stable growth rate 
slows to a nadir (preadolescent dip) just before the onset of puberty and thereafter accelerates 
during mid-puberty. Although pubertal development in both genders takes about 4.5 years to 
complete, there is a marked difference in the timing of pubertal growth spurt between males 
and female. In girls, growth spurt occurs earlier compared to boys. However the growth spurt 
in girls does not reach the same magnitude of that in boys (Clark and Rogol 1996).  
In girls, the growth spurt is commonly detected with the first sign of puberty (breast 
development and pubic hair) (Pinyerd and Zipf 2005). Peak height velocity occurs between 
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Tanner stage 2 and 3 (breast stage 2 [B2] and breast stage 3 [B3]) at about 11 to 12 years of 
age that averages about 9 cm annually with about 25 cm of total height gained (Marshall and 
Tanner 1969). However, peak height velocity varies between individual around this median 
pattern; 40% occurring at B2, 30% at B3, 20% at B4 and 10% at B1 (Coste et al. 2002). As 
the peak height velocity is about a year before menarche, the growth slows down to about 2.5 
cm in height until completion of growth although it varies among individuals (Styne and 
Grumbach 2011). In males, peak growth velocity is observed at the Tanner genital stage 3 to 
4 between the age of 13 and 14 years with an average of 10.3 cm per year, gaining about 28 
cm of height during the pubertal growth period (Marshall and Tanner 1970). In boys, peak 
height velocity also varies between individuals with 60% occurring at genital stage 3 (G3), 
28% at G4 and less than 8% at G2 and G5 (Coste et al. 2002). 95% of boys complete height 
velocity by Tanner genital stage 5 (Styne and Grumbach 2011). The pubertal growth rate 
decreases rapidly after the gender-specific peak in height velocity with increase of 1 cm per 
year or less in height after the age of 14.5 and 17 years in girls and boys, respectively 
(Veldhuis et al. 2005). In boys, the combination of higher peak velocity and for a longer 
duration of growth compared to girls results in an average height difference of 13 cm 
between men and women (Greiner and Kerrigan 2006). Peak height velocity is also greater in 
youths who mature earlier (Veldhuis et al. 2005).  
Pubertal growth spurt is marked by the significant increase of growth hormone (GH), 
insulin-like growth factor l (IGF-1), estrogens and androgens. During childhood, the GH 
hormone secretion rates are stable and secretion pattern is similar in both genders with 
striking day-night rhythm (Martha et al. 1989). The secretion of GH is highest at early hours 
of sleep followed by small episodic bursts throughout the night/day (Finkelstein et al. 1972). 
The GH pulses are also released during the day, however at low levels (Miller et al. 1982).  
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During puberty, the activation of GH/IGF-1 axis and gonadal sex steroids not only 
demonstrates independent effects on growth, but the synergistic effect between them alters 
linear growth and body composition. Normal growth is attained with the presence of both GH 
and gonadal sex steroids. The growth spurt is impaired in conditions when either hormone is 
absent (Rogol et al. 2002). The increase in GH/IGF-1 axis during puberty is influenced by 
sex steroids. Elevated concentration of sex steroids especially estrogens stimulate 24-hours 
GH levels in a maximal pulse amplitude and increase in mass of GH released per burst which 
subsequently stimulate the hepatic IGF-1 production (Mauras 2001). Pulsatile secretion of 
GH increases between 1.5 and 3 fold which is accompanied by more than 3 fold serum IGF-1 
concentration increase during puberty (Juul et al. 1994). The secretion of GH differs between 
genders that are parallel with the pattern of height velocity. In girls, the GH/IGF-1 levels rise 
significantly at Tanner B2 and peaks at Tanner B3-B4. Meanwhile in boys the increase of 
GH/IGF-1 occurs later during the pubertal development, peaking at Tanner G4 (Albertsson-
Wikland et al. 1994). At the end of pubertal stage and adulthood, the levels of GH and IGF-1 
reduces significantly even though the gonadal steroids levels are high (Martha et al. 1989).      
The growth plate of bones undergoes functional and structural changes during growth. 
The growth plate contains chondrocytes and is divided into three zones; resting (containing 
immature cells close to the epiphyseal bone), proliferative (containing replicating and mature 
chondrocytes) and hypertropic (containing large chondrocytes). In both boys and girls, 
estrogens play an important role to modulate the secretion of GH and act directly on the 
growth plate maturation and fusion that leads to termination of longitudinal growth rates 
(Nilsson et al. 2005). During early puberty, low circulating levels of estradiol increases GH 
secretion followed by IGF-1 synthesis that stimulate chondrocyte growth in the proliferation 
zone of the growth plate and initiates pubertal growth spurt. As puberty progresses, 
augmentation of estradiol leads to apoptosis of hypertropic chondrocytes and stimulates 
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invasion of the growth plate by osteoblast. The completion of growth depends on estrogen 
action via ERα that induces exhaustion of chondrocytes proliferation that leads to fusion of 
the epiphyseal plate (Lazar and Phillip 2012, Weise et al. 2001). In conditions such as 
precocious puberty when premature exposure of estrogen occurs, skeletal growth accelerates 
leading to early epiphyseal fusion and decreased in final height (Carel et al. 2004). On the 
contrary, conditions featuring lack of estrogens (e.g. hypogonadism) causes delay in 
epiphyseal fusion and tall stature (Sedlmeyer and Palmert 2002).  
Testosterone requires aromatization to estradiol in order to influence the GH/IGF-1 
axis. This is evident in patients with aromatase deficiency where lack of estradiol lead to 
reduced epiphyseal closure, lack of pubertal growth spurt and the linear growth continues 
even after reaching adulthood (Morishima et al. 1995). Other studies have also shown 
administration of a non-aromatized androgen (DHT) in pre- and peripubertal boys does not 
increase GH secretion (Eakman et al. 1996, Veldhuis et al. 1997). Testosterone exerts its 
effect indirectly by enhancing the abundance and responsive of IGF-1 receptors in the growth 
plate chondrocytes (Lazar and Phillip 2012). Although non-aromatized androgens do not alter 
the GH/IGF-1 axis, they may have direct effects on bone growth independent of estrogens as 
AR expression is present within the growth plate cartilage (Nilsson et al. 2003).  
1.5.4 Body composition during puberty 
Dramatic changes in body composition occur in utero, across infancy, childhood and puberty. 
Endocrine factors play a key role in these dimorphic changes regulating the increase in bone 
density, fat free mass (lean mass) and the distribution and amount of adipose tissue. In early 
development, infant boys are heavier than girls due to greater lean mass whereas the fat mass 
are unchanged between the sexes (De Bruin et al. 1996). Thus proportionally newborn female 
have more subcutaneous fat than males with slightly higher mean skin-fold thickness 
(Rodriguez et al. 2005, Rodríguez et al. 2004). During prepubertal years, the differences in 
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body composition in both sexes are modest compared to postpubertal. Boys and girls weigh 
approximately 23 kg and 22 kg respectively by the age of 7 years (Veldhuis et al. 2005).  
As puberty progresses, the body composition markedly changes. In girls, the total 
body fat increases steadily with the mean of approximately 5.5 kg at the age of 8 years to 
about 15 kg at 16 years. The increase beyond this stage is considerably slow. In boys, the 
total body fat increases from 5.5 kg to 11 kg between the age of 8 and 14 years and falls 
beyond this stage to approximately 9 kg at the age of 16 years and reaches a plateau 
(Siervogel et al. 2000). The fat free mass increases in girls by the age of 6 years and attain 
stability by the age of 15 to 16 years. Boys acquire fat free mass more quickly and for longer 
duration than girls during puberty with a steady increase between the age of 8 and 18 years 
(Siervogel et al. 2000, Veldhuis et al. 2005). The pattern of higher fat distribution and lower 
fat free mass in girls is not only hormonally driven but is also related to lower energy 
expenditure during puberty (Goran et al. 1998). Body mass index (BMI) calculated as weight 
(kg) divided with the square of stature (m
2
) provides useful information to define over-weight 
and obesity (Siervogel et al. 2000).  
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1.6 Analytical measurements of LH and FSH. 
The importance of gonadotropin measurement as biochemical indicator of endocrinological 
status and for therapy monitoring has led to development of various specific and sensitive 
assays. The measurement of LH and FSH can be divided into two assay systems. The first 
type of measurement is the immunoassays that quantitate the mass of immunoreactive 
hormone molecules of the sample. This assay includes the radioimmunoassay (RIA), 
immunofluorometric assay (IF) and immunochemiluminometric assay (ICL). The second 
type of assay measures the biological activity of the gonadotropin such as receptor binding 
assay and bioassays that quantitate functional aspects of gonadotropins. The bioactive to 
immunoactive ratio provides a useful index to assess qualitative changes in the gonadotropin 
for clinical diagnostics (Jaakkola et al. 1990).    
RIA: The first immunoassay was developed by Yalow and Benson for peptide hormones 
measurements in the late 1950s, for which their work was awarded a Nobel Prize in Medicine 
to Yalow in 1972 (Yalow and Berson 1959). The development of RIA proved to be beneficial 
in studying gonadotropin regulation in health and disease conditions (Jaffe and Midgley Jr 
1969). The RIA technique is based on competitive binding of unlabeled gonadotropin in 
biologic fluid and radiolabelled gonadotropin to a limited number of binding sites on a 
specific antibody. As the amount of unlabeled hormone increases, the binding of radioactive 
labeled hormone binding to the antibody decreases. Immunoradiometric assays (IRMA) on 
the other hand are a variation of RIA in which the antibody is labeled instead of antigen. For 
LH RIA, antisera from hCG were initially used based on the resemblance in structure and 
immunologic properties (Wide et al. 1961). However, the hCG antisera were replaced with 
the availability of highly purified human LH and its antibodies (Odell et al. 1967, Odell et al. 
1966). Although this assay for gonadotropin measurement is known to be robust and is 
extensively employed for endocrine research, there are a number of limitations associated 
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with it. This includes considerable cross-reactivity of the free α-subunit of LH in some RIAs 
system (Dahl and Sarkissian 1993). RIA is also limited in sensitivity to measure low levels of 
gonadotropins. This hampers the assay application for measurement of low or suppressed 
gonadotropin levels for physiological or clinical assessment. Some IRMA and RIA were  
unable to measure LH pulses in prepubertal children (Clark et al. 1997). Studies have also 
shown discrepancy in the gonadotropin values measured by polyclonal antibodies in RIA 
compared to monoclonal antibodies immunoassays (enzyme linked immunoassay) possibly 
due to the differences in the antibody specificity (Olivares et al. 2000). Other disadvantages 
such as radiation hazard associated with, short half-life of the iodine tracer and costly gamma 
counter gradually lead to the replacement of RIA methods with new non-radioactive 
immunoassays such as IF and ICL (Munro et al. 1991).   
IF and ICL assays: These immunometric assays make use of two antibodies forming a 
sandwich. The first antibody bound to solid phase is used to capture the antigen. Whereas the 
second antibody labeled to signal transducer, commonly fluorescence (IF assay) or 
luminescence (ICL assay) is used to measure the concentration of the analyte. No 
radioactivity is involved in these assays. The gonadotropin molecules present in the sample 
will be enclosed (“sandwiched”) between the antibodies. The development of commercially 
available two-site-directed assays has overcome the limitation of gonadotropin RIAs 
associated with sensitivity and cross-reactivity of the α-subunit. IF assays are able to measure 
low serum LH and FSH during early puberty development that was difficult to obtain with 
the RIA assays (Apter et al. 1989).  
The dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) is a 
commercially available IF assay that utilizes europium as a label and time-resolved 
fluorescents as the detection method. This solid-phase assay is based on two site sandwich 
technique with high affinity monoclonal antibody. The monoclonal capture antibody is 
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immobilized on the plate which is directed against the specific β subunit of the glycoprotein 
hormone. The europium labeled detector monoclonal antibody is directed against the 
common α subunit (Lövgren et al. 1984). The long fluorescent decay time of the europium 
label enhances the sensitivity of the assay (Hemmilä et al. 1984).  
Immulite is another widely used automated immunoassay technology which utilizes the 
enzyme-amplified chemiluminescent technology. The solid phase of the system consists of a 
polystyrene bead sealed in the test unit and coated with a capture monoclonal antibody 
against LH or FSH.  The gonadotropin standard or sample binds to the monoclonal antibody 
coating the bead. A detector polyclonal antibody which is conjugated to alkaline phosphatase 
enzyme binds to the gonadotropin bound to the monoclonal antibody forming a sandwich. 
Finally, the chemiluminescent substrate added to the complex undergoes hydrolysis through 
the action of the alkaline phosphatase enzyme creating unstable anion that emits sustained 
light which is then measured using a luminometer (Reimers et al. 1996).    
FSH Bioassay: The Steelman-Pohley was the earlier in vivo assay to assess FSH. For this 
assay, immature female rats are pretreated with hCG to increase sensitivity to exogenous 
FSH. This is detected by measuring its response to exogenous FSH which results in a linear 
dose-response increase in mean ovarian weight (Steelman and Pohley 1953). The problems 
associated with this ovarian augmentation assay includes that it is too susceptible to serum 
interference, lacks sensitivity and is cumbersome for routine clinical studies (Wang 1988). 
The granulosa cell aromatase bioassay (GAB) and Sertoli cell aromatase assay are in vitro 
FSH bioassays that provide sufficient sensitivity for measurement of serum FSH. This non-
species-specific assay is based on stimulation of estrogens production by the rat ovarian 
granulosa cell primary culture to measure biologically active FSH. Serum samples are 
pretreated with polyethylene glycol to remove inhibitory substances prior to assay (Dahl et al. 
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1988, Jia and Hsueh 1986). Meanwhile, the Sertoli cell bioassay is based on measurement of 
estradiol production from exogenous testosterone in the presence of FSH (Van Damme et al. 
1979). 
LH/hCG Bioassays: The mouse interstitial cell testosterone assay (MICT) or the rat 
interstitial cell testosterone assay (RICT) are in vitro bioassays commonly used by 
laboratories for LH and hCG bioactivity measurements. These assays are based on the 
stimulation of testosterone from dispersed Leydig cells and the assays measure all LH/hCG 
like bioactivity but do not cross-react with the biologically inactive free subunits of the 
gonadotropins (Dufau et al. 1976).     
Receptor-binding assays: These assays are competitive protein binding assays similar to RIA 
but using a binding protein other than antibody, typically a receptor that utilizes radioligand 
gonadotropin (
125
I-hCG/
125
I-LH or 
125
I-FSH) as a ligand and crude rat homogenate from rat 
testes or corpora lutea which is rich in LH/CG and FSH receptors, respectively (Catt et al. 
1972, Leidenberger and Reichert Jr 1972, Sanzo and Reichert 1982). 
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1.7 Analytical techniques of steroid measurement  
Steroid hormone analysis plays an indispensable role for the diagnosis of endocrinological 
disorder or gonadal function in clinical laboratories. Steroid hormones and their metabolites 
can be measured in various biological fluids such as plasma, serum, urine, amniotic fluid, 
saliva and tissue extracts (Table 1.3). Generally, binding assays or chromatographic methods 
are used for steroid quantitation. Quantitation of steroids using gas chromatography-mass 
spectrometry (GC-MS) and liquid chromatography-mass spectrometry (LC-MS) are superior 
to immunoassays with regards to specificity and sensitivity (Krone et al. 2010). Rapid growth 
in the mass spectrometry (MS) technology has enabled routine analyses of steroids in clinical 
and research laboratories (Stanczyk and Clarke 2010). Table 1.4 shows comparison studies 
between immunoassays and GC/LC-MS for testosterone and estradiol measurements.  
1.7.1 Immunoassay 
RIA to measure steroid was first developed in 1969 for estradiol analysis in serum/plasma 
(Abraham 1969). The ‘indirect’ RIA method involves extraction of steroid with organic 
solvent (to remove conjugated steroids and denature the SHBG or CBG protein bound to the 
steroids) and Celite or Sephadex column chromatography separation (to remove possible 
interfering structurally related precursor or metabolites) prior to RIA quantitation that 
increases the specificity of the assay (Abraham et al. 1972, Giton et al. 2009). Since steroid 
molecules are too small to be antigenic, they are covalently attached to carrier protein such as 
bovine serum albumin forming hapten (Abraham 1974). The specificity of the assay antibody 
increases when the binding of protein to the steroid is distant from the functional groups 
(Honour 2010).  
The antibodies used for RIAs are available commercially for many but not all 
steroids. Tritiated steroid were used in earlier RIA methods which was then replaced with 
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iodinated derivatives that increased the assay sensitivity (Stanczyk 2004). The assay involves 
displacement of radioactively labelled steroid from the antibody binding site by steroid in the 
assay sample. Then the antibody-bound and the unbound steroid are separated either by 
activated charcoal where the unbound steroids is adsorbed (Wu and Lundy 1971) or by 
precipitation of the antibody-bound steroid complex forming a pellet upon centrifugation 
(Honour 2010). The liquid scintillant fluid is then added to the radioactive sample (only for 
the tritiated label) that produces light which is then measured using a photomultiplier (beta 
counter).   
The RIA has high throughput of samples. Pre-assay purification method removes 
interfering metabolites so as to provide accurate and reliable steroid measurements. However, 
RIAs are cumbersome, requires prolonged incubation and time-consuming purification steps. 
Large sample volume is also required especially when quantifying samples with low steroid 
concentrations (Stanczyk and Clarke 2010). Due to all these disadvantages, direct (non-
extracted) immunoassay such as IF, ICL or enzymatic assays were developed. These assays 
do not require radioactive ligands and steroid purification prior to steroid analysis. 
Additionally the direct immunoassays are simple, rapid and more affordable. However, 
steroid immunoassays generally lack in specificity because the antibodies cross-react with 
steroids having or sharing structural similarities, especially when present at higher 
concentration than the steroid of interest. For example in women and children, high DHEAS 
concentration may cross-react with testosterone measurements and in such condition there 
will be an overestimation of testosterone steroid concentrations (Heald et al. 2006, Moal et al. 
2007). Cross-reactivity also occurs due to conjugated metabolites of the steroid of interest 
resulting in erroneous steroid measurement (Yarrow et al. 2013). Other inherent problem of 
using immunoassays includes inaccuracy and limited sensitivity to measure steroids at low 
concentrations. These immunoassays are unsuitable for steroids quantitation below the assay 
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validated range for example quantitation of estradiol in children, postmenopausal women and 
men (Stanczyk et al. 2010, Taieb et al. 2002) and testosterone measurement in children and 
women (Moal et al. 2007, Rothman et al. 2011, Taieb et al. 2003). Assay comparison studies 
demonstrated large inter-assay variability for testosterone and estradiol measurements (Table 
1.4) (Handelsman et al. 2014, Sikaris et al. 2005).  
The presence of heterophilic and auto-antibodies that form complexes with the 
reagent antibodies may also interfere with the immunoassays giving false negative or positive 
measurements (Boscato and Stuart 1988, Boscato and Stuart 1986). Additionally, direct 
immunoassays utilizing samples without extraction, chromatographic separation or authentic 
tracers (H
3
, C
14
) are susceptible to matrix and SHBG interference (Handelsman et al. 2014, 
Sikaris et al. 2005, Taieb et al. 2003). Removing the pre-immunoassay purification step was 
reported to falsely underestimate or overestimate analyte measurements (Marks 2002). 
Immunoassay performance was improved with extraction method prior to assay for samples 
with low estradiol in children (Ankarberg-Lindgren and Norjavaara 2008). However, studies 
have also reported positive bias in assays involving extraction and chromatographic 
separation methodologies compared to reference methods (Cawood et al. 2005, Wang et al. 
2004). Furthermore, the presence of endogenous compounds such hydrophobic and 
amphiphatic lipids in serum samples has been reported to interfere with the RIA assays by 
interacting with the steroids or the antigen-antibody reaction (Rash et al. 1980).  
1.7.2 Gas chromatography- mass spectrometry   
The first gas chromatography (GC) to measure steroids was developed in 1960 which 
preceded the use of immunoassay in endocrine studies (Sweeley and Horning 1960, Vanden 
Heuvel et al. 1960). The coupling of GC and MS to measure sterols was first carried out in 
1964 (Eneroth et al. 1964) followed by the GC-MS steroids analysis in the late 1960s in 
biological matrices (Sjövall and Vihko 1968).  
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GC-MS is a robust and widely used method for detection and analysis of major 
steroids and their metabolites in complex matrices such as urine (Weykamp et al. 1989). The 
GC consists of flexible silica-based column (approximately 30 m in length) that utilizes large 
gas volumes (normally helium) with high pressure as mobile phase and for chromatographic 
separation. Samples injected into the column are vaporized upon reaching the analyte boiling 
point which is about 300°C for steroids. The volatile analytes then move into the vacuum 
detector such as flame ionization detector (FID), electron-capture detector (ECD) or the mass 
spectrometer (MS). The MS detector is preferred for steroid analysis as it provides highly 
sensitive and selective detection.  
The GC-MS is capable of providing baseline separation of steroids with structural 
similarities or α/β stereoisomers (Krone et al. 2010). However, prior to GC-MS analysis, non-
volatile and thermolabile analytes have to be chemically derivatized, for example, using 
methyloxime-trimethylsilyl ether (MO-TMS) to enhance volatility and to withstand the GC 
high temperature during vaporization. Derivatization with suitable reagents increases the 
ionization efficiency by changing the steroid physical and chemical property by forming 
covalent linkage to the specific functional group of the analyte. Common concerns with 
derivatization includes incomplete derivatization, nonspecific derivatization and production 
of multiple products (Liberato et al. 1987). Steroids in conjugated form have to be 
enzymatically or chemically hydrolyzed before analysis as steroid conjugates have low 
volatility and degrade at high temperature (Caulfield et al. 2002). There are two types of 
enzyme solutions normally used for steroid deconjugation which includes Escherichia coli 
and Helix pomatia. β-glucuronidase extracted from E.coli deconjugates the glucuronide 
moiety from steroids whereas the β-glucuronidase/arylsulfatase extracted from H. pomatia 
hydrolyses both the glucuronide and sulfate conjugates. However, the use of H. pomatia 
yields unwanted steroid by-product (e.g. conversion of DHEA to androst-4-ene-3,17-dione) 
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and incomplete deconjugation (e.g. androsterone-3-sulfate and testosterone-17-sulfate) 
(Messeri et al. 1984, Vanluchene et al. 1982, Venturelli et al. 1995). This is not a problem 
with the enzymatic hydrolysis using the enzyme from E.coli. The GC-MS run time for 
multiple steroid profile analysis is also commonly very long thereby limiting the sample 
throughput. Although only small volume of sample is required for GC-MS analysis (1-5 μL), 
it requires extensive sample cleanup before analysis.  
1.7.3 Liquid chromatography-mass spectrometry 
In the 1980s, the development of liquid chromatography (LC)  technology coupled with MS 
provided a much simpler and faster analysis of steroid compared to the GCMS (Liberato et al. 
1987). To date, LC-MS/MS is now considered the most accurate method to measure small 
molecules from variety of biological matrices (Xu et al. 2007). The LC consists of pumps that 
delivers mobile phase under high pressure to maintain a constant flow rate thereby ensuring 
reproducible chromatography. Mobile phase for steroids separation consist of a mixture of 
organic solvents (e.g. methanol and acetonitrile) and water with modifiers (e.g. formic acid, 
ammonium acetate, ammonium formate). Samples injected into the column (stationary phase) 
separates the steroids and the effluent is then transferred into the MS. The LC separation is 
dependent on the physical or chemical characteristics of the analytes such as molecular size 
and presence of functional groups.   
LC-MS analysis is highly sensitive and specific for steroid quantitations. A robust 
LC-MS method to quantitate steroids requires high quality chromatography to separate the 
steroid of interest from isobaric compounds (i.e. identical nominal mass to charge ratios) 
(Keevil 2013). Examples of isobaric compound pairs include cortisone/prednisolone, 
testosterone/DHEA and 11-deoxycortisol/corticosterone. However, separating these isobaric 
or interfering compounds may increase the assay runtime and requires more mobile phase. 
Multiple analytes can be measured with lesser sample preparation compared to GC-MS. 
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Additionally LC-MS steroid profile provides more useful data than single steroid 
measurement such as from using immunoassay. With the LC-MS system, the analysis 
operates at low temperature which is beneficial for measurement of unstable analytes such as 
conjugated steroids and thermolabile steroids (Borts and Bowers 2000, Bowers 1996). 
Derivatization step is added to increase the sensitivity of LC-MS methods for certain steroids 
analysis especially for analytes that are not effectively ionized such as estradiol and DHEA 
(Kushnir et al. 2008) (Table 1.3). Derivatization reagent reacts with a functional group (eg 
hydroxyl) to improve column retention and ionization efficiency (Xu et al. 2011). Dansyl 
chloride is commonly used for hydroxyl group to esterify estrogens (Nelson et al. 2004, Xu et 
al. 2005). However, derivatization for LC-MS adds complexity to the method, possibility of 
artifact formation and requires certain functional groups (Ja  ntti et al. 2010, Xu et al. 2010). 
Unlike GC-MS, the LC-MS has generally shorter run time and is not limited to measurement 
of volatile compounds and is able to measure heat-labile steroidal compounds.  
The LC is combined with ionization source that ionizes compounds delivered by the 
LC in liquid droplet. The atmospheric pressure ionization (API) which was introduced in the 
1980s facilitates ionization for MS analysis. Ionization techniques commonly used for 
steroids LC-MS/MS analysis includes electrospray ionization (ESI), atmospheric pressure 
chemical ionization (APCI) and atmospheric pressure photo ionization (APPI) (refer section 
1.8.2 for details on ionization interface). The ESI, APCI and APPI are considered as “soft” 
ionization technique as they form protonated or de-protonated molecules without 
fragmentation (Souverain et al. 2004). This type of ionization is achieved by transferring 
minimum internal energy to the analytes during ionization (El-Aneed et al. 2009). However, 
conjugated steroids could be fragmented by the ion source (Field 2013). 
The ionization technique selected for LC-MS method is dependent on the molecular 
weight and the polarity of the analytes (Figure 1.14). APCI and APPI are known to be less 
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susceptible to ion suppression or enhancement due to matrix effect as the ionization occurs in 
gas phase compared to ESI (liquid phase ionization) (Elviri et al. 2010, Holčapek et al. 2010). 
However, ionization with APCI is not completely free from ion suppression for certain 
compounds and the analyst should perform through investigation on ionization technique 
selection during method development (Sangster et al. 2004). Table 1.3 shows different 
ionization techniques used in previous studies to determine free and conjugated steroids 
measurement using MS. 
 
 
 
 
 
 
 
  
Figure 1.14 Ionization capabilities of ESI, APPI and APCI according to the 
molecular weight and polarity of the analytes (Holčapek et al. 2010).  
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Table 1.3 Examples of endogenous steroids analysis by GC/LC-MS. 
Analyte Analytical 
method 
Biological 
Matrix 
Sample preparation Derivatization Deconjugation Assay 
validation 
LOD/LOQ Reference 
T,  ET,  A, Etio, DHEA 
(Sulfates and 
glucuronides )  
LC-ESI-
MS/MS 
(- mode) 
Urine 
(human) 
SPE (Oasis WAX) No No Yes Not reported  (Strahm et 
al. 2008) 
T, E, DHEA, DHT, 
5α3α17β, 5β3α17β, 
5A3β17α, 5A3β17β, 
EpiA, A, Etio  
GC-MS Urine (human) SPE (C18) ITMS/MSTFA Chemical and 
Enzymatic 
(E.coli) 
Partial Not reported   (Dehennin 
et al. 1996) 
ADT, CORT, E1, E2, 
E3, T,  5AD, ALD, 
17OHPreg, DHEA, 
5αDHT, 5βDHT, P5, 
THS, DOC, 5a-THB, 
HC, S, M, 2-OH E1; 
16α-OH E1, 17-OHP, 
A4  
LC-ESI-
MS/MS 
(+ mode) 
Urine (human) SPE (Oasis HLB) DMAB (all 
steroids accept 
for P5, 17-OHP, 
A4) 
No No LOD:  5-500 
pg/mL  
(Dai et al. 
2012)  
15 estrogen and 
estrogen 
metabolites  
LC-ESI-
MS/MS 
(+ mode) 
Urine (human) LLE 
(dichloromethane) 
Dansyl chloride Enzymatic 
(H. pomatia) 
Partial LOQ: 0.04 
ng/mL  
(Xu et al. 
2005)  
23 estrogens, 
androgens and 
pregnanes  
(free/glucuronide 
conjugated)  
LC-ESI-
MS/MS 
(+ mode for 
all steroids 
except 
pregnandiol) 
Urine (primate) LLE 
(MTBE) 
No Chemical and 
Enzymatic 
(E.coli) 
Yes LOQ: 0.3-3 
ng/mL  
(Hauser et 
al. 2008)  
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E1, E2, E3, P4, P5 LC-ESI-
MS/MS 
(+ mode for 
P4 and P5, - 
mode for 
estrogens) 
Urine (human) Online SPE (C18) No Enzymatic 
(E.coli) 
Partial 6-61 pg on 
column  
(Alvarez 
Sanchez et 
al. 2008)  
T, ET, DHEA, A, Etio 
(free, sulfates and 
glucuronides)  
LC-MS/MS (+ 
mode for free 
steroids and 
– mode for 
sulfates and 
glucuronide 
staeroids) 
Urine (bovine 
and human) 
SPE (Strata X) No No No LOD: 80-100 
ng/mL  
(Buiarelli et 
al. 2004)  
TG, ETG, AG, EtioG  LC-ESI-
MS/MS 
Urine (human) Filtration or LLE (ethyl 
acetate) 
No No Yes Filtration 
method: 0.25-
1 ng/mL  
LLE method: 
0.05-0.25 
ng/mL  
(Pozo et al. 
2008)  
AG, TG, E23G, E2-
17G, E2-3G,17diG, 
DHEAS, TS, E1S, E2S, 
E2-3G17S, E2-
3S17G, CRLG, CRLS, 
CRNS 
LC-ESI-
MS/MS 
(-mode) 
Urine (human) SPE No No No Not reported  (Antignac et 
al. 2005)  
E1, E2  LC-APPI-
MS/MS 
(- mode) 
Tissues, serum 
(human) 
Tissue homogenization 
(water), LLE 
(hexane:ethylacetate) 
No No Yes LOQ: 2.5-5.0 
pg/mL  
(Huhtinen 
et al. 2012)  
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T, DHT, 3α-diol, 3β-
diol,  E2, E1  
LC-APPI-
MS/MS 
(- mode: 
estrogens; 
+ mode: 
androgens) 
Tissues 
(Mouse testis, 
prostate, 
ovary, uterus 
Tissue homogenization 
(EDTA in PBS), LLE 
(hexane:ethyl acetate) 
No No Yes LOQ: 0.3-40 
pg  
(McNamara 
et al. 2010)  
E1, E2, E3, 17βT, 
17αT, 5βDHT, 
5αDHT, A, Etio  
GC-MS/MS 
(- mode: 
estrogens; + 
mode: 
androgens) 
Serum (human) LLE (ether), 
SPE (ChromP), SiOH SPE 
column, HPLC 
MSTFA-TNIS-
DTT mixture 
  
Enzymatic 
(H.pomatia) 
Yes LOD: 0.03-1.8 
pmol/L 
LOQ: 0.07-3.7 
pmol/L  
(Courant et 
al. 2010) 
DHEAS, A, 
F, CORT, S  
A4, E2, T, 17α-OHP, 
DHEA, P4  
LC-APPI-
MS/MS 
(- mode: A; + 
mode:  all 
other 
steroids 
studied) 
Serum 
(human) 
PP (ACN) No No Yes LOD: 1.5-10 
pg/mL  
(Guo et al. 
2006) 
Seven C-21 adrenal 
steroids 
LC-APCI-
MS/MS (+ 
mode) 
Serum 
(human) 
PP (ZnSO4/MeOH) 
Online extraction C18 
silica monolithic  pre-
column 
No No Yes LOD: 0.10-
2.75 nmol/L) 
LOQ: 0.30-
12.40 nmol/L)  
(Carvalho et 
al. 2008)  
DHEAS, F, A4, E3, P4, 
DHEA, S, 17α-OHP, 
E2  
LC-APPI-
MS/MS (+ 
mode) 
Serum 
(human) 
PP (ACN) No No Yes Not reported  (Guo et al. 
2004) 
E1, E1S, E2, E13G, 
E2, 2MeOE1,  
2MeOE2  
TS-LC-MS/MS  
(- mode) 
Serum (human) LLE and SPE (Strata X) No No Partial Not reported (Caron et 
al. 2009)  
                                                                                                                                                                                                                                                                      Chapter 1 
 
        62 
 
17OHP, T, A4 LC-APCI-
MS/MS 
(+ mode) 
Plasma/ 
Serum 
(human) 
Online SPE (Oasis HLB) No No Yes LOD: 0.14-
0.17nmol/L 
LOQ: 0.30-
0.35 nmol/L  
(Rauh et al. 
2006) 
A4, T, DHT LC-ESI-
MS/MS 
(+ mode) 
Plasma SPE (Oasis MAX) No No Yes LOQ: 0.29 
ng/dL  
(Kulle et al. 
2010)  
A4, T, DHT  LC-ESI-
MS/MS 
(+ mode) 
Cultured 
human cell 
lines 
Online SPE (C4-alkyl-diol 
silica) 
No No Yes Not reported  (Chang et 
al. 2003) 
T, DHEA  LC-ESI-
MS/MS 
(+ mode) 
Saliva (human) SPE (Strata-X) HMP No Yes LOQ: 10 
pg/mL  
(Shibayama 
et al. 2009) 
17OHPreg, 17OHP  LC-ESI-
MS/MS 
(+ mode) 
DBS 
(human) 
SPE (Strata-X) HP No Yes LOQ: 0.5-1 
ng/mL  
(Higashi et 
al. 2008)  
CORT, DOC, P4, 17α-
OHP, F, DF, A4, T, 
DHT, F  
LC-ESI-
MS/MS 
(+ mode) 
DBS 
(human) 
LLE (acetone/ACN) No No Yes LOQ: 0.75-6.3 
nmol/L  
(Janzen et 
al. 2008) 
 
 
 
 
 
Abbreviations: HMP: 2-hydazino-1-methylpyridine; HP: 2-hydrazinopyridine; DMAB: 4-Dimethlamino-benzoic acid; ACN: acetonitrile; MTBE: methyl tert-butyl ether; MSTFA-TNIS-DTT: N-methyl-
N-(trimethylsilyl-trifluoroacetamide/trimethyliodosilane/dithiothreitol; T: testosterone; ET: epitestosterone; A: androsterone; M: mesterolone; Etio: etiocholanolone; DHEA: 
dehydroepiandrosterone; E1: estrone; E2: Estradiol; E3: estriol; 2-OH E1: 2-hydroxyestrone; 16α –OH E1; 16α-hydroxyestrone ; E1S: Estrone sulfate; E13G: Estrone glucorunide; 2MeOE1: 2-
methoxy estrone; 2MeOE2: 2-methoxy estradiol: CORT: corticosterone; A4: Androstenedione; ADT: Androsterone; ALD: Aldosterone; P5: pregnenolone; 17α-OHP: 17α-hydroxyprogesterone; 
17OHPreg: 17αhydroxypregnenolone; P4: progesterone; S: 11-Deoxycortisol; 21-Deoxycortisol: DF ; deoxycorticosterone: DOC; F:Cortisol;  THS: tetrahydrodeoxycortisol; 5a-THB: 5a-
tetrahydrocorticosterone; HC: Hydrocortisone; 17α-OHP: 17α-hydroxyprogesterone; E: epitestosterone; 5AD: 5-androstenediol; 5α3α17β: 5α -androstane-3 α,17β-diol; 5β3α17β: 5β-
androstane-3 α,17β-diol ; 5A3β17α: 5androstane-3 β;17α –diol; 5A3β17β: 5androstane-3 β,17 β –diol; EpiA: epiandrosterone; AG: 5-androstane-17-glucuronide; TG: testosterone-17-
glucuronide; E2-3G: 17-estradiol-3-glucuronide; E2-17G: estradiol-17-glucuronide; E23,17diG: estradiol-3,17-diglucuronide; DHEAS: dehydroepiandrosterone sulfate; TS: testosterone-17-sulfate; 
E2-3S: 17-estradiol-3-sulfate; E2-3G17S: estradiol-3-glucuronide,17-sulfate; E2-3S17G: estradiol-3-sulfate,17-glucuronide; CRLG: cortisol 21-glucuronide; CRLS: cortisol 21-sulfate; CRNS: cortisone 
21-sulfate; TS: Turbo IonSpray; ESI: electrospray ionization; APCI: atmospheric pressure chemical ionization; APPI: atmospheric pressure photoionization; LC: liquid chromatography; GC: gas 
chromatography; MS: mass spectrometry; SPE: solid phase extraction; LLE: liquid-liquid extraction; PP: protein precipitation; LOD: lower limit of detection; LOQ: lower limit of quantitation: 
HPLC: High performance liquid chromatography; DBS: dried blood spot 
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Table 1.4 Examples of immunoassay and GC/LC-MS comparative studies for quantitation of testosterone (T) and estradiol (E2). 
Analyte Analysis technique 
comparisons 
Samples 
(number) 
Findings Reference 
T GC-MS versus 10 
immunoassay (8 direct  
non-isotopic immunoassays 
and 2 direct RIAs) 
Serum from 
normal 50 men, 
55 women and 
11 children 
• Men: Immunoassays underestimate T with 12% below GC-MS measurement.  
• Women: Degree of bias significantly higher in women with 46% above GC-MS 
concentration.  
• Children: Immunoassays measured higher T concentration for undetectable  GC-MS levels 
(< 4.3 ng/dL).  
(Taieb et al. 
2003)  
T LC-API- MS/MS versus 6 
immunoassays (4 
automated and 2 RIAs) 
Serum from 62 
normal and 60 
hypogonadal 
male. 
• Deming regression demonstrated variability (underestimation or overestimation) of T 
measurements with most of the immunoassays studied compared to LC-MS/MS. 
• 90% of the samples measured with immunoassays demonstrated T concentrations of more 
than 20% from LC-MS/MS measurements.      
(Wang et al. 
2004) 
T LC-ESI- MS/MS versus 5 
immunoassays (2 
automated non-isotopic and 
3 RIAs) 
Serum from 28 
children and 31 
women 
• Immunoassays overestimated T concentration and unreliable for T below 100 ng/dL.  (Moal et al. 
2007) 
T LC-APCI- MS/MS versus 
one automated 
immunoassay 
Serum/plasma 
from 107 
children  
• Immunoassay underestimated T for samples with concentrations >5 nmol/L. 
• High variability samples with T <5 nmol/L determined by immunoassay. 
(Rauh et al. 
2006) 
T GC-MS versus 7 automated 
immunoassays 
Serum from 124 
healthy men 
• Deming and Passing-Bablok regression demonstrated variability in six immunoassays with 
significant difference in slope and intercept when compared to GC-MS measurements.  
• Reported wide variability in immunoassay performance against valid healthy young men 
reference population. 
(Sikaris et al. 
2005) 
E2 LC-APPI-MS/MS versus 5 
direct non-isotopic 
immunoassays 
Serum from 101 
healthy older 
men 
• Only three immunoassays were able to measure E2 concentrations in all the samples.  
• Upward bias ranging between 6 and 74% for E2 measured with immunoassays compared 
LC-MS/MS (method certified with 3 certified reference materials).  
(Handelsman 
et al. 2014) 
E2 GC-MS/MS versus 7 
immunoassays (3 indirect 
and 4 direct assays) 
Serum from 40 
postmenopausal 
women 
• The three indirect assays that involve extraction prior to assays demonstrated better 
correlation (0.94, 0.91 and 0.88) with GC-MS/MS measurements compared to the 4 direct 
assays (without extraction).  
(Lee et al. 
2006) 
                                                                                                                                                                   Chapter 1 
 
   64 
 
1.8 Mass spectrometry 
All MS comprise of four basic components - the inlet, ion source, mass analyzer and detector 
(Figure 1.15). Six basic types of mass analyzers are currently available. These includes 
quadrupole, ion trap, time-of-flight (TOF), Orbitrap, double focusing magnetic analyzer and 
Fourier transform ion cyclotron resonance (FT ICR) (Holčapek et al. 2010). Each has 
different mass accuracy, mass resolution parameters and capability to measure different of 
mass-to-charge (m/z) range (Holčapek et al. 2010). Recent advancement to the MS with 
higher mass resolution allowed separation of co-eluting isobaric compounds that have the 
same nominal masses but different exact masses (Xian et al. 2012). The mass analyzer 
measures gas phase ions according to their m/z ratio, where the charge is produced by 
addition or loss of proton(s), cation(s), anion(s) or electron(s). Utilizing electrical fields, these 
charged molecules are separated according to their m/z that further allows its mass 
measurements. Table 1.5 lists the basic principles of the six mass analyzers in use today. The 
most common mass analyzer for quantitative steroid analysis is the triple quadrupole 
instrumentation which is also known as tandem MS (Keevil 2013, Rauh 2010).  
1.8.1 Triple quadrupole mass spectrometer 
The triple quadrupole MS consists of two resolving quadrupoles (Q1 and Q3) and a collision 
cell positioned in between the quadrupole (Q2) (Kushnir et al. 2011). Sample steroids 
separated by the LC are first ionized by the ion source before further transfer into the mass 
spectrometer where the first quadrupole monitors the precursor ions. The analyte(s) of 
interest (precursor ion) is selected at Q1 according to the m/z ratio and all other compounds 
are filtered out. Then, the second quadrupole (collision cell) performs the collision between 
the collision gas (e.g. argon, helium and nitrogen) and the introduced steroids producing 
fragmented or product ions. Finally, the third quadrupole monitors the product ions of the 
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steroids according to the radiofrequency set and removes the unwanted fragment ion. The 
targeted precursor and product ion finally reaches the ion detector (Figure 1.15).    
New LC-MS/MS method development requires infusion of the standard steroid 
reference and its isotope labeled internal standard separately using a syringe pump and a ‘tee 
mixer’ to introduce the analyte into the LC mobile phase and the ion source. Analyte 
quantitation can be carried out by two common techniques, selected-ion-monitoring (SIM) or 
multiple-reaction-monitoring (MRM), which are commonly used for a single or triple 
quadrupole mass spectrometer, respectively. MRM (also known as selected-reaction-
monitoring; SRM) mode provides high selectivity and sensitivity compared to SIM. High 
background chemical noise in SIM mode caused by isobaric compounds and impurities leads 
to lower signal to noise ratio (S/N) for the target analyte (Bakhtiar and Majumdar 2007). The 
analyte of interest should be tested in positive or negative ion modes to determine the most 
suitable and efficient ionization conditions with highest S/N ratio. For MRM, the specific ion 
transition for each analyte is selected based on precursor ion and product ions pairs, which is 
then used for quantitation of steroids from the biological samples (Shibata et al. 2014). 
During the method development, other MS parameters such as ion source voltage and 
temperature, collision cell energy, declutering potential, entrance potential, collision cell exit 
potential and dwell time are optimized. Biological samples have to be pretreated prior to 
sample quantitation by MS and the method has to be validated for limit of quantitation (lower 
and upper), accuracy and precision, recovery, reproducibility, stability and matrix effect 
according to the appropriate guidelines such as US Food and Drug Administration guidance 
(FDA 2001) or European Medicines Agency (EMA 2011).    
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Mass analyzer                  Main principles 
Quadrupole  •   Consist of four metal rods installed in parallel orientation 
•   RF and DC voltages applied to rods guide the ions with desired m/z ratios to pass through and move towards the detector while  
  other molecules are guided out and neutralized 
•   Mass range: <4000 Da; Resolution: <4000 
Ion trap  •   Consist of three hyperbolic electrodes: ring, entrance and exit end cap electrode 
•   RF and DC potential applied to the ring electrode produces 3-dimensional quadrupolar potential field 
•   The ions losses kinetic energy and are trapped forming an ion “cloud” 
•   Ions are ejected according to their m/z ratios into the detector 
•   Mass range: <4000 Da; Resolution: <4000 
Time-of-flight  
(TOF)  
•   Ion generated by ion source is accelerated into flight-tube 
•   Smaller ions travel faster compared to molecules with higher mass 
•   Molecules with different m/z travel at different time intervals into the detector  
•   Mass range: >1 MDa; Resolution: 4000  
Orbitrap  •   Consist of two electrodes: outer electrode (barrel shape) and inner electrode (spindle shape) 
•   DC voltage applied  
•   Ions are pulsed into the orbitrap, rotates around the central electrode and oscillate along the horizontal line   
•   m/z of different ions are determined from different frequencies of the oscillation by Fourier transform  
•   Mass range: <6000 Da; Resolution: 150,000 
Double focusing  
magnetic analyzer  
•   Involves two sectors: electrostatic and magnetic 
•   Ions with same kinetic energy are directed from electrostatic sector (act as a kinetic energy selector) to the   
                  magnetic sector before ion separation and detection  
•   Mass range: 10,000 Da; Resolution: 60,000  
Fourier transform  
ion cyclotron resonance 
(FT ICR)  
•   Consist of an analyzer cell (or known as Penning trap) with two excitation, detection and trapping plates each 
•   Analyzer cell is located within strong magnetic field 
•   Ions generated by ion source moves into the analyzer cell and RF applied to the excitation plates causes excitation of the ions  
•   Ions starts to precess in center of magnetic field resulting it to orbit (known as cyclotron motion) 
•   Ions with lower m/z have higher cyclotron frequencies compared to ions with higher m/z 
•   Ion packets frequencies are detected by the detection plates and the frequency analysis is performed using Fourier transformation 
•   Frequencies are converted to m/z to give a mass spectrum.  
•   Mass range:  10,000 Da; Resolution: >500,000  
 Abbreviations: RF: radiofrequency; DC: direct current; m/z: mass/charge  
Table 1.5 Basic principles of different types of mass analyzers 
(Barrow et al. 2005, El-Aneed et al. 2009, Glish and Vachet 2003, Ho et al. 2003, Hu et al. 2005, Moens and Jakubowski 1998, Nikolaev et al. 2014, Vogeser and Parhofer 2007).  
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Figure 1.15 Representation of precursor ion and product ion selection of MS1 and MS2, 
respectively in the tandem mass spectrometer 
 
1.8.2 Ionization interfaces 
The eluent from the LC column must be effectively converted into gaseous phase before 
being measured by the MS. Since the introduction of electrospray ionization (ESI), 
atmospheric pressure chemical ionization (APCI) and atmospheric pressure photoionization 
(APPI), LC-MS/MS has become widely used for steroid analysis with superior sensitivity and 
specificity (Table 1.3).  
1.8.2.1 Electrospray ionization (ESI) 
This ionization method, developed by Fenn and co-workers in 1988 (Fenn et al. 1989), led to 
award of a Nobel Prize in Chemistry to Fenn in 2002. ESI technique is based on the 
production of ions from liquid phase into gas phase by the dispersal of highly charged 
droplets at near atmospheric pressure followed by the formation of evaporated droplet. The 
LC mobile phase is sprayed from the tip of the metal capillary. The needle is applied with 
high voltage typically between 3-5 kV that leads to the formation of Taylor cone (Taylor 
1964) (Figure 1.16). A fine spray of highly charged droplets is generated which then 
undergoes rapid evaporation due to heat and dry nitrogen (desolvation gas). The ion polarity 
is controlled by adjusting the capillary voltage that forms either positive or negative charged 
(El-Aneed et al. 2009). 
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ions. Evaporation of the solvent further reduces the droplet diameter and increases the droplet 
surface charge density. The parent droplets undergoes “Coulomb explosion” or “Coulomb 
fission” when the electrostatic forces overcome the surface tension of the droplets (Rayleigh 
limit is reached) forming smaller offspring droplets. This process continues until the charged 
analyte molecules escapes the droplets by field desorption and these analyte ions are guided 
into the mass analyzer by the electric field gradient (Banerjee and Mazumdar 2012, Gomez 
and Tang 1994) (Figure 1.16). To facilitate ionization, the presence of ionic solution is 
important. Mobile phase consisting of methanol/water or acetonitrile/water containing weak 
acids such as formic or acetic facilitate protonation (for positive mode ionization), whereas 
diluted ammonium hydroxide in aqueous solution or diluted volatile buffers (ammonium 
acetate or formate) facilitates deprotonation (for negative mode ionization) (Cech and Enke 
2001). ESI is a soft ionization technique (i.e. non-disintegrating) suitable for polar 
compounds such as labile conjugates (glucuronides and sulfates) (Figure 1.14)  (Kostiainen et 
al. 2003) or compound that forms charged adduct with ammonium or alkali cations 
(Himmelsbach 2012). The LC-ESI-MS/MS method is able to measure steroids in free and 
conjugated forms simultaneously (Moeller and Stanley 2012). However, steroids are 
commonly measured after hydrolysis, which is enzymatic or chemical deconjugation. 
Steroids with high proton affinity such as androgens, glucocorticoids and mineralocorticoids 
are easily ionized with ESI source due to the 3-oxo-4ene structure (Shibata et al. 2014). 
Derivatization is commonly carried out to improve ESI ionization efficiency and sensitivity 
for trace steroids or steroids with low ionization potential. Although derivatization may 
increase the sensitivity of steroids measurement for LC-ESI-MS methods (1-10,000 fold) 
(Dai et al. 2012) (Table 1.3), the derivatization step increases sample preparation time, causes 
loss or degradation of target steroids and increases “noise” (Higashi and Shimada 2004, Mao 
et al. 2004, Santa 2011).  
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Figure 1.16 Schematic diagram of ESI source. 
 
 
1.8.2.2 Atmospheric pressure chemical ionization (APCI)   
This is a chemical ionization process that ionizes analytes in gas phase. Mobile phase and 
analytes are first vapourized in the ion source with heat (from the nebulizer probe) and 
nebulizing gas flow. A sharp needle is positioned directly in the forming gas cloud and this 
needle generates electron from corona discharge which bombards the vapour. Solvent 
molecules become charged and the electrical charge is transferred to the analyte molecules 
(Figure 1.17). The LC mobile phase commonly used is a mixture of water and organic 
solvent (e.g. methanol and acetonitrile) which forms either protonated or deprotonated ions of 
these solvents that transfers their charge to ionizable analytes. APCI is preferred over ESI for 
steroid analysis as it is capable of ionizing non-polar or poorly ionized compounds (Kushnir 
et al. 2010) (Figure 1.14). 
 
 
 
The highly charged capillary releases charged droplets. Size of the droplets decreases with the 
desolvation process and further droplet fission produces the gas phase analyte ions (Banerjee 
and Mazumdar 2012, Robb and Blades 2008).   
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1.8.2.3 Atmospheric pressure photoionization (APPI) 
This is a newer API source for LC-MS that also operates by chemical ionization in gas phase. 
Similarly to APCI, the solvent first undergo vaporization as it passes the heated nebulizer. 
Instead of the corona discharge needle used in APCI source, krypton lamp produces 
ultraviolet (UV) light that induce ionization via emission of photons in vacuum (Figure 1.18). 
The analyte ionization in this system is enhanced with the addition of dopant such as toluene 
and acetone that is involved in the chemical ionization (Robb and Blades 2006). Krypton 
lamp delivers photons energy (hv) of 10.0 and 10.6 eV and only ionizes ions with lower 
ionization energy (IE) including the dopant (e.g. toluene IE: 8.82 eV). Common LC mobile 
phase such as water (12.61 eV), methanol (10.85 eV) and acetonitrile (12.19 eV) with IE 
above the lamp photons hv are not ionized therefore do not aid analyte ionization (Robb and 
Blades 2008). APPI produces charged ions via two mechanisms: (1) direct photoionization of 
analyte by absorbing a photon of light from Krypton emission, (2) the dopant ionized by the 
UV lamp form free radicals followed by the reaction with the analyte by charge exchange 
(non-polar compounds) or proton transfer (polar compounds) (Robb and Blades 2006) 
(Figure 1.19). APPI ionization is more suitable for compounds with mid to low-polarity that 
 
Figure 1.17 Schematic diagram of APCI source (Grebe and Singh 2011). 
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cannot be ionized by ESI and APCI (Figure 1.14). The sensitivity of APPI for steroid 
measurement in biological matrices is 3-5 fold higher than APCI (Alary 2001). Table 1.6 
summarizes the properties of ESI, APCI and APPI.   
 
Figure 1.18 Schematic diagram of APPI source 
 
 
 (Robb and Blades 2008). 
 
Figure 1.19 Schematic diagram of APPI ionization mechanism. 
Adapted from http://www.chem.agilent.com/Library/technicaloverviews/Public/5990--
7413EN.pdf 
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Table 1.6 Summary of ionization techniques (ESI, APCI and APPI) commonly used for steroid LC-MS/MS analysis 
 ESI APCI APPI 
Ionization reaction phase  Liquid Gas Gas 
Compound suitability  
(common mass range)  
Polar and ionic compound  
(less than 100,000 Da) 
Neutral or less polar 
(less than 1500 Da) 
Mid to low polarity 
(less than 1500 Da) 
Ideal compounds  non-volatile chargeable large 
molecules e.g. protein, peptide, 
polysaccharide, bile acids, steroid 
conjugates 
Volatile, thermally stable and small 
molecules 
e,g. non-polar lipids, pesticides, 
drugs, steroids with conjugated 
double bond or keto group 
Volatile, thermally stable and small 
molecules 
e.g. polycyclic aromatic 
hydrocarbons, drugs, non-polar 
lipids, pesticides, steroids with 
conjugated double bond and low 
polarity (pregnanes) 
Matrix interference  More prevalent compared to APCI 
and APPI 
 
Less prevalent compared to ESI 
 
Less prevalent compared to ESI and 
APCI 
Suitable flow rate  Few µL/min (operates at very low 
flow rate) 
Up to 2 mL/min Suitable for both low and high flow 
rates 
Suitable solvents  Polar and medium polar Polar and  non-polar Polar and  non-polar 
Abbreviations: ESI: electrospray ionization; APCI: atmospheric pressure chemical ionization and APPI: atmospheric pressure photoionization 
(Bakhtiar et al. 2002, Bos et al. 2006, Cech and Enke 2001, Kostiainen and Kauppila 2009).  
 
                                                                                                                                                                   Chapter 1 
 
   73 
 
1.8.3 Matrix effect 
Urine, whole blood, serum, plasma and saliva are matrices commonly used for bioanalytical 
analysis. These matrices contain endogenous (e.g. phospholipids, salts, urea, amines and 
metabolites) and exogenous substances (e.g. buffers, anticoagulants, polymers from 
collection tubes, drugs and chemicals) that may co-elute with the compound of interest that 
may lead to ion suppression or enhancement (Antignac et al. 2005, Matuszewski et al. 1998, 
Mei et al. 2003). This phenomenon, known as matrix effect is defined as “The direct or 
indirect alteration or interference in response due to the presence of unintended analytes (for 
analysis) or other interfering substances in the samples” (Shah et al. 2000). It is important to 
identify and eliminate matrix effect using adequate validation procedure for bioanalytical 
method development as matrix effect dramatically affects the LC-MS method performance 
(especially for quantitative analysis) in terms of detection capabilities, reproducibility, 
linearity, selectivity, accuracy and limit of quantitation, leading to erroneous results (Gosetti 
et al. 2010, Trufelli et al. 2011).   
For LC-MS analysis, matrix effects can be assessed either by post-column infusion 
(qualitative), post-extraction spike method (quantitative) or assessment of “relative” matrix 
effect (also known as standard line-slope method). The post-column infusion assessment 
involves simultaneous injection of sample extract and continuous infusion of analyte into the 
LC-MS/MS system. This assessment allows identification of the chromatographic region that 
could possibly be affected by matrix effects and appropriate changes should be made to the 
elution condition to shift the analyte of interest retention time away from the area affected in 
the chromatogram (Bonfiglio et al. 1999). However, this assessment does not provide the 
degree of matrix effect that is affecting the analyte quantitatively and is time consuming 
especially for optimizing a method with multiple analytes.  
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Post-extraction spike method is based on the response of analyte spiked after sample 
preparation against neat standard solution and is expressed as a percentage, with values above 
or below 100% indicates ion enhancement or suppression, respectively  (Matuszewski et al. 
2003). This method allows quantitative assessment for ion suppression or enhancement of 
multiple analytes simultaneously. The presence of matrix effect can also be determined by 
“relative” matrix effect assessment by directly comparing standard line slopes (made from 
five different lots of a biofluid) constructed using identical compound, IS, sample preparation 
and chromatographic conditions. The standard line slopes and precision of the slopes were 
calculated to determine the absence or presence of “relative” matrix effect on the 
quantification of the analytes assessed. For a method to be acceptable (free from matrix 
effect), the precision value of the standard line slopes should not exceed a cut-off value of 3-
4% (Matuszewski 2006). Figure 1.20 illustrates the block diagram and MS chromatogram for 
the two most commonly used matrix effect assessments: post-column infusion and post-
extraction spike.  
The degree of interference caused by matrix effect in LC-MS analysis does not only depend 
on the sample matrix. Selection of sample preparation, mobile phase, reagents, 
chromatographic separation and ionization interface used for the LC-MS method developed 
also influences the extent of matrix effect (Annesley 2007, Chambers et al. 2007). There are 
steps that can be taken to overcome matrix effects such as appropriate modification to a 
cleaner sample preparation technique, sample dilution (limited by the method sensitivity and 
not suitable for monitoring trace compound), use of smaller sample volume (also limited by 
the method sensitivity) and utilization of stable labelled internal standard. Matrix effect can 
also be minimized by using lower LC flow rate, so that the ion source is exposed to lesser 
amount of contaminants. Other strategies include to separate the interfering compound from 
target analyte(s) by changing the chromatographic conditions and if possible, use other 
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ionization technique that minimizes matrix effects (Chambers et al. 2007, Van Eeckhaut et al. 
2009). Selection of appropriate MS ionization source (ESI, APPI, APCI) and mode (positive 
or negative) may also eliminate matrix effects (Hsieh et al. 2001, Janzen et al. 2008, 
Matuszewski et al. 1998, Mei et al. 2003).  
Ion sources are prone to different degree of signal suppression or enhancement mainly 
because of difference in the ionization mechanisms (Himmelsbach 2012). A comparative 
study of LC-MS/MS method using three different ion sources, ESI, APCI and APPI for 
estradiol analysis in human serum and endometrial tissue demonstrated that ESI efficiently 
ionizes estradiol in negative polarity but estradiol is highly susceptible to ion suppression 
compared to the latter two ion sources (Keski-Rahkonen et al. 2013). APCI is also susceptible 
to signal suppression due to matrix effect but at a lower degree compared to ESI especially in 
the presence of hydrophobic interferences (Dams et al. 2003, Matuszewski 2006). For ESI, it 
is postulated that the signal suppression occurs when the analyte of interest competes for 
charge with co-eluting analyte. The co-analyte that has higher gas-phase proton affinity will 
be protonated first therefore reducing the intensity of the target analyte (Matuszewski et al. 
2003). This is not the case for APPI, where its ionization mechanism is not based on charge 
affinity, therefore is less susceptible to ion suppression compared to ESI and APCI (Chen et 
al. 2009, Chu and Letcher 2008). The presence of high concentration non-volatile compounds 
(e.g. salts, ion-pairing agents, drugs) in the extracted sample matrix also lead to ion 
suppression by decreasing the ESI efficiency to form droplet and prevent evaporation (King 
et al. 2000). Furthermore, ESI is more susceptible to ion suppression in the presence of more 
polar analytes and the presence of molecules with higher mass that suppresses the signal of 
smaller molecules (Bonfiglio et al. 1999, Sterner et al. 2000). On the contrary, ion 
enhancement is caused by overlap of ions with specific m/z ratios, thus proper fragment ions 
selection with different combination of m/z may resolve the problem (Trufelli et al. 2011). 
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The degree of ion suppression differs between sample, compound and sample preparation 
(Bonfiglio et al. 1999).  
 
Figure 1.20 Matrix effects evaluation (a) post-column infusion and (b) post-extraction 
spike. 
  
 
 
 
 
 
a) For the post-column infusion, the analyte is infused into the LC stream using a ‘tee-mixer’ at a 
stable and constant flow to the MS ion source using an infusion pump. Sample extract (blank 
matrix) is injected via autosampler after extraction into the LC column. Elution of endogenous 
compound that interferes with the infused analyte will result in negative or positive peaks in 
the MS response due to ion suppression or enhancement, respectively. The arrow in the 
example above indicates ion suppression.  
b) In the post-extraction spike method, comparison is made between the signal response of 
standard in sample extract (indicated as full peak in the chromatogram above) against the 
response obtained from standards in neat solution (dashed line). A reduction or increase in the 
response indicates ion suppression or enhancement, respectively. Adapted from (El-Aneed et 
al. 2009, Van Eeckhaut et al. 2009) 
 
a. Post-column infusion 
b. Post-extraction spike 
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1.8.4 Sample preparation 
Sample pretreatment prior to LC-MS is required to reduce the complexity of the sample. 
Sample preparation is necessary for the development of highly sensitive, accurate and 
specific steroid LC-MS/MS analysis (Shibata et al. 2014). Sample preparation involves 
extraction of the steroids typically with an organic solvent followed by purification step to 
remove unwanted matrix component from biological samples. Protein precipitation (PP), 
liquid-liquid extraction (LLE) and solid phase extraction (SPE) are common methods to 
separate analytes from sample matrix. However, it is important to evaluate whether the 
sample preparation technique selected: (1) provides a cleaner extract instead of magnifying 
(pre-concentrate) matrix effect and (2) is appropriate for the biofluids analyzed (Dams et al. 
2003).  
 PP is achieved by adding solvent (e.g. acetonitrile, methanol and acetone) with low 
solubility and the precipitate of insoluble compounds is then separated from the soluble phase 
(e.g. centrifugation). The supernatant can be directly injected for analyte analysis or 
reconstituted in LC mobile phase before LC/MS analysis (Bakhtiar et al. 2002).  PP is 
generally preferred for MS analysis for its simplicity but generally does not provide clean 
extract as many endogenous compounds such as fatty acids, lipids, phospholipids and 
endogenous peptides remains in the extract (Chambers et al. 2007). This is particularly a 
problem for ESI where the interfering compounds competes and co-elute with the target 
analyte by interfering with the droplet desolvation process (Bakhtiar and Majumdar 2007, 
Chambers et al. 2007). This co-eluting compound may also form adducts or react with the 
analyte of interest and interfere with the signal intensity (Gosetti et al. 2010). Studies have 
combined PP with other sample preparation to achieve cleaner samples (refer Table 1.3 for 
examples) (Carvalho et al. 2008). Some laboratories utilize a LC divert valve to elute early 
eluting compounds such as unwanted endogenous substances and salts to waste before the 
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extract is directed to the MS that may reduces matrix effect and MS contamination (Harwood 
and Handelsman 2009).  
 SPE is also widely used sample extraction method and provide cleaner extracts in 
comparison to PP (Chambers et al. 2007, Dams et al. 2003). This method involves separation 
of compounds between mobile and stationary phases which can be carried out either off-line 
(manual extraction) or on-line (automated extraction that is directly connected to the 
chromatographic system). On-line separation is less labour-intensive and time consuming 
compared to off-line SPE. The separation mechanism for SPE is similar to analytical 
chromatography where the analytes are retained in the stationary phase through the reverse-
phase or ion exchanged SPE than removal of sample matrix followed by eluting the analyte 
with a strong organic solvent at the appropriate pH (Berrueta et al. 1995). Although SPE 
provides a cleaner extract compared to PP, studies have shown occurrence of matrix effect 
with this sample preparation method (Souverain et al. 2004). This is due to the pre-
concentration step that increases unwanted interfering substance together with the target 
analyte(s). Possible alternative to remove the pre-concentration step (i.e. direct injection or 
dilution) but this will reduce the sensitivity (Dams et al. 2003).  
 LLE is widely used for extraction of small molecules such as drugs and hormones 
which gives clean extracts with high reproducibility (Janzen et al. 2008, Souverain et al. 
2004, Xu et al. 2005). Besides being cost effective and highly selective, LLE sample 
extraction method is less susceptible to matrix effects compared to PP and SPE for common 
API ionization sources (Souverain et al. 2004). However, recovery of polar compounds has 
been reported to be low using LLE extraction depending on solvent pairs (Chambers et al. 
2007). This extraction method involves separation of analytes from biological sample based 
on two different solubility properties. Non-polar analytes in aqueous sample (biological fluid) 
are extracted using an immiscible solvent (e.g. ethyl acetate, methy tert-butyl ether and 
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hexane), with phase separation leaving the salts and proteins in the aqueous phase. Samples 
are normally vortex-mixed with the organic solvents followed by centrifugation to separate 
the solvent from aqueous phase. The organic solvent is recovered by freezing the aqueous 
phase or pipette. The organic layer is then dried and the residue that consist the analyte is 
reconstituted in the LC mobile phase. However, in some cases, the hydrophobic extract is 
directly injected upon method optimization (Medvedovici et al. 2011). The drawbacks of 
using LLE include low recovery for polar analyte and ionic compounds, multiple extraction 
steps may be required, difficulty to automate the extraction method and formation of 
emulsion in samples containing high levels of phospholipids that may affect the accuracy and 
extraction recovery of the target analyte (Leung and Fong 2014, Van Eeckhaut et al. 2009). 
Neutralizing compound with ionizable functional groups by adjusting the pH prior to organic 
solvent extraction helps to achieve high extraction recovery (Hendriks et al. 2007). Examples 
of studies utilizing different sample purification methods for MS steroid analysis are listed in 
Table 1.3. 
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1.9 Aims of study 
The overall aim of this study is to develop and validate sensitive LC-MS/MS assays for 
quantitative endogenous and exogenous steroids analysis from various biological matrices for 
specific clinical applications. Androgens (testosterone, DHT, nandrolone), pro-androgens 
(DHEA) and estrogen (17β-estradiol) were measured in various biological matrices including 
urine, serum and dried blood spots (DBS). LH was measured using validated ICL and IF 
assays for urine and serum. Urine is a preferred sample collection method as it provides 
convenience and is less intrusive especially for longitudinal field studies in children and 
adolescents. Urine sampling also avoids impracticality of multiple blood sampling for healthy 
volunteers and provides an integrated measurement especially for hormones secreted in 
pulsatile (LH) or diurnal (sex steroids in early puberty) manner. DBS is also a less invasive 
sampling method that requires only small volume of blood, simplified sample processing and 
is cost effective (i.e. shipping and sample storage without needing refrigeration). DBS 
sampling method is suitable for long-term pharmacological studies because the samples can 
be collected by the patients themselves with minimum training without the need of frequent 
visits to the clinic.  
The specific aims of this thesis were: 
I. To determine whether an androgen ester (nandrolone decanoate) marketed for 
intramuscular injection can be delivered effectively and safely as subcutaneous 
injection. To achieve this aim, DBS sampling method was optimized and LC-MS/MS 
method was developed and validated to measure testosterone and nandrolone from 
DBS.  
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II. To determine whether commercially available IF and ICL LH immunoassays 
optimized for blood samples can be used for urine samples kept after prolonged 
frozen storage.  
III. To determine whether first morning void hormonal assessments in growing 
adolescents at various stages of pubertal progression requires adjustment to correct for 
hydration status and, if so, to determine whether creatinine or specific gravity are 
better adjustments. 
IV. To validate the feasibility of frequent urine sampling regimen and urine assay 
methodology for LH and sex steroids measurements using ICL and LC-MS/MS, 
respectively. Samples were collected from growing adolescents for a longitudinal 
study to assess changes in urine LH, estradiol and testosterone over 12 months by 
reference to contemporaneous changes in anthropometry and self-reported Tanner 
stages.    
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Chapter 2 Materials and Methods 
The chemicals, sample preparation and instrument settings used in this study are described in 
this section.  
2.1 LC-MS/MS assay 
2.1.1 Chemicals 
The chemicals and reagents used are listed in Table 2.1 and Table 2.2. All reagents used were 
analytical and chromatographic grade.  
2.1.2 Instrumentation 
LC analysis was carried out on a Shimadzu Nexera UHPLC system (Shimadzu Scientific 
Instruments, Columbia, MD). MS/MS analysis was performed on an API-5000 triple-
quadrupole mass spectrometer (Applied Biosystem/MDS SCIEX, Ontario, Canada) equipped 
with an APPI source. The MS/MS nitrogen gas was supplied by a nitrogen gas generator 
(Peak Scientific Instruments Ltd, Scotland).  
2.1.3 LC-MS/MS method for DBS steroids analysis 
2.1.3.1 Preparation of calibration standards and quality control  
Calibration standards and quality controls (QCs) were made from artificial blood according to 
a modified method described previously (Higashi et al. 2008). Briefly, venous whole blood 
was collected from a volunteer in a lithium heparin tube (Vacuette
®
, Greiner Bio-one). The 
plasma separated from red blood cells by centrifugation at 1500 x g (at 4°C, 15 min) was 
discarded and the red blood cells were washed with 30 mL of saline (0.9% NaCl in distilled 
water) (to remove remaining plasma), centrifuged at 1500 x g for 15 min at 4 °C followed by 
discarding the supernatant; this step was repeated four times to remove any remaining 
plasma. Charcoal treated plasma was prepared by adding 50 mg of activated charcoal (BDH
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 Table 2.1 List of chemicals for steroid LC-MS/MS assay. 
Chemical Chemical name Type MW 
(g/mol) 
Manufacturer  
Testosterone 17β-hydroxyandrost-4-en-3-one Standard 288.4 NMI, Sydney, Australia  
Nandrolone                                                              17β-hydroxy-19nor-4-andro-sten-3-one Standard 274.4 Steraloids, Newport, RI, USA 
17β-Estradiol 17β-estra-1,3,5(10)-estratriene Standard 272.4 Steraloids, Newport, RI, USA 
Dihydrotestosterone 17β-hydroxy-5α-androstan-3-one Standard 290.4 NMI, Sydney, Australia  
Dehydroepiandrosterone 5-androsten-3β-ol-17-one Standard 288.4 NMI, Sydney, Australia 
Testosterone glucuronide 17β-3-oxoandrost-4-en-17-yl b-D-glucopyranosiduronic acid Standard 464.6 NMI, Sydney, Australia  
17β-Estradiol glucuronide 1,3,5(10)-estratrien-3, 17β-diol 17-glucosiduronate Standard 448.5 Steraloids, Newport, RI, USA 
Dihydrotestosterone glucuronide 3-oxo-5α-androstan-17β-yl glucosiduronic acid Standard 466.6 NMI, Sydney, Australia 
Dehydroepiandrosterone glucuronide 5-androsten-3β-ol-17-one glucosiduronate Standard 464.5 Steraloids, Newport, RI, USA 
d3-Testosterone 16,16,17-d3-17β-hydroxyandrost-4-ene-3-one Internal standard 291.4 NMI, Sydney, Australia  
d4-Estradiol 2,4,16,16-d4-17β-estra-1,3,5(10)-estratriene Internal standard 276.4 Cambridge Isotope Laboratory, USA 
d3-Dihydrotestosterone 5α-(16,16,17α-
2
H3)-5α-Androstan-17β-ol-3-one Internal standard 293.5 NMI, Sydney, Australia 
d2-Dehydroepiandrosterone 16,16- d2-5-androsten-3β-ol-17-one Internal standard 290.4 Steraloids, Newport, RI, USA 
 
Table 2.2 List of reagents for steroid LC-MS/MS assay. 
 
 
 
 
 
 
Reagent Type MW 
(g/mol) 
Manufacturer 
Methanol  Solvent (HPLC grade) 32.04 RCI LabScan, Bangkok, Thailand 
Toluene Solvent (HPLC grade) 92.14 RCI LabScan, Bangkok, Thailand 
Methyl tert-butyl ether Solvent (AR grade) 88.15 RCI LabScan, Bangkok, Thailand 
Potassium carbonate (K2CO3) Buffer 138.21 Sigma-Aldrich, St Louis, MO, USA 
Disodium hydrogen phosphate 
(NaHPO4 anhydrous)  
Buffer 141.98 Sigma-Aldrich, St Louis, MO, USA 
Sodium dihydrogen phosphate 
(NaH2PO4.2H2O)  
Buffer 156.01 UNIVAR Analytical Reagent, NSW, Australia  
Sodium chloride (NaCl) Salt   58.44 UNIVAR Analytical Reagent, NSW, Australia 
Sodium azide (NaN3) Preservative 65.01 Ajax Chemical, Sydney, Australia 
Abbreviations: NMI: National Measurement Institute; MW: molecular weight; d: deuterated; AR: analytical reagent; HPLC: high performance liquid chromatography. 
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Chemicals, Victoria, Australia) to every milliliter of plasma. The mixture was stirred gently 
for an hour at room temperature followed by centrifugation at 1200 x g for 30 min. The 
supernatant was then filtered (filter paper #1, Advantec Co, Tokyo, Japan) to remove the 
remaining charcoal. The steroid-free plasma (tested with LC-MS/MS assay to ensure the 
plasma is free from endogenous testosterone) was added to the washed red blood cells to 
obtain a hematocrit of 0.45. The artificial blood prepared was then spiked with stock solution 
of testosterone (T) and nandrolone (N) to attain final concentrations of 0.05-32 ng/mL for T 
and 0.156-10 ng/mL for N. QCs were made up from a separate lot of artificial blood at low, 
medium and high concentrations (0.1, 1, and 16 ng/mL for T; 0.3, 1.25 and 5 for N). Fifty 
microliters of standards and QCs was spotted onto filter card (Whatman 903 protein saver 
cards, WHAT10534612; GE Healthcare, Westborough, MA), allowed to dry overnight at 
room temperature and stored in a sealed plastic bag at room temperature until analysis. 
2.1.3.2 DBS sample preparation 
Steroids were extracted from the whole DBS which were cut and transferred into 15 mL 
disposable borosilicate glass tubes (16×150 mm). One milliliter of methanol:water (1:1) was 
added followed by 10 µL of internal standard (25 ng/mL d3-T). The mixture was shaken 
mechanically for 30 min and then again for another 20 min after addition of methyl tert-butyl 
ether (MTBE) (1.5 mL). The tubes were centrifuged at 300 x g for 5 min and followed by the 
transfer of the organic layer into 5 mL disposable borosilicate glass tubes tube (12 × 75 mm). 
The solvent was evaporated to dryness in heating block at 50 °C overnight in a fume hood. 
The dried residue was reconstituted in 70 μL of 50% methanol in water, transferred into 96-
well polypropylene V-bottom microtiter plate (PerkinElmer, MA, USA) and 45 μL was 
injected into the LC-MS/MS system.  
Abbreviations: MW: molecular weight; AR: analytical reagent; HPLC: high performance liquid chromatography. 
Abbreviations: MW: molecular weight; AR: analytical reagent; HPLC: high performance liquid chromatography. 
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2.1.3.3 Blood volume determination 
We aimed to use the whole capillary blood volume on the filter card rather than taking a 
subsample (e.g. by a punch) as that risked non-homogenous distribution of blood 
impregnation on the filter paper. To determine the capillary blood volume on the filter card, a 
linear equation was derived from a plot of weight of blood on filter card (weight of blood-
impregnated filter paper minus weight of unused filter paper) versus volume of blood spotted 
on filter card (R
2
= 0.997) (Figure 2.1). To generate this calibration, venous blood was 
collected from a volunteer (hematocrit, 0.45) and immediately a set of increasing volume of 
blood (10-250 µL) was spotted using a calibrated pipette onto filter cards with five replicates. 
The spots were dried overnight, cut out and weighed. To determine the accuracy of this 
equation, known volumes (40, 50, 60, 70 µL) of whole venous samples collected from 10 
male volunteers (hematocrits 0.40-0.50) were spotted onto filter cards in triplicate and dried 
overnight. The estimated weight of the blood spot on the filter card (using a Mettler balance 
AE240) was then compared with the nominal volume of blood and accuracy (nominal 
volume x 100/actual volume) was 95-106% with coefficient of variation (CV) of 0.2-7.1% 
for all volumes tested.  
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Figure 2.1 Relationship between amount of blood and weight of filter card (n=5). 
 
 
2.1.3.4 Comparison between whole DBS and fixed-sized disc 
To determine the variation using whole DBS and fixed-sized paper disc, correlation between 
T venous DBS concentration obtained from two different sampling methods (1) whole blood 
spot and (2) 6 mm punch disc, were compared against plasma T concentration. For this 
purpose, venous blood was collected in lithium heparin tube from twenty male volunteers 
(hematocrit, 0.40-0.51). Fifty microliters of blood was spotted directly on the filter card using 
a calibrated pipette and the remaining blood was centrifuged at 1500 x g for 15 min at 4 °C to 
separate plasma. Plasma was extracted according to method described in Section 2.1.5.1. 
After overnight drying at room temperature, the DBS was either cut out entirely using a pair 
scissors or discs were punched out using a 6 mm puncher (n=3) from the same blood sample 
To determine the capillary blood volume on the card, a linear equation derived from a plot; 
weight of blood on filter card versus volume of blood spotted on filter card (y= 0.629x + 1.748; 
R2= 0.997) was used.  
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followed by extraction and measured using LC-MS/MS assay. The plasma and DBS T 
concentration were correlated according to the formula [plasmaT = DBST/(1-hematocrit)]. 
Venous whole DBS T was unbiased in relation to plasma T (standard deviation 6.3 ± 7.2 
(SD) % in Bland-Altman analysis; Pearson correlation r=0.98) whereas the punch disc 
produced an upward bias (deviation 28 ± 9.2 %; r=0.97) (Figure 2.2). The finding indicates 
that the venous whole DBS T measurements correlate well with the corresponding plasma T 
levels. However, the punch disc overestimates the T concentration in comparison to plasma T 
levels. All further DBS measurements used whole blood spotted on the filter card and the 
volume of blood was determined by first cutting the whole DBS and weighing the blood spot 
followed by calculation using the equation from Figure 2.1 and adjusted for hematocrit.  
 
Figure 2.2 Bland-Altman plots for comparison of testosterone (T) concentration 
obtained from whole DBS versus plasma (left panel) and 6 mm punch disc versus 
plasma (right panel). 
 
 
 
 
The Bland-Alman plots represent the difference between two sampling methods: 1) whole blood spot 
and 2) 6 mm punch disc against plasma T concentration. The solid and the dashed lines represents the 
observed average and 95% limit of confidence (± 1.96 SD), respectively.  
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2.1.3.5 LC-MS/MS parameters 
The LC column was an Ascentis
®
 Express Phenyl-Hexyl column (10 cm x 2.1 mm, 2.7 µm; 
Supelco, Sigma-Aldrich, PA; Cat. no. 53336-U) equipped with an Ascentis
®
 Express Phenyl-
Hexyl guard cartridge (0.5 cm x 2.1 mm, 2.7 µm; Supelco, Sigma-Aldrich, PA; Cat. no. 
53524-U). The column temperature and autosampler were set at 35 and 4 °C, respectively. 
The elution solvents were water (A) (18MΩ quality; Millipore Milli-Q system, Bedford, MA, 
USA) and methanol (B). The gradient elution was performed at the flow rate of 0.75 mL/min 
with the organic solvent started with 10% B (0-0.10 min), 55-65% B (0.11-4.99 min), 100% 
B (5.00-5.70 min), 10% B (5.71-6.50 min). Toluene was used as the APPI dopant, delivered 
at the flow rate of 0.07 mL/min. T and N MS/MS analysis was carried out in positive ion 
mode. The MS conditions of N, T and d3T are listed in Table 2.3. N, T and d3T eluted at 3.62, 
4.15 min and 4.19 min, respectively (Figure 2.3). The following MS parameters were used: 
ion source gas 1: 55 psi; ion source gas 2: 50 psi; curtain: 12 psi; collision gases: 6 psi; ion 
source temperature: 500 °C; ion spray voltage: 750V. Data were quantified using Analyst 
software (version 1.6, AB Sciex). 
Table 2.3 Mass spectrometry parameters for nandrolone, testosterone and d3-
testosterone measurements. 
Steroid 
Ion Fragmented 
 
MRM 
transition 
Q1→Q3 
Dwell time 
(msec) 
DP EP CE CXP 
N [M+H]+ 275.2→109.1 500 190 10 40 12 
T [M+H]+ 289.3→109.1 500 190 10 35 12 
d3T [M+H]
+ 292.3→109.1 250 190 10 35 12 
 
 
Abbreviations: N: nandrolone; T: testosterone; d3T: deuterated testosterone; MRM: multiple-reaction-
monitoring; DP: declustering potential; EP: entrance potential; CE: collision energy; CXP: collision cell exit 
potential. 
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2.1.3.6 Method validation  
Linearity, lower limit of quantification (LLOQ), recovery, process efficiency, within and 
between day precision and accuracy were evaluated during the validation of the analytical 
method according to FDA guidance (FDA 2001). The linearity was evaluated on the basis of 
three calibration curves. Response of peak area ratio of T and N to internal standard (d3T) 
was plotted against known steroid concentrations. The assay acceptance criterion for each 
back-calculated standard concentration was 15% CV from the nominal value. The LLOQ was 
evaluated by five replicates of the lowest concentrations of the calibration curve with the 
accepted deviation values of 20%. The calibration curve was quadratic for both T and N with 
1/x weighing with correlation coefficient (r) greater than 0.999. The LLOQ was 50 pg/mL for 
T and 156 pg/mL for N using a 50 µL blood sample.  
For within and between-day assay validation, QC samples were prepared in artificial blood as 
described in Section 2.1.3.1 with the T and N at three concentration levels of low, medium 
and high (0.1, 1, and 16 ng/mL for T; 0.3, 1.25 and 5 ng/mL for N) in five separate runs. The 
within-day precision (% CV) was 2.5-4.4% with accuracies of 95-108% and the between-day 
precision was 4.9-13.5% with accuracies of 100-106% at all QC levels (Table 2.4). 
The recovery, matrix effect and process efficiency of the method was carried out according to 
the method described previously (Matuszewski et al. 2003) at low, medium and high 
concentrations of each compound. All extraction recoveries and process efficiencies were 
between 96-107% with no ion suppression or enhancement for either analyte (matrix effect 
recoveries between 96-102%). Refer Table 2.4 for the detailed validation data.  
Specificity of T against isomers with same molecular weight, DHEA and epitestosterone (16 
ng/mL) were evaluated. The retention time of these compounds did not co-elute with the 
retention time of T. 
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Stability of T and N on DBS was evaluated at 4°C, room temperature and 37°C for short term 
(42 days) and long term (742 days) at low, medium and high concentrations (0.1, 1, and 16 
ng/mL for T; 0.3, 1.25 and 5 ng/mL for N) measured against fresh calibration spotted onto 
filter card and extracted immediately after overnight drying.  
The stability of T on DBS was well maintained at 3 temperatures and all QCs tested with 
accuracies of 79.2-113.7% (CV 0.4 -11.8%) (Table 2.4). N was also stable on DBS at all 3 
conditions and all QCs tested up to 42 days (accuracies 82.5-110.7%; CV 0.4-13%). Long 
term storage of DBS showed a decline in N stability at room temperature and 37°C in the 
medium and high QCs (accuracies 65.6-75.7%; CV 0.9-9.6%). The N stability was well 
maintained at 4°C for all QCs up to 742 days with accuracies of 99.9-116.6% (CV 4.2-7.7%) 
(Table 2.5). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 Dried blood spot method analytes chromatogram. 
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Table 2.4 LC-MS/MS DBS method validation data. 
 
 
Analyte LLOQ 
(pg/ml) 
QC 
Within-day (%) Between-day (%) 
ER 
(%) 
ME 
(%) 
PE 
(%) Accuracy CV Accuracy CV 
T 
 
 
50 
 
 
Low 99.8 4.4 100.3 13.5 104.2 99.8 104.0 
Medium 98.4 3.0 103.1 5.2 106.4 95.6 101.7 
High 107.5 2.5 105.9 4.9 106.3 96.3 102.4 
N 
 
 
156 
 
 
Low 95.0 3.0 101.5 10.6 106.5 95.8 102.0 
Medium 105.8 4.1 102.6 8.4 96.4 100.9 97.3 
High 105.2 3.8 103.8 5.7 99.5 101.7 101.2 
Abbreviations: LLOQ: lower limit of quantitation; QC: quality control; ER: extraction recovery; ME: matrix 
effect; PE: process efficiency; CV: coefficient of variation  
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Table 2.5 Stability data of testosterone and nandrolone on DBS at three different storage conditions for short (42 days) and long term storage (742 
days). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Testosterone Nandrolone 
Time (days) 
Storage condition 
Low Medium High Low Medium High 
Accuracy CV Accuracy CV Accuracy CV Accuracy CV Accuracy CV Accuracy CV 
3 
RT 90.9 7.4 106.7 3.0 105.6 5.3 105.3 5.5 105.7 4.2 106.3 6.2 
4C 97.6 3.1 101.1 3.4 107.3 5.5 110.7 2.8 93.8 9.2 105.5 7.0 
37C 94.4 3.5 96.7 1.6 108.7 3.7 98.6 6.2 107.0 2.4 107.7 3.9 
7 
RT 91.8 9.0 98.7 4.0 103.9 4.0 99.4 6.8 94.6 5.2 96.3 2.2 
4C 101.3 5.5 104.7 3.9 105.3 0.6 108.3 0.9 103.3 4.3 100.7 1.2 
37C 94.0 11.6 99.5 3.5 108.3 0.9 90.4 4.5 103.2 3.6 101.7 1.4 
14 
RT 96.5 7.1 94.8 4.4 98.2 1.9 103.8 6.9 87.6 1.1 88.7 0.9 
4C 104.6 5.7 99.9 4.5 98.7 3.5 91.4 5.2 98.1 6.0 98.1 1.0 
37C 93.2 6.0 97.5 5.8 93.7 5.0 88.3 2.9 85.7 5.2 85.5 3.2 
28 
RT 99.0 8.0 97.0 1.5 101.5 4.7 85.7 2.1 86.6 12.2 91.5 3.8 
4C 88.1 8.1 103.0 8.3 106.0 2.4 94.2 9.5 94.8 2.6 97.0 4.6 
37C 87.0 11.8 95.0 4.4 95.6 4.4 86.4 13.0 82.5 8.1 88.4 6.4 
42 
RT 105.0 11.0 89.9 3.1 91.1 4.2 87.0 3.0 85.7 2.3 91.2 6.4 
4C 101.4 6.8 99.5 10.1 98.3 0.4 99.9 7.5 92.8 11.0 98.1 0.4 
37C 93.8 2.3 86.3 2.1 87.9 5.2 86.3 3.6 83.0 7.3 85.0 7.0 
742 
RT 107.0 8.1 92.9 1.4 94.4 0.7 101.4 4.3 75.7 9.6 74.0 4.0 
4C 109.3 6.7 104.3 2.4 107.7 2.9 111.6 7.7 109.63 7.4 99.9 4.2 
37C 113.7 5.2 89.2 4.3 79.2 3.9 106.7 3.0 74.1 6.6 65.6 0.9 
Abbreviations: RT: room temperature; CV: coefficient of variation  
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2.1.4 LC-MS/MS method for urinary steroids analysis 
2.1.4.1 Urine sample preparation  
Urine samples were extracted by LLE. Urine (500 µL) was transferred into 15 mL disposable 
borosilicate glass tubes (16×150 mm), spiked with 10 μL of internal standards (25 ng/mL 
d3T, 75 ng/mL d4E2, 200 ng/mL d2DHEA and 250 ng/mL d3DHT) and had 500 μL of 0.1M 
phosphate buffer (pH 6.2) and 10 μL β-glucuronidase from Escherichia coli K12 (Roche 
Diagnostic, Mannheim, Germany; Cat. no.: 03707598001) added. After overnight incubation 
at room temperature, 100 μL of potassium carbonate (20%: w/v) was added followed by 1.5 
mL of MTBE. The mixture was shaken mechanically for 15 min, centrifuged at 2700 x g for 
15 min followed by transfer of the organic layer into clean 5 mL disposable borosilicate glass 
tubes tube (12×75 mm) and evaporated to dryness in a heating block at 50 C overnight in a 
fume hood. The dried residue was reconstituted in 75 μL of 20% methanol in water, 
transferred into 96-well polypropylene V-bottom microtiter plate and 50 μL was injected into 
the LC-MS/MS system.  
2.1.4.2 LC-MS/MS parameters 
The LC elution solvents were water (A) and methanol (B). For urine extracts, separation was 
achieved on a Ascentis
®
 Express Phenyl-Hexyl column (10 cm x 2.1 mm, 2.7 µm) equipped 
with a Ascentis
®
 Express Phenyl-Hexyl guard cartridge (0.5 cm x 2.1 mm, 2.7 µm). The 
gradient elution was performed at the flow rate of 0.6 mL/min with the organic solvent 
starting with 10% B (0-0.10 min), 55% B (0.11-4.99 min), 65% B (5.00-6.50 min), 65-100% 
B (6.50-7.00 min), 100% B (7.01-8.00 min), 10% B (8.01- 9.50 min). The column 
temperature and autosampler were set at 40 and 4 C, respectively. Toluene was used as the 
APPI dopant, delivered at the flow rate of 0.06 mL/min. 
                                                                                                                                                                   Chapter 2 
 
   94 
 
Following LC separation, samples were subjected to MS/MS analysis. E2 was detected in 
negative ion mode whereas the androgens (T, DHT and DHEA) were detected in positive ion 
mode. The optimization of MRM settings and LC-MS/MS system conditions for each analyte 
have been listed in Table 2.6. The following MS parameters were used: ion source gas 1: 55 
psi; ion source gas 2: 50 psi; curtain: 12 psi; collision gases: 6 psi; ion source temperature: 
500 °C; ion spray voltage: 750V (for positive mode) and -750V (for negative mode).  
 
Table 2.6 Mass spectrometry parameters for estradiol, testosterone, 
dihydrotestosterone, dehydroepiandrosterone and its corresponding isotopically labeled 
internal standards. 
 
 
 
 
Steroid 
Ion Fragmented 
 
MRM 
transition 
Q1→Q3 
Dwell time 
(msec) 
DP EP CE CXP 
E2 [M-H]
- 271.1→145.0 100 -100 -10 -57 -15 
d4E2 [M-H]
- 275.1→147.0 75 -100 -10 -57 -15 
T [M+H]+ 289.3→109.1 100 80 10 35 15 
d3T [M+H]
+ 292.3→109.1 75 80 10 35 15 
DHT [M-H2O+H]
+ 273.3→123.3 100 80 10 31 15 
d3DHT [M-H2O+H]
+ 276.3→123.3 75 80 10 31 15 
DHEA [M-2H2O+H]
+ 253.1→197.1 100 80 10 30 15 
d2DHEA [M-2H2O+H]
+ 255.3→197.2 75 80 10 30 15 
Abbreviations: E2: estradiol; d4E2: deuterated estradiol T: testosterone; d3T: deuterated testosterone; 
DHT: dihydrotestosterone; d3DHT: deuterated dihydrotestosterone; DHEA: dehydroepiandrosterone; 
d2DHEA: deuterated dehydroepiandrosterone; MRM: multiple-reaction-monitoring; DP: declustering 
potential; EP: entrance potential; CE: collision energy; CXP: collision cell exit potential; Q1: first 
quadrupole; Q3: third quadrupole.  
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2.1.4.3 Method validation 
The LC-MS/MS method for urinary steroid quantitation was validated for linearity, LLOQ, 
recovery, matrix effects, process efficiency, within and between day precision and accuracy 
according to FDA guidance for bioanalytical method validation (FDA 2001). For the 
validation and calibration, blank urine comprised a pool of urine from two children aged 3-4 
years of age was used. The linearity was evaluated on the basis of three calibration curves. 
Response of peak area ratio of the steroids to internal standard was plotted against known 
steroid concentrations using quadratic regression with 1/x weighing. The assay acceptance 
criterion for each back-calculated standard concentration was 15% CV from the nominal 
value. The LLOQ was evaluated by five replicates of the lowest concentrations of the 
calibration curve with the accepted deviation values of 20% using 500 µL of urine.  
The calibration curves fitted quadratic functions ranging from; 0.05-32 ng/mL E2, 0.025-32 
ng/mL T, 0.1-32 ng/mL DHT and 0.2-128 ng/mL DHEA, with correlation coefficient (r) 
greater than 0.999. The precision was 2.6-7.2% (within-day) and 4.8-9.7% (between-day) 
with accuracies of 97-110% (within-day) and 95-108% (between-day) for all QC levels 
(steroids spiked as glucuronides at 0.2, 4 and 32 ng/mL for T; 0.8, 4 and 32 ng/mL for E2, 
DHT and DHEA) (Table 2.8).  
The recovery, matrix effects and process efficiency were quantified as described previously 
(Matuszewski et al. 2003) at low (0.4 ng/mL), medium (1.6 ng/mL) and high (16 ng/mL) 
concentrations of each compound. The extraction recovery and process efficiency were 
between 91-118%, whereas the matrix effect recoveries were between 92-119% for all the 
analytes spiked at low, medium and high concentrations (Table 2.8).  
The β-glucuronidase enzyme was evaluated for hydrolysis efficiency at room temperature 
(overnight). Five replicates were spiked with testosterone glucuronide (TG), estradiol 
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glucuronide (E2G), dihydrotestosterone glucuronide (DHTG) and dehydroepiandrosterone 
glucuronide (DHEAG) at 40 ng/mL and another five replicates were spiked with the 
unconjugated steroid at the equivalent amount (25 ng/mL of T, DHT and DHEA; 24 ng/mL 
of E2). The samples were then extracted according to the method described in section 2.1.4.1. 
The area ratios of the analyte to internal standards were compared and the enzyme 
deconjugation efficiency was between 88-102% after overnight incubation at room 
temperature for all the analytes. 
For specificity, structurally related compounds that potentially may interfere with the method 
were also evaluated (Table 2.7). All the steroids listed did not interfere with the retention 
time of E2, T, DHT and DHEA.  
 
Table 2.7 List of possible interfering compounds for LC-MS/MS urinary and serum 
methods. 
Analyte Possible interfering compound(s) Manufacturer 
E2 Estrone (1,3,5[10]-estratrien-3-ol-17-one) Steraloids, 
Newport, RI, 
USA 
T Epitestosterone (17α-hydroxyandrost-4-ene-3-one) 
Dehydroepiandrosterone (5-androsten-3β-ol-17-one) 
National 
Measurement 
Institute, Sydney 
Australia 
DHT Androsterone (17β-hydroxy-5α-androstan-3-one), 
3α-diol (5α-androstane-3α,17β-diol) 
3β-diol (5α-androstane-3β,17β-diol) 
National 
Measurement 
Institute, Sydney 
Australia 
Etiocholanolone (5β-Androstan-3α-ol-17-one), 
Epietiocholanolone (5β-Androstan-3β-ol-17-one), 
5-androstenediol (5-androsten-3β,17β-diol), 
Epiandrosterone (5α-androstan-3β-ol-17-one), 
Steraloids, 
Newport, RI, 
USA 
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Table 2.8 LC-MS/MS urinary steroids method validation data. 
 
Analyte 
LLOQ 
(pg/ml) 
QC 
Within-day (%) Between-day (%) 
ER 
(%) 
ME 
(%) 
PE 
(%) Accuracy CV Accuracy CV 
 
 
E2 
 
 
 
 
50 
 
 
Low 99.9 4.5 95.4 6.3 97.0 106.4 103.2 
Medium 104.4 3.4 100.1 5.6 96.0 101.6 97.5 
High 105.0 2.6 104.2 9.7 95.1 106.3 101.1 
 
T 
 
 
25 
 
Low 97.2 3.6 103.2 7.2 97.3 103.9 101.1 
Medium 100.7 4.4 104.3 7.8 94.4 106.0 100.0 
High 102.4 2.8 95.6 6.7 92.7 107.9 100.0 
DHT 100 
Low 103.4 7.2 99.1 6.6 100.5 105.0 105.6 
Medium 102.6 3.7 99.7 5.8 103.3 91.7 94.7 
High 102.6 4.4 95.6 7.7 90.6 107.7 97.6 
DHEA 200 
Low 110.2 5.2 97.3 4.8 97.5 118.6 115.6 
Medium 101.1 5.5 101.4 7.8 101.7 117.3 118.1 
High 99.3 5.6 107.9 6.4 98.5 111.5 109.8 
 
Figure 2.4 Urinary steroids method chromatogram. 
Abbreviations: LLOQ: lower limit of quantitation; QC: quality control; ER: extraction recovery; ME: matrix effect; PE: 
process efficiency; CV: coefficient of variation.  
                                                                                                                                                                   Chapter 2 
 
   98 
 
 2.1.5 LC-MS/MS method for serum steroids analysis 
2.1.5.1 Serum sample preparation 
Serum samples were extracted by LLE. Serum aliquots (200 µL) were transferred into 5mL 
disposable borosilicate glass tubes (12×75 mm), spiked with 50 μL of internal standard (5 ng/mL d3T 
and d4E2; 6.25 ng/mL d3DHT; 7.5 ng/mL d2DHEA) and had 1 mL of MTBE added. The tubes were 
vortex mixed for 1 min, allowed to phase separate at 4 °C for 1 h before being placed in a −80 °C 
freezer for 30 min to freeze the lower aqueous layer. The upper organic layer was decanted into clean 
glass tubes and the solvent evaporated overnight at 50 °C in a fume hood. The residue was then 
reconstituted in 75 μL of 20% methanol in water, transferred into 96-well polypropylene V-
bottom microtiter plate and 50 μL was injected into the LC-MS/MS system.  
2.1.5.2 LC-MS/MS parameters 
LC separation was achieved on a Phenomenex Kinetex XB-C18 column (5 cm x 2.1 mm, 1.7 µm; 
Cat. no. OOB-4498-AW) protected by Phenomenex C18 guard cartridge (Cat. no. AJO-8782). The 
LC column temperature and autosampler were set at 40 and 4 °C, respectively. The elution solvents 
were water (A) and methanol (B). A gradient elution was performed at a flow rate of 0.5 mL/min with 
25% B (0-0.10 min), 52-62% B (0.11-4.30 min), 100% B (4.31-5.45 min), 25% B (5.46-7.00 min). 
Toluene was used as the APPI dopant, delivered at the flow rate of 0.05 mL/min. The 
optimization of LC-MS/MS MRM settings and system conditions for serum assay was 
identical with the urine assay. Please refer section 2.1.4.2 for the MS/MS parameters.   
2.1.5.3 Method validation 
The LC-MS/MS method for urinary steroid quantitation was validated for linearity, LLOQ, 
recovery, matrix effects, process efficiency, within and between day precision and accuracy 
according to FDA guidance for bioanalytical method validation (FDA 2001). For the 
validation and calibration, 4% bovine serum albumin in phosphate buffer was used. The 
linearity was evaluated on the basis of three calibration curves. Response of peak area ratio of 
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the steroids to internal standard was plotted against known steroid concentrations using 
quadratic/linear regression (according to analyte) with 1/x weighing. The assay acceptance 
criterion for each back-calculated standard concentration was 15% CV from the nominal 
value. The LLOQ was evaluated by five replicates of the lower concentrations of the 
calibration curve with the accepted deviation values of 20% using 200 µL of serum. 
The calibration curves were quadratic for T and DHEA (ranging between 0.01-16 ng/mL and 
0.02-32 ng/mL, respectively) and linear for E2 and DHT (ranging between 5-800 pg/mL and 
0.01-16 ng/mL, respectively) with the r greater than 0.999. The precision was 5.3-13.5% 
(within-day) and 8.1-15.0% (between-day) with accuracies of 90-113% (within-day) and 95-
111% (between-day) for all QC levels (0.01, 0.04 and 0.4  ng/mL for E2; 0.025, 0.8, and 8 
ng/mL for T; 0.2, 0.8 and 8 ng/mL for DHT; 0.05, 1.6, and 16 ng/mL for DHEA) (Table 2.9). 
The recovery, matrix effects and process efficiency were quantified as described previously 
(Matuszewski et al. 2003) at low, medium and high concentrations of each compound (0.005, 
0.08 and 0.4  ng/mL for E2; 0.05, 0.4, and 8 ng/mL for T and DHT; 0.02, 0.8, and 16 ng/mL 
for DHEA). All the extraction recovery and process efficiency were within the range of 79-
113%, whereas, the matrix effect were between the range of 81-107% for all the analytes 
spiked at low, medium and high concentrations (Table 2.9).  
For specificity, structurally related compounds that potentially may interfere with the method 
were also evaluated (Refer Table 2.7 for compound list). All the steroids listed did not 
interfere with the retention time of E2, T, DHT and DHEA. 
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Table 2.9 LC-MS/MS serum steroids method validation data. 
 
 
 
 
 
 
 
 
 
 
Analyte 
LLOQ 
(pg/ml) 
QC 
Within-day (%) Between-day (%) 
ER 
(%) 
ME 
(%) 
PE 
(%) 
Accuracy CV Accuracy CV 
 
 
E2 
 
 
 
 
5 
 
 
Low 96 13.0 101 14.5 79 101 80 
Medium 90 11.2 104 11.0 103 93 96 
High 103 7.7 104 9.9 111 81 89 
 
T 
 
 
25 
 
Low 104 13.4 103 15.0 92 87 91 
Medium 97 5.3 103 9.0 92 83 83 
High 113 8.4 105 11.0 100 103 105 
DHT 100 
Low 101 13.5 111 12.9 89 88 91 
Medium 102 8.9 95 10.4 112 107 113 
High 107 8.9 100 11.3 87 102 89 
DHEA 50 
Low 99 12.5 106 14.6 98 97 100 
Medium 110 7.1 106 8.1 99 104 95 
High 107 5.6 107 9.7 91 91 100 
Abbreviations: LLOQ: lower limit of quantitation; QC: quality control; ER: extraction recovery; ME: matrix effect; PE: 
process efficiency; CV: coefficient of variation.  
 
Figure 2.5 Serum steroids method chromatogram. 
                                                                                                                                                                   Chapter 2 
 
   101 
 
2.2 LH immunoassay 
Urine and serum LH were measured by commercially available immunoassays an ICL 
immunoassay system: IMMULITE
®
 1000 LH, Siemens and IF assay: Delfia hLH assay, 
Perkin Elmer, Rowville, Melbourne, Victoria. The within-assay CV were <10%. Urine FSH 
assays (Immulite, DELFIA) did not pass validity tests (dilutional linearity, quantitative spike 
recovery) and were not used in this study.  
2.2.1 Immulite  
The ICL is a solid-phase two-site chemiluminescent immunometric assay that detects intact 
LH and LHβ subunit. The solid phase of the system consists of a polystyrene bead sealed in 
the test unit and coated with a capture monoclonal antibody against LH. The standards or 
samples (approximately 100 µL) were first aliquot in the disposable sample cups. Each 
sample cup was loaded on the loading rack followed by a test unit containing the bead. The 
sample (50 µL) and alkaline phosphatase (conjugated to polyclonal goat anti-LH) were 
automatically pipetted into the test unit by the programmed Immulite system. Following 
incubation (with intermittent agitation), the reaction fluid was removed by high speed mixing 
followed by series of washing to remove the unbound material. Chemiluminescent substrate 
added to the complex undergoes hydrolysis through the action of the alkaline phosphatase 
enzyme creating unstable anion that emits sustained light emission measured by the photon 
counter.  
2.2.2 DELFIA 
The IF assay utilizes the immobilized monoclonal human LHβ subunit as capture antibody 
and europium-labeled human LHβ subunit as detector antibody. The assay was carried out 
according to the manufacturer instructions. Briefly, 25 µL of standards and samples were 
aliquot in microtitration strip coated with mouse monoclonal anti-hLH followed by 200 µL of 
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assay buffer. The strips were incubated for an hour on a plate shaker (Wallac 1296-001 
Plateshaker) at room temperature. The strips were then aspirated and each strip was washed 
with a plate washer (Wallac 1296-026 Platewasher). Two hundred microliter of tracer 
solution (europium labeled anti-β human LH IgG) was added followed by 15 min incubation 
on a shaker at room temperature. The strips were aspirated and washed before adding 200 µL 
of enhancement solution. The fluorescence was read using a time-resolved fluorometer 
(Perkin Elmer Multimode Plate Reader Enspire).  
2.3 Urine creatinine measurement 
Creatinine concentrations were determined by the colorimetric alkaline-picrate (Jaffé) 
method (CREJ2, Roche Diagnostics, Cat. No. 04810716 190) on a Cobas C501 analyzer 
(Roche Diagnostics GmbH, Indianapolis, IN). Calibrators (Roche Diagnostics, Cat. No. 
10759350 190) were used for this automated system to generate a linear curve ranging 
between 375 and 55000 µmol/L and the limit of detection of 375 µmol/L. The assay requires 
13 µL of potassium hydroxide (900 mmol/L, phosphate 135 mmol/L, pH > 13.5) and 17 µL 
of picric acid (38 mmol/L, pH 6.5) diluted in 77 µL and 30 µL of distilled water, respectively 
for sample volume of  10 µL. All reagents were from ready to use cassettes and were handled 
automatically by the analyzer.   
2.4 Urine specific gravity measurement 
Urine specific gravity (SG) was measured by immersing a reagent strip (ChoiceLine 10, 
Roche Diagnostics) in freshly voided urine sample. Dipstick color changes were compared 
visually with the color chart to estimate the SG (range between 1.000 and 1.030; 0.005 unit 
difference between consecutive colour). 
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Subcutaneous Injection of Depot Nandrolone 
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The content in this chapter has been published in The Journal of Clinical Endocrinology and 
Metabolism 2014, 99: 2592-2598
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Chapter 3 Pharmacokinetic-Pharmacodynamic Study of 
Subcutaneous Injection of Depot Nandrolone Decanoate Using 
Dried Blood Spots Sampling Coupled With LC-MS/MS Assays 
 
3.1 Introduction 
Since the first clinical use of T in 1937 (Hamilton 1937), two years after its Nobel Prize-
winning discovery as the primary mammalian androgen (Butenandt and Hanisch 1935, David 
et al. 1935, Ruzicka and Wettstein 1935), its sole unequivocal therapeutic indication remains 
as replacement therapy for T deficiency states due to usually life-long hypothalamic, pituitary 
or testicular disorders (Handelsman 2010). Although exogenous T can be administered by 
implantable, transdermal or oral products, depot injectable formulations have long been the 
most widely used and affordable products for delivering T treatment aiming to maintain long-
term adherence and sustained effective T replacement therapy for many years.  
 
Depot injectable T products consist of T esterified to fatty acid side-chains with the length 
increasing hydrophobicity for partitioning into the vegetable oil vehicle as a depot for deep 
intramuscular (im) injection. These injections require skilled medical personal for slow 
administration, usually into the upper outer quadrant of gluteal muscle. While self-injection is 
feasible for the dexterous, most patients consider it too difficult so self-administration is rare. 
Im injections cause local pain or discomfort (Mackey et al. 1995, Sartorius et al. 2010), risk 
local injection site infection or bruising and, rarely, pulmonary oil micro-embolisation (Gu et 
al. 2009, Mackey et al. 1995, Svendsen and Aaes-Jorgensen 1979, Svendsen et al. 1980). 
Among patients with bleeding disorders or those taking anti-coagulants or antiplatelet 
therapy, deep im injections may be less suitable due to risk of im hematoma. In those 
situations daily-use oral or transdermal T products can be substituted; however, they have 
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high rates of discontinuation (Schoenfeld et al. 2013) as they lack the convenience of low-
demand reliability of long-acting depot T products. Hence, a more convenient, self-
administered method to inject T esters would be advantageous and cost-saving.  
 
Clinical pharmacological studies to define drug pharmacokinetics and pharmacodynamics 
requires frequent blood sampling to generate sufficient data to define the time of peak and 
peak concentrations as well as circulating half-times and other derived pharmacological 
variables (Gibaldi and Perrier 1982, Minto et al. 1997). For long-acting depot products, this 
makes necessary many clinic visits for venesection followed by sample processing to separate 
serum for frozen storage until assay. These features add greatly to cost and complexity of 
conducting such pharmacological studies. We previously validated DBS technology for field 
studies of steroid pharmacology (Howe and Handelsman 1997) and now apply this remote 
sampling technology for repeated blood sampling at convenient times in the participants own 
home. This eliminate the need for medical professional to take blood samples, process and 
freeze samples while reducing the total blood sampled. As the time course of subcutaneous 
(sc) injections of steroids in an oil vehicle is not reported and may differ from the im route of 
administration (Handelsman et al. 1995, Minto et al. 1997), we investigated the 
pharmacokinetics of a single sc injection of nandrolone decanoate (ND) and the 
pharmacodynamics of its effects on endogenous serum T. As a generic androgen ester in an 
oil vehicle, this may demonstrate the feasibility of sc injection of T esters in an oil vehicle 
with potential to simplify injectable T replacement therapy. Nandrolone (N), also known as 
19-nortestosterone has structural similarities with T but lacking a methyl group at the 19
th
 
position (Hemmersbach and Grobe 2009) (Figure 3.1). ND consists of a long aliphatic side 
chain (10 carbons) (Figure 3.1) that provides sustained release of this steroid into the 
circulation. ND is further hydrolyzed into its active steroid, N which inhibits the pituitary 
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gonadotropin release through the negative feedback loop resulting in decrease of endogenous 
T production (Minto et al. 1997).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2 Study Design 
Healthy eugonadal volunteer men (n=8, age 31 ± 10 (SD) year, height 175 ± 7 cm, weight 
80.7 ± 0.8 kg, BMI 26.3 ± 3.0 kg/m
2
) were administered 100 mg ND in 2 mL arachis oil 
vehicle (MSD, Australia) by sc injection (21 gauge needle (0.8x25mm) Becton Dickinson 
Medical) into a single subdermal abdominal site. Participants were instructed in collecting 
capillary blood by finger prick using a single-use lancet (BD Microtainer, Contact-Activated 
Lancet 2.0x1.5mm; Becton Dickinson, Franklin Lakes NJ  07417) and applying blood onto 
filter cards (McDade 2014). Blood spots were applied to the 1
st
, 3
rd
 and 5
th
 of the five pre-
 
Nandrolone Nandrolone 
decanoate 
Nandrolone decanoate, a synthetic anabolic steroid has a long duration of action due to its 
10-carbon aliphatic side chain. Nandrolone decanoate is released into the extracellular fluid 
gradually with oil/water partitioning of the steroid ester from the oil vehicle with rapid 
hydrolysis of the ester to form active steroid (nandrolone) in the bloodstream (Minto et al. 
1997). 
Figure 3.1 Structures of nandrolone and nandrolone decanoate. 
                                                                                                                                                                   Chapter 3 
 
   107 
 
marked rings allowing for a gap to avoid overlap of blood samples. Capillary blood was 
obtained before and daily for 21 days recording the exact time of sampling. Venous blood 
was also sampled before and at weekly intervals to store serum and to spot venous blood 
directly onto filter cards. Serum samples were stored at -20°C until assayed. The dried blood 
spots were allowed to dry overnight at room temperature and were then stored in a sealed 
paper bag at room temperature until extracted. The participants provided written informed 
consent and the study was approved by the Sydney Local Health District Human Ethics 
Committee within National Health and Medical Research Council Guidelines for Human 
Experimentation (NHMRC) guideline for human experimentation. Volunteers received $200 
for their time and effort on completing the full study (5 visits, 22 finger-prick blood samples). 
3.3 Data analysis 
Comparison of T and N concentrations in different fluids (serum, capillary blood, venous 
blood) was performed by non-parametric (Passing-Bablok) regression, deviance analysis of 
differences (modified Bland-Altman) and Spearman rank correlation using NCSS and 
MedCalc software. Peak or nadir concentrations and time of peak or nadir were determined 
directly from the serial daily hormone concentrations as well as from population 
pharmacokinetic/pharmacodynamic modelling using the exact time of finger-prick sampling 
(rather than nominal day) by non-linear curve fitting (Gibaldi and Perrier 1982, Minto et al. 
1997). Data were expressed as mean and standard error of mean (SEM) for data with a 
Gaussian distribution and median (range) otherwise. 
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3.4 Results 
All scheduled samples (finger-prick, venous) were collected without complaints about finger-
prick blood collection. There were no complaints of discomfort following the injections. 
Hematocrit was unchanged by participation in the study (pre 0.45 ± 0.01, post 0.45 ± 0.01, 
difference 0.0 ± 0.01 or -0.5 ± 2.4 % of baseline, paired t-test p>0.8).   
Capillary T and N concentration displayed a high correlation (r=0.95, 0.96, respectively) and 
was unbiased (mean deviation -2.5 ± 60(SD) %, -27 ± 39 %) compared with measurements in 
serum for T (Figure 3.2) and for N (Figure 3.3). Similar findings were obtained with high 
correlation (r=0.97 for all) and lack of bias between venous whole blood spot and serum or 
capillary T and N.  
Serum N rose to a peak concentration of 2.50 ± 0.25 (SEM) ng/mL at a median (range) of 6 
(4-13) days (Figure 3.4). Serum T declined from 3.50 ± 0.57 ng/mL at baseline to a nadir of 
0.38 ± 0.13 (SEM) ng/mL representing 89 ± 3% maximal suppression at a median (range) of 
8 (5-16 days) (Figure 3.5). Using non-linear curve fitting, N peaked at 1.72 ng/ml at 6.4 days 
while serum T reached a nadir of 0.53 ng/ml (suppressed by 2.9 ng/ml) at 10.3 days (Figure 
3.5). Capillary T and N displayed virtually identical patterns following sc ND injection 
(Figure 3.6). Serum LH and FSH were both suppressed maximally at day 7 (median 7 days, 
range 7-14 days) to reach a nadir of 1.2 IU/L (LH) and 1.1 IU/L (FSH) after injection, 
representing a median 60% and 49% suppression from baseline, respectively, and recovered 
towards, but not full reaching, baseline by day 21 (Figure 3.6). 
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Figure 3.2 Plot of correlation (Passing-Bablok-upper panel) and deviance 
(modified Bland-Altman-lower panel) of individual capillary and serum 
testosterone in 32 samples obtained from 8 participants before and weekly for 3 
weeks after sc injections of ND 
 Line of best fit is shown as a solid line with upper and lower 95% confidence 
intervals in dashed lines and the line of identity shown as a dotted line. Inset are the 
(Passing-Bablok) regression formula and 95% confidence limits on intercept and 
slop. The deviance (modified Bland-Altman) plot show the deviation of capillary 
from serum testosterone expressed as a percentage. For further details see text. 
                                                                                                                                                                   Chapter 3 
 
   110 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Plot of correlation (Passing-Bablok-upper panel) and 
deviance (modified Bland-Altman-lower panel) of individual capillary 
and serum nandrolone in 32 samples obtained from 8 participants 
before and weekly for 3 weeks after sc injections of ND. 
 Line of best fit is shown as a solid line with upper and lower 95% confidence intervals in 
dashed lines and the line of identity shown as a dotted line. Inset are the (Passing-Bablok) 
regression formula and 95% confidence limits on intercept and slop. The deviance (modified 
Bland-Altman) plot showing the deviation of capillary from serum nandrolone expressed as a 
percentage. For further details see text. 
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Figure 3.4 Plot of mean and SEM of capillary nandrolone, testosterone and change in 
testosterone from pre-injection baseline in 8 participants before and daily for 21 days 
after subcutaneous injections of 100 mg nandrolone decanoate in 2 mL arachis oil. 
 Note: Some SEM are not visible when smaller than the data symbol.  
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Figure 3.5 Plots of non-linear curve fitting of T (left panel), N (right panel) and T 
suppression (lower panel) of capillary blood collection from 8 participants before and 
daily according to exact individual collection time points after SC injection of ND 
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Figure 3.6 Plot of mean and SEM of capillary, serum and venous nandrolone (left 
panel), testosterone (right panel) and serum LH and FSH (lower panel) in 8 participants 
before and weekly for 3 weeks after subcutaneous injections of 100 mg ND 
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3.5 Discussion 
DBS technology has been used for over 50 years mostly to measure individual analytes at a 
single time-point in screening assays or cross-sectional studies (McDade 2014, McDade et al. 
2007) for its simplified sample collection, processing and storage. It has been extended to 
measuring multiple analytes from a single filter spot (Edelman et al. 2007, Magnisali et al. 
2011, Worthman and Stallings 1997) but few studies have reported serial DBS sampling of 
ambulatory, community-dwelling individuals (Howe and Handelsman 1997) and its 
feasibility has been doubted (Kissinger 2011). This study shows that this advantageous 
feature is feasible for pharmacological studies of depot steroids, where remote sampling at 
home is more convenient than requiring repeated clinic visits for venipuncture as well as 
centrifugation for separating serum or plasma and bulky, frozen sample storage until assay 
and decreases in hemoglobin from frequent venesection. Furthermore, the use of population 
PK/PD modelling employing the exact time of finger-prick sampling also relaxed the 
stringency of time of day requirements for remote sampling. By reducing cost and 
complexity, thereby features facilitate community-based studies involving steroid 
measurements such as for the pharmacology of long-acting depot steroids and drugs.  
For over 6 decades, injectable T esters have been administered in a vegetable oil vehicle 
marketed solely for im injection (Junkman 1957). The pharmacokinetics and 
pharmacodynamics are primarily determined by ester chain side-length, volume of oil vehicle 
and injection site, all determining the hydrophobic physicochemical partitioning between the 
oil vehicle and aqueous extracellular fluid wherein ubiquitous esterases liberate the free 
steroids from their esters (Minto et al. 1997). However, there are no reports of the 
pharmacology of sc injections of androgen esters in an oil vehicle, other than a pilot study of 
22 hypogonadal men where blood T was measured by immunoassay a day before and a day 
after sc injection of low dose of T enanthate (mean 55 mg weekly, <0.3 ml oil) (Al-Futaisi et 
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al. 2006). No adverse effects or discontinuations were reported but the data provides minimal 
insight into the pharmacology of sc injection of androgen esters. In the present study using 
DBS technology to facilitate intensive and yet simplified blood collection from participants at 
home, we provide the first detailed pharmacological analysis of sc injection of ND in arachis 
oil vehicle. The present finding of sustained depot-like effects is expected given the known 
pharmacology of im N esters (Bagchus et al. 2005, Howe and Handelsman 1997, Minto et al. 
1997) together with the observations that most im injections are actually sc (see below). 
Using prior pharmacological data of im ND injections with  steroids measured by 
immunoassays, sc injection of 100 mg in 2 mL oil most closely resembles gluteal injection of 
100 mg in 4mL (rather than gluteal or deltoid in 1  mL) in pharmacokinetics (time of peak 6.0 
vs 5.0 days; peak concentration 2.5 vs 3.7 ng/mL) and pharmacodynamics (time of nadir 8.0 
vs 9.2 days; nadir concentration 0.38 vs 0.69 ng/mL) (Minto et al. 1997). Another study of 
gluteal im injection of 100 mg ND in 1 mL oil reported higher peak N concentrations (4.9 
ng/mL) and earlier (1.25 days) peak time (Bagchus et al. 2005) consistent with the reported 
effects of injection volume (Minto et al. 1997).  
Nevertheless, inadvertent and unrecognized sc injection of T and N esters in oil vehicle is 
common. It has been known for decades that sc fat is so thick that gluteal im injections 
frequently deposit the injectate into sc fatty tissue rather than muscle tissue (Cockshott et al. 
1982). Using computed tomography or ultrasound scanning to measure sc fat thickness and 
placement of injectate or comparison with length of injection needles, it is estimated that 12-
85% of im injections in men and 55-95% in women are actually sc (Boyd et al. 2013, 
Burbridge 2007, Chan et al. 2006, Cockshott et al. 1982, Haramati et al. 1994, Joo and Sohng 
2010, Nisbet 2006), the higher estimate in women corresponding to their greater sc fat 
thickness. This may also explain our observation that im T injections were less painful in 
overweight or obese men (Sartorius et al. 2010). Experimental studies in pigs show that sc 
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and im injections of drugs in an oil vehicle have similar pharmacokinetics (Perry et al. 1997, 
Svendsen et al. 1985). Although injection site granulomata have been reported more 
frequently  in sc fat compared with muscle (Baumann 2012, Cockshott et al. 1982), this 
observation is derived from hospital-based im injections, usually non-steroids in aqueous 
solutions, rather than the smaller minority of less toxic, oil vehicle based im injections 
typically administered in ambulatory care settings (Svendsen 1983, Svendsen et al. 1985).  
Although the tolerability of sc injections of androgen esters in an oil vehicle requires more 
extensive validation through further pharmacological studies of T esters as well as experience 
in its use, it is likely to be safe and tolerable. Extensive experience with T pellets indicates 
that sc implantation of pure crystalline T is safe and acceptable for months to years, marred 
only by a low rate of extrusions (Handelsman et al. 1997) due to a sterile reaction to 
implantation which is unrelated to mechanical factors (Kelleher et al. 2001, Kelleher et al. 
1999) or prevented by antibiotic cover (Kelleher et al. 2002). Similarly, the vegetable oils 
used as injection vehicles (e.g. sesame, arachis, castor, cottonseed and mellaleuca oils) for 
androgen esters are well tolerated clinically when administered intramuscularly (Mackey et 
al. 1995). They are better tolerated than mineral oils which are much more irritating when 
injected subdermally (Darsow et al. 2000, McWillams 1927, Rollins et al. 1997, Symmers 
1955) whereas vegetable oils also reduce local muscular damage compared with aqueous 
injections (Svendsen 1983, Svendsen et al. 1985). Previous studies have already shown that 
the pharmacology of androgen esters depends on site and volume of injection (Minto et al. 
1997) and further studies using T esters in men with differing body weight and after repeated 
injections are required to evaluate duration of action and usefulness in clinical practice of sc 
relative to im injections.  
The present study suggests that sc injections of T esters may prove safe and tolerable. If so, 
this would make self-injection of T esters feasible with the potential benefits of reducing 
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medical care costs, demand on medical personnel time and injection site pain or bruising as 
well as allowing freer use among those with bleeding disorders or on anticoagulants to use 
this more convenient long-acting depot form of T delivery. 
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Chapter 4  Immunoreactive LH in long-term frozen human urine 
samples. 
4.1 Introduction 
LH together with FSH are principal pituitary hormones exerting dynamic neuroendocrine 
control of the initiation and maintenance of mature reproductive functions. In addition to 
initiating puberty, in women LH drives follicle maturation and ovulation while in men it 
governs Leydig cell production and secretion of T. Consequently measuring LH is 
fundamental to understanding of reproductive neuroendocrinology. Urine has always been 
the preferred sampling format for anti-doping testing as well as for long-term and field 
studies such as neonatal (Kuijper et al. 2006), adolescent (Hayes and Johanson 1972, 
McNeilly et al. 2012), occupational (Kesner et al. 1999, Whelan et al. 2002) or toxicological 
(Kesner et al. 1999, Kuijper et al. 2006, Whelan et al. 2002) cohort studies where urine 
collections avoid the need for repeated venipuncture. Urinary LH measurement has a role in 
confirming androgen doping because exogenous androgens suppress urinary LH (Cowan et 
al. 1991, Goebel et al. 2009, Handelsman et al. 2009, Kicman et al. 1990). Furthermore, 
abuse of anti-estrogens, GnRH analogs and recombinant LH (Handelsman 2006) may also be 
detected by increased urinary LH levels. 
One limitation is that modern commercial human LH immunoassays have been established 
and validated solely for blood samples and not urine sample, unlike hCG immunoassays 
which were always developed for qualitative urine pregnancy testing as well as for blood 
samples although quantitative urinary hCG assays are described (Cole and Khanlian 2009). 
Urine LH immunoreactivity may depend on urine sample storage conditions as well as 
immunoassay epitope specificity. For example, pre-storage extraction by acetone 
precipitation (Reiter et al. 1973, Saketos et al. 1994) or by addition of glycerol or albumin 
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(Kesner et al. 1995, Livesey et al. 1983, Saketos et al. 1994) stabilize immunoreactivity. 
Furthermore, whereas two-site assays with epitopes on different subunit of the heterodimer 
optimizes detection of intact LH (Alonso-Whipple et al. 1988, Nilsson et al. 2001, Pettersson 
et al. 1991), dissociation of LH into its subunits, influenced by exposure to high urinary 
concentrations of urea (Lempiainen et al. 2012), may be reflected in loss of immunoreactivity 
whether or not the subunit remain intact especially at -20 °C storage (Lempiainen et al. 
2012). This is consistent with the stability of a urinary LH assay based on a different strategy 
of pre-assay dissociation into subunits with detection aimed at the LHβ subunit (Brindle et al. 
2006), an assay displaying prolonged stability during frozen storage (Brindle et al. 2006, 
O'Connor et al. 2006). However, it is simpler for field studies to implement urine LH 
immunoassays that do not require pre-storage manipulation. In addition, as glycerol is on the 
World Anti-Doping Prohibited List as a banned chemical for athletes, it cannot be used with 
urine samples collected for anti-doping testing. Therefore, this study aimed to evaluate the 
stability of urinary LH immunoreactivity using two commercially available immunoassays, 
an immunofluorometric (IF, Delfia, Perkin-Elmer) and an immunochemiluminometric (ICL, 
Immulite, Siemens) assay, before and after 4 years of storage at -20 °C without addition of 
any preservatives. 
4.2 Study Design 
Urine samples were obtained from a previous study that evaluated the potential of 
recombinant hCG (rhCG, Ovidrel, MerckSerono Pty Ltd) as an indirect androgen doping 
agent (Handelsman et al. 2009). The effects of two doses of rhCG, with or without 
concomitant administration of ND (Deca-Durabolin, Organon Australia Pty Ltd, Lane Cove, 
Sydney) to suppress endogenous LH and T (Minto et al. 1997), on urine and serum LH and 
testosterone were examined in 24 healthy young men aged 18-45 years who received a single 
sc injection of rhCG (250 or 750 μg). Spot urine samples were collected before and daily for 
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8 days after dosing and stored frozen at -20 °C until analysis in a single batch at the end of 
study (2008) and then again (2012) after 4 years of unthawed storage at -20 °C. At both 
times, the full batch was analysed in duplicate by ICL (Immulite 1000 LH, Siemens) and IF 
(Delfia hLH assay, Perkin Elmer, Rowville, Melbourne, Victoria) assays (refer Chapter 2 for 
assay details). Urinary SG was measured by a refractometer and urine LH values were 
adjusted to a standard SG of 1.020. Prior to assay, urine samples were thawed and warmed at 
37°C in a sealed container for 10-15 minutes with shaking to redissolve sediments.  
4.3 Data analysis 
Results are expressed as mean ± SEM. The LH concentrations measured in either assay at 
each time were compared by Passing-Bablok non-parametric regression and deviance (Bland-
Altman plot) analysis using MedCalc software. 
4.4 Results 
The comparison of urinary LH concentrations measured using IF and ICL immunoassays, 
adjusted to standard SG, when run in either 2008 or after 4 years frozen storage (2012) is 
shown in Figure 4.1. The comparison between the two LH assays when both were run in 
2008 and then again when both were run in 2012 after 4 years frozen storage, is shown in 
Figure 4.2. The details of the Passing-Bablok regression equations to compare urinary LH 
using the IF and ICL at both times is given in Table 4.1.  
The urine LH concentrations measured using the ICL assay when comparing measurements 
in 2008 and 2012 shows good correlations (Figure 4.1, Table 4.1). By contrast, the IF assay 
showed marked reduction (~70%) in LH concentration when measured in 2012 compared to 
2008 (Figure 4.1, Table 4.1).  
When comparing LH assays performed in 2008, and then again after 4 years frozen storage, 
the two LH assays were discrepant. In 2008 the IF assay provided LH measurements which 
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were ~50% of those in the concurrent ICL LH assay (Figure 4.2, Table 4.1). In 2012, the IF 
LH assay was reduced to ~30 % compared with the contemporaneous ICL assay (Figure 4.2, 
Table 4.1).  
The mean urinary LH concentration (adjusted for urine SG) in the original study measured 
with IF and ICL in year 2008 and 2012 is depicted in Figure 4.3. The pattern of the urinary 
LH profile was very similar but not identical using either immunoassays at the end of study 
(2008) and again after 4 years of frozen (-20 °C) storage. Despite loss of immunoreactivity 
according to one (IF) but not the other (ICL) assays in all series the suppression of urine LH 
was clearly evident.  
The details of the Passing-Bablok regression equations to compare urinary (ICL and IF) and 
serum LH (IF) is given in Table 4.2. The intercept of all the four comparisons was not 
significantly different from 0 although there were variations in the slope and correlations 
(Table 4.2). 
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Figure 4.1 Comparison of urinary LH concentrations obtained using IF (left panels) and 
ICL (right panels) measured before and after four years of storage at -20 °C. 
 
Levels of urinary LH between the same assays were compared using Passing and Bablok 
regression analysis (upper panels). The slope (solid line) is calculated with 95% confidence 
bands (dotted lines) and line of identity (fine dotted line). The Bland-Altman plots (lower 
panels) represent urinary LH differences against averages of the two measurements. The solid 
line and the dotted line represent the observed average agreement and 95% limit of 
confidence respectively. 
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Figure 4.2 Comparison of urinary LH concentrations measured by IF and ICL in 2008 
(left panels) and 2012 (right panels). 
 
Levels of urinary LH between the two assays were compared using Passing and Bablok 
regression analysis (upper panels). The slope (solid line) is calculated with 95 % confidence 
bands (dotted lines) and line of identity (fine dotted line). The Bland-Altman plots (lower 
panels) represent urinary LH differences against averages of the two measurements. The solid 
line and the dotted line represent the observed average agreement and 95 % limit of 
confidence respectively. 
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Figure 4.3 Plot of urine LH assayed with Delfia (left panels) and Immulite (right panels) 
for year 2008 (upper panels) and 2012 (lower panels). 
Data represents the mean and SEM of spot urine collected before and after dosing of hCG 
(with or without nandrolone suppression). Note all LH concentrations are adjusted to 
standard urine SG of 1.020.  
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Table 4.1 Comparison of urine LH determined using two immunoassays. 
The number of urine samples (n) with the slope, intercept and correlation coefficient (r) and 
their 95% confidence intervals in parentheses determined by Passing-Bablok regression. 
Assays compared n Slope  Intercept  r  
Delfia 2008 vs 2012 156 0.30 (0.27, 0.36) 0.04 (-0.01, 0.10) 0.72 (0.63, 0.78) 
Immulite 2008 vs 2012 180 1.06 (0.94, 1.19) -0.25 (-0.57, 0.15) 0.70 (0.61, 0.76) 
Immulite vs Delfia 2008 156 0.49 (0.45, 0.53) -0.11 (-0.41, -0.02) 0.84 (0.79, 0.88) 
Immulite vs Delfia 2012 156  0.16 (0.14, 0.18) -0.03 (-0.07, 0.00) 0.78 (0.71, 0.83) 
 
Table 4.2 Comparison of urine LH determined using Immulite and Delfia (2008 and 
2012) versus serum LH determined using Delfia (2008). 
The number of samples (n) with the slope, intercept and correlation coefficient (r) and their 
95% confidence intervals in parentheses determined by Passing-Bablok regression. 
Urine LH  vs  
Serum LH (Delfia 2008) n Slope  Intercept   r 
* Delfia 2008 156 0.34 (0.28, 0.40) 0.02 (-0.05, 0.09) 0.70 (0.61,0.77) 
Delfia 2012 180 1.22 (1.04, 1.41) -0.03 (-0.11, 0.04) 0.61 (0.51, 0.69) 
*Immulite 2008 180 0.16 (0.13, 0.19) -0.03 (-0.08,0.02) 0.64 (0.54, 0.72) 
Immulite 2012 180 0.15 (0.11, 0.19) 0.03 (-0.05,0.07) 0.43 (0.30, 0.54) 
 
* Note: Data obtained from (Handelsman et al. 2009) 
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4.5 Discussion  
The present study demonstrated that two available commercial LH immunoassays optimized 
for blood samples can also be used for urinary LH measurement. However, the performance 
of both LH assay with urine samples differed markedly. The ICL immunoassay showed 
quantitatively reproducible LH measurement even after prolonged storage at -20 °C for 4 
years without addition of preservatives. By contrast, the IF immunoassay demonstrated 
consistently but proportionately lower LH measurements relative to the ICL assay both 
initially and then exhibited a further decrease after 4 years of frozen storage. Yet, despite the 
reduced absolute LH measurements by the IF immunoassay, both LH immunoassays 
displayed sufficiently similar patterns of urine LH measurements to confirm the findings of 
the original study that hCG administration produces LH suppression (Handelsman et al. 
2009). Hence either assay used before or after prolonged frozen storage may be sufficient for 
a research study whereas only one provides quantitative results after frozen storage as might 
be required for look-back of stored anti-doping samples, an application which requires 
reproducible quantification of absolute levels. Similar findings were reported for serum LH 
measurements where the performance of the ICL was reported to be more sensitive and 
accurate compared to the IF immunoassay for the determination of reference range during 
sexual development in normal children (Resende et al. 2007). 
Commercially available immunoassays designed for serum or plasma LH measurements 
require careful validation for use with urine samples particularly when inference is to be 
drawn from suppressed urine LH values (Cowan et al. 1991, Goebel et al. 2009, Kicman et al. 
1990, Mareck et al. 2010, Palonek et al. 1995, Perry et al. 1997). In addition to the two LH 
immunoassays in this study, thorough validation has been published for two LH 
immunoassays (Access and Elecsys) (Robinson et al. 2007) and indirectly for a third 
(Axsym) (Llouquet et al. 2013, Perry et al. 1997). Other studies reported good correlation of 
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urine and serum LH in children and cycling women as determined by IF immunoassay 
(Demir et al. 1994, Saketos et al. 1994). Validation after prolonged frozen conditions has not 
been evaluated by available commercial immunoassays.  
These discrepancies between LH immunoassays most probably reflect the diversity of 
immunoreactive LH species in human urine compared with the bloodstream (Birken et al. 
2001, Birken et al. 2007, Stenman et al. 2008). This diversity reflects the metabolism of the 
gonadotropins which produces nicked dimers and free subunits including the core fragment. 
Like hCG where the metabolism is more fully characterized (Bristow et al. 2005), the 
homologous LH heterodimer is metabolized and excreted in the urine in various fragments 
which are largely in the forms of free subunits and fragmented forms of LHβ (Birken et al. 
1996, Kovalevskaya et al. 1995). The differences between the two LH assays presumably 
reflect on the capability of the two-site immunoassays to detect various LH epitopes 
(O'Connor et al. 1998). Both the assays detect intact LH and some fragmented forms 
probably including the core beta fragment. It is possible that the ICL immunoassay detects 
other unknown fragment(s) which are not detected by the IF immunoassay. This could 
explain the consistently lower LH levels measured by the IF assay than the ICL assay. Earlier 
studies have also reported IF immunoassays meant to detect intact LH failed to detect variant 
forms either in urine or serum samples that lead in discrepancies in measurements of LH 
using different immunoassays (Nilsson et al. 2001, Pettersson et al. 1991). LH immunoassays 
with both β-directed monoclonal antibodies are reported to give higher urinary LH 
concentrations compared to assays that only detect intact LH (Nilsson et al. 2001). Assays 
that have highly specific antibodies may also be problematic in that they may not measure all 
forms of LH (Pettersson et al. 1991, Pettersson et al. 1992, Pettersson and Soderholm 1991). 
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Loss in urinary LH and hCG immunoreactivity after 7 to 70 days of storage at -20 °C 
(unpreserved) measured with the IF immunoassay (Lempiainen et al. 2012, Saketos et al. 
1994), RIA (Livesey et al. 1983) and immunoenzymatic assay (Robinson et al. 2007) was 
also reported previously which was attributed to the dissociation of the heterodimeric 
glycoprotein into its subunits in the presence of urinary urea in specimens (Lempiainen et al. 
2012, Livesey et al. 1983). Loss of immunoreactivity of urinary LH (measured with IF 
immunoassay) was also reported after 24 weeks of -80 °C storage (Kesner et al. 1995). 
Acetone extraction and addition of preservatives such as bovine serum albumin and glycerol 
was reported to stabilize LH immunoreactivity in frozen storage (Kesner et al. 1995, Livesey 
et al. 1983, Saketos et al. 1994). However, using sample preservatives for research sample 
collection is inconvenient and adds to time and expense (Brindle et al. 2006) and similarly 
some preservatives such as glycerol are unsuitable for anti-doping purpose. Previous studies 
have reported that plasma LH is stable after storage for 8 and 14 days after refrigeration (4 
°C) (Kubasik et al. 1982, Livesey et al. 1980), for 14 days stored frozen (-6 °C) (Kubasik et 
al. 1982) and for up to 9 months after -20 or -70 °C storage (Tsatsoulis et al. 1988). 
The quantitative reproducibility of the ICL immunoassay indicates it is more robust for 
measurements of urinary LH for anti-doping purposes compared with the IF assay. 
Nevertheless despite the quantitative reduction in urine LH by the IF assay, the reduction was 
proportionate over the four years frozen storage. Consequently the IF assay remains 
applicable in research studies where, rather than absolute quantification, relative 
measurements confined to within-study inference, may still be useful. 
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Chapter 5 Requirement for Specific Gravity and Creatinine 
Adjustments for Urinary Steroids and Luteinizing Hormone 
Concentrations in Adolescents 
5.1 Introduction 
Measurements of urinary gonadotropins and steroids in children and adolescents emerged as 
methods to estimate pubertal development and gonadal function early in the immunoassay era 
(Kulin and Santner 1977, Raiti et al. 1969, Vestergaard et al. 1966). Subsequently, urine 
sampling was replaced by serum or plasma immunoassays due to preferences for blood 
collection over cumbersome and time-consuming urine collections (e.g. 24 hr sampling) and 
extraction procedures required to assess urine solute concentrations. In recent years, however, 
measurements of urinary gonadotropins and steroids have reappeared with the development 
of highly sensitive assays that can measure urinary gonadotropins without extraction (Brindle 
et al. 2006).  
Urine may be collected either as untimed spot collection at random times, first morning void 
or timed (e.g. 24 hours urine collection) collections. Urine sampling provides an integrated 
measurement especially for hormones secreted in pulsatile manner such as LH (Kulin et al. 
1975) or diurnally like sex steroids in early puberty, and is more acceptable to children and 
adolescents than venipuncture. Further, for longitudinal studies, spot urine hormone 
measurements are more convenient and/or less intrusive than blood or saliva collections, a 
simplification which enhances the feasibility and participant compliance with repeated 
sampling over time. The relatively high hormone concentrations in urine compared with 
blood or saliva, together with the ability to concentrate urine, is advantageous for assays with 
low sensitivity or analytes at low concentrations. However, an inherent problem of using 
urine is the wide and unregulated variation reflecting the individual’s fluid status.  
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Urine dilution or concentration creates corresponding changes in urine solute concentrations 
so that adjustment of urine concentration may be required to avoid misinterpreting hormone 
excretion due to variation in hydration (Cone et al. 2009). Osmolality, SG and creatinine 
measurements are used to adjust for hydration (Barr et al. 2005). Although measurement of 
osmolality by freezing point depression is considered the reference method (Chadha et al. 
2001), it is laborious, time consuming and expensive so is usually replaced by SG and 
creatinine measurements particularly for large scale, field studies. Urinary SG is measured 
using a refractometer to compare light refraction of a urine sample against pure water 
standard or by reagent strips which measure the ionic strength of urine by color changes. 
Urine SG of sample is normalized to a population reference value. While SG measurement 
has been largely superseded by urine creatinine adjustment in clinical laboratories, SG 
adjustment for urine dilution remains standard in anti-doping laboratories and is used in some 
toxicology studies (Aylward et al. 2014). Creatinine adjustment is based on the assumption 
that (a) this end-product formed endogenously from muscle creatine is released into the 
bloodstream and excreted in urine at a constant rate depending only on total muscle mass 
(Boeniger et al. 1993) and (b) endogenous hormones and creatinine undergo renal excretion 
at the same rate (Barr et al. 2005). Yet, creatinine excretion rate may be influenced by the 
growing muscle mass during puberty leading to potential systemic errors in using creatinine 
adjustments (Heavner et al. 2006).  
Some (Denari et al. 1981, Haddow et al. 1994) but not other (Alessio et al. 1985, Berlin et al. 
1985, Jatlow et al. 2003, Thompson et al. 1990, Zacur et al. 1997) studies suggest creatinine 
or SG adjustment for measurement of urinary substances although such adjustments may be 
either unnecessary or even introduce additional measurement errors. Furthermore, none have 
focused on situations where creatinine is changing systematically due to somatic growth. 
Thus the present study aimed to determine whether the first morning void hormonal 
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assessments carried out in growing young adolescents at various stages of pubertal 
progression require adjustments and, if so, to determine whether creatinine or SG adjustment 
was better.   
5.2 Study Design 
Urine samples were from the Adolescent Rural Cohort, Hormones, Health, Education and 
Relationships (ARCHER) study, a three year longitudinal study aiming to determine how temporal 
changes in pubertal hormones influence the physical status, behavior and mental health of 
adolescents. The details of the study design have been published previously (Steinbeck et al. 2012). 
Briefly, the study involves a total of 342 adolescents from the regional towns Dubbo, Orange and 
their surrounding rural region in western NSW, Australia. The samples reported in the present study 
were from those collected in the first year of the study (n=644; age distribution ranging between 10.1 
and 14.3 years at initial sampling). Ethical approval was obtained from the Human Research 
Ethics Committee, University of Sydney (HREC 13094). Fasting morning blood samples 
were collected at 0 and 12 months (n=343) and first morning urine collected three monthly 
after 12 hr fasting at home by the adolescents between 7.00 am and 8.30 am (n=644). Post-
menarcheal girls provided samples in the mid-follicular phase (day 7-10) with the assumption 
of 28-32 day cycle. Serum and urine samples were stored at -80 C until analysis. The 
adolescents also provided a self-rating of puberty using line drawings based on the Tanner 
stages at 0 and 12 months. 
The LH and steroid concentrations were adjusted to standard SG of 1.020 according to the 
formula [hormone concentrationsample X (1.020-1)/(SGsample-1)] (Wallis et al. 1985) and to 
standard CR measurement of the present study adolescent population (12.40 mmol/L [n=644; 
F 331]) using the formula [hormone concentrationsample X (Creatininepopulation/Creatininesample)] 
where Creatininepopulation was defined as the mean of the urinary creatinine of the whole 
sample. 
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5.3 Data Analysis 
The steroid and LH concentrations unadjusted and adjusted for SG or creatinine were 
compared by Deming (orthogonal) regression and deviance (Bland-Altman) analysis using 
MedCalc software. Based on using the same analyte with different adjustments, the variance 
ratio in the Deming regression was assumed to be unity. Non-independence according to 
variations in the number of samples provided by each individual was ignored in this analysis. 
Descriptive statistics including mean, SD and SEM were performed by SPSS version 21. The 
F- ratios of age and Tanner stage group comparison for each hormone were calculated by 
one-way ANOVA separately for each gender.  
5.4 Results 
In first morning urine void samples (n=644), the mean (SD, range) creatinine concentration 
was 12.4 (4.5, 1.4 - 31.5) mmol/L with an overall gender difference being higher in males 
(P<0.05). The SG was 1.020 (0.0054, 1.005 - 1.030) without significant gender difference 
(P=0.054). Urine creatinine concentrations were progressively increased according to 
chronological age and to Tanner stage (Figure 5.1) for both genders. Pooling genders, there 
were significant differences in urine creatinine concentrations by age and Tanner stage 
(P<0.05, two-way ANOVA) but not for urine SG according to age (P=0.29) or Tanner stages 
(P=0.22).  
Urinary LH, E2, T, DHT and DHEA concentrations, adjusted for either SG or creatinine, are 
compared according to Deming regression line and the deviance plots are shown in Figure 
5.2. For each urinary hormone concentration, there was a good correlation between the SG 
and creatinine adjusted concentrations (correlation of determination-R
2
: 0.69 - 0.85) free 
from proportional bias between adjustment methods.  
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Similarly, Deming regression and Bland-Altman comparison between the unadjusted and 
adjusted hormone concentrations with either SG or creatinine (Table 5.1) also demonstrate 
lack of bias whether adjusted or not by either creatinine or SG.  
The mean, SD and F-ratios of the unadjusted, SG adjusted and creatinine adjusted hormones 
according to Tanner stages and age groups in females and males are shown in Tables 5.2-5.3 
and Table 5.4-5.5, respectively. The results show consistent estimates and progression 
according to age and Tanner stage of unadjusted, SG adjusted and creatinine adjusted urine 
LH and steroid concentrations. The mean, SD and F-ratios of serum hormones according to 
Tanner stage and age groups are shown in Table 5.6 and 5.7.  
The r of paired urinary and serum hormone concentrations is given in Table 5.8. The 
unadjusted and adjusted (creatinine and SG) urinary LH, E2, T, DHT and DHEA 
concentration showed similar correlation against serum. The samples were also grouped into 
three creatinine and SG percentile ranges (up to 25th percentile, between 25th to 75th 
percentile and above 75th percentile) and regression analysis was performed between 
unadjusted/adjusted urine hormone concentrations against serum hormone concentrations. 
There were no improvements in the r values within the groups. Dividing the same percentiles 
according to gender also did not improve the correlations between the urine 
unadjusted/adjusted hormones against serum hormones concentrations. 
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Figure 5.1 Plot of urinary creatinine measurements of adolescents groups according to 
age (upper panel) and Tanner stage (lower panel). 
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Data represents the creatinine mean and SEM. For the age plot, samples were from 3-
monthly intervals (n=644) whereas for the Tanner stage plot, samples were from 0 and 12 
months (n=359). 
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Comparisons were made according to Deming regression analysis (left panels) and Bland-Altman plots (right panels). 
For the Deming plots, the slope is shown as a solid line and line of identity in fine dotted line. Insets are the regression 
formula and 95% confidence limits on the intercept and slope. The Bland-Altman plots represent the differences 
between creatinine and SG adjusted hormone concentrations against the averages of the hormone concentrations 
adjusted with the two-correction method. The solid line and the dashed lines represent the observed average and the 
95% limit of confidence (± 1.96 SD), respectively. Note: A small number (n=6) of outliers were removed for graphical 
purposes. For the Deming regression, the variance ratio was assumed to be unity. To convert steroids from ng/mL to 
nmol/L multiply 3.47 for T and DHEA, 3.67 for E2 and 3.44 for DHT  
 
 
 
Figure 5.2 Comparison of urinary LH, E2, T, DHT and DHEA concentrations adjusted by SG and creatinine. 
                                                                                                                                                                   Chapter 5 
 
   138 
 
Table 5.1 Comparison of unadjusted against SG and CR adjusted urinary hormone 
measurements. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The slope, intercept and 95% confidence interval (CI) were determined by Deming regression. 
The mean and 95% CI (± 1.96 SD) were derived from the Bland-Altman plots.  
 
 
Note: UA- unadjusted; SG- specific gravity adjusted; CR- creatinine adjusted; R2-correlation of 
determination. For the Deming regression, the variance ratio was assumed to be unity. 
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Table 5.2 Comparison of mean urinary hormone measurements (unadjusted, SG 
adjusted and CR adjusted) and F- ratios according to Tanner stage in female. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*All the P values were <0.05 unless indicated in parentheses  
(n)# Indicates number of samples  
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Table 5.3 Comparison of mean urinary hormone measurements (unadjusted, SG 
adjusted and CR adjusted) and F- ratios according to Tanner stage in male. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*All the P values were <0.05 unless indicated in parentheses  
(n)# Indicates number of samples  
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Table 5.4 Comparison of mean urinary hormone measurements (unadjusted, SG 
adjusted and creatinine adjusted) and F- ratios according to age groups in female. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*All the P values were <0.05 unless indicated in parentheses.  
(n)# indicates number of samples  
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Table 5.5 Comparison of mean urinary hormone measurements (unadjusted, SG 
adjusted and creatinine adjusted) and F- ratios according to age groups in male. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*All the P values were <0.05 unless indicated in parentheses.  
(n)# indicates number of samples  
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Table 5.6 Comparison of mean serum hormone measurements and F- ratios according 
to Tanner stage in female and male. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*All the P values were <0.05 unless indicated in parentheses  
(n)# indicates number of samples  
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Table 5.7 Comparison of mean serum hormone measurements and F- ratios according 
to age groups in female and male. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
*All the P values were <0.05 unless indicated in parentheses  
(n)# indicates number of samples  
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Table 5.8 Pearson’s correlation coefficient and confidence intervals (in parentheses) of 
paired urinary and serum LH, E2, T, DHT and DHEA (n=343). 
 
 
 
 
 
 
 
5.5 Discussion  
Urinary measurement of reproductive hormones is a convenient means to evaluate pubertal 
status and gonadal function for field population studies. In clinical settings, adjustment based 
on the assumption of stable urine creatinine excretion is commonly used to adjust for 
variations in hydration although other techniques such as regression normalization or log 
transformation are proposed (Gaines et al. 2010, Heavner et al. 2006). As an end metabolite 
of muscle creatine, urine creatinine is determined by total muscle mass in addition to other 
factors such as age, gender, diet (meat consumption), physical activity, and BMI some of 
which exert their effects via changes in muscle mass (Alessio et al. 1985, Barr et al. 2005, 
Carrieri et al. 2000, Suwazono et al. 2005). Hence one aim of the present study was to 
determine for the first time whether creatinine adjustment was valid or required for 
longitudinal studies of growing adolescents.  
Our findings confirm that the first morning urine creatinine concentration increases with age 
and Tanner stages and was higher among males. However, adjustment for urine creatinine 
was no better or worse than adjustment for SG or even no adjustment. This may reflect the 
fact that we studied first morning void urine samples which control hydration, whereas 
similar interpretation may not apply to urine sampled at random when hydration state may 
 
Note: UA- unadjusted; SG- specific gravity adjusted; CR- creatinine adjusted.   
 
                                                                                                                                                                   Chapter 5 
 
   146 
 
vary more. Our findings are consistent with previous studies showing prominent intra- and 
inter-individual variability in creatinine excretion of second morning and 24h urine samples 
in adults due to variable fluid intake (Alessio et al. 1985). Significantly higher creatinine 
levels in morning versus afternoon (Colombi et al. 1983), in evening spot samples (Barr et al. 
2005) and creatinine loss due to multiple freeze-thaw cycles have also been reported (Garde 
et al. 2003, Schneider et al. 2002) all of which introduce systematic errors in use of urine 
creatinine for dilution adjustments. Thus, although studies have suggested alternative 
adjustment based on SG in adult humans and primates (Miller et al. 2004, White et al. 2010), 
none have focused on the need for SG adjustments in first morning voids of growing 
adolescents.   
SG is readily measured by reagent strip for field studies without needing a laboratory. 
Previous studies demonstrate good agreement between SG measurements by reagent strip 
versus refractometer (Frew et al. 1982, Moore Jr et al. 1997) or osmolality (Dorizzi et al. 
1987, Frew et al. 1982, Gounden and Newall 1983). SG measurement by reagent strip is 
widely used in clinical applications (Burkhardt et al. 1982, Gounden and Newall 1983). 
Although refractometer urine SG may be influenced by disease states leading to high serum 
protein or glycosuria,(Chadha et al. 2001, Voinescu et al. 2002)  reagent strip SG is not 
affected by glucose, only minimally by urea and albumin, but may be affected by the rare 
instances of alkaline urine (Dorizzi et al. 1987). Urine SG reading may also be influenced by 
diet, environment and the renal reabsorption capacity (Trevisan 1990). Among adolescents, 
we find that urine SG measured with reagent strips is systematically not influenced by age or 
gender consistent with previous reports (Nermell et al. 2008, Suwazono et al. 2005). 
Limits of acceptable creatinine and SG measurements vary between studies. Generally, urine 
is considered too dilute when the SG and creatinine levels are lower than 1.010 and 0.5 g/l 
(4.4 mmol/L), respectively, and too concentrated where SG and creatinine levels higher than 
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1.030 (or 1.035) and 3 g/l (26.5 mmol/L), respectively (Alessio et al. 1985, Trevisan 1990). 
However, due to the standardized method of collection and hydration (first morning void), 
the present study did not discard any samples as too dilute or too concentrated. 
 The present study demonstrated that the fasting first morning void urine hormone 
concentrations adjusted by creatinine correlated well with those adjusted by SG in this 
adolescent population. This is consistent with previous reports that used randomly collected 
or timed urine collection from children and adults showing good correlations when creatinine 
and SG adjustments were compared directly (Carrieri et al. 2000, Cone et al. 2009, Gaines et 
al. 2010, Haddow et al. 1994, Parikh et al. 2002, Trevisan 1990) or with adjustment 
according to both (Cone et al. 2009, Miller et al. 2004, White et al. 2010) including a reduced 
variation using these adjustments in some studies (Haddow et al. 1994, Heavner et al. 2006). 
However, the present study shows that neither of the adjustment methods for first morning 
void urine sample of adolescents were significantly improved compared to unadjusted 
hormone concentrations. These observations are consistent with previous reports for 
creatinine adjustment of urine steroid measurements in adult women (Hakim et al. 1994, 
Miyakawa et al. 1981).  
In studies where the urinary hormone concentrations were correlated with paired circulating 
serum concentrations, the urinary unadjusted concentration or concentration expressed by 
volume of urine correlates better than the adjustment based on analyte to creatinine ratios 
(Demir et al. 1994, Denari et al. 1981, Zacur et al. 1997), although some studies have shown 
improved correlation with creatinine adjustments (Munro et al. 1991, Seki et al. 1985). The 
present study demonstrated that the urinary hormone concentrations adjusted with creatinine 
and SG did not improve the correlation with paired serum concentrations. These samples 
were also grouped into three creatinine and SG percentile ranges (25th, 25-75th and 75th) to 
replicate non-fasting conditions with wider variation in hydration status. However, no 
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improvement was observed in terms of correlation between the unadjusted or adjusted urine 
hormone and paired serum concentrations. These findings further support that the 
adjustments may not be necessary for first morning void urine samples. 
In conclusion, the present study shows that adjustment of urinary steroid and LH 
concentration for hydration state may not be required for first morning void specimens of 
even growing adolescents. If adjustments are required, then either creatinine or SG are 
equally suitable and provide comparable results. Reagent strip SG measurements are simple 
and sufficiently reliable, economical and time-saving for large numbers of urine sampling in 
long-term field studies. 
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Chapter 6  Urinary Sex Steroids, Luteinizing Hormone and 
Anthropometric Markers of Puberty 
 
6.1 Introduction 
The circulating gonadotropin,  T and E2 changes that drive the external manifestations of 
puberty are well described from cross-sectional studies according to chronological age or 
Tanner staging interpreted quasi-longitudinally (Dorn et al. 2006, Lee and Houk 2006). Such 
cross-sectional analysis artificially smooths longitudinal data due to a low resolution in 
temporal sampling, markedly underestimating the underlying within-subject variability. 
Hence the large, normal variability in both time of onset and tempo of completing puberty 
has been insufficiently considered as important intermediate factors in the marked physical 
and psychological changes wrought by puberty. Furthermore previous studies have relied 
upon older methods of often direct (unextracted) sex steroid immunoassays, an inaccurate 
technology especially at low circulating steroid levels concentrations (Handelsman and 
Wartofsky 2013), which is now being supplanted by more sensitive and specific MS-based 
steroid assays (Handelsman and Wartofsky 2013, Sikaris et al. 2005). Similar more sensitive 
MS-based methods have been recently described for serum sex steroids in pre-pubertal 
children (Courant et al. 2010). 
 
In clinical settings the usual methods to appraise pubertal development comprise hormone 
measurements and anthropometry, with emphasis on timing of the height growth spurt, 
clinical inspection and bone age (Biro et al. 1995, Bordini and Rosenfield 2011). In 
epidemiological studies the definition of puberty has to be simplified to be based on 
adolescent self-report or parental report against either Tanner stage line drawings (Marshall 
and Tanner 1969, Marshall and Tanner 1970) or Petersen’s Pubertal Development Scale 
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(Dorn et al. 2006). Self-rated Tanner staging is less intrusive and more feasible than clinician 
assessment for epidemiological studies despite some loss of reliability, especially in early 
puberty, which can be overcome by larger sample size (Bonat et al. 2002, Desmangles et al. 
2006, Hergenroeder et al. 1999, Morris and Udry 1980). Menarche (a late pubertal event), 
spermarche (Ji 2001, Nielsen et al. 1986) which is difficult to evaluate (Sivananthan et al. 
2012), semenarche, and voice breakage have all  been described in relation to age and/or 
Tanner stage (Laron 2010, Sun et al. 2012) but as solitary time points provide minimal 
information on either timing of onset or tempo of puberty. To date there have been no reports 
describing individual puberty hormone change with sufficient measurement frequency to 
adequately capture individual variation, which is necessary to adequately describe onset and 
tempo of puberty for a community-based study. 
The first aim of this study is to validate the feasibility of the frequent urine sampling regimen 
and the urine assay methodology for LH, E2 and T. The second aim is to validate the changes 
in urine LH, E2 and T over 12 months by reference to contemporaneous changes in 
anthropometry and self-reported Tanner stage. 
6.2 Study design 
Adolescents between the ages of 10 and 12 years were recruited from local schools of two 
regional towns in the state of New South Wales (NSW), Australia. Fasting morning blood 
samples were collected at 0 and 12 months for the measurement of LH, E2 and T, and first 
morning (fasting) urine collected three monthly for the same measures. No participants had 
an endocrine disorder or were on any type of gonadal steroid hormone therapy. Height was 
measured using a portable stadiometer (to 0.1 cm). Weight was measured in light clothing 
using a Tanita TBF-300 Pro Body Composition Analyzer (Kettaneh et al. 2005). Height, 
weight and BMI (kg/m
2
) were expressed as z-scores using the Centres for Disease Control 
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(CDC 2000) and World Health Organization (WHO 2006) standard age and gender reference 
charts. The adolescents provided a self-rating of puberty using line drawings based on the 
Tanner stages (Marshall and Tanner 1969, Marshall and Tanner 1970). Self-report of Tanner 
stage (Bonat et al. 2002, Desmangles et al. 2006, Hergenroeder et al. 1999, Morris and Udry 
1980) was the only feasible and ethically acceptable measure of pubertal staging available to 
the investigators. 
First morning urine following a 12 hour fast was collected at home before blood samples 
were collected between 7:00 am and 8:30 am to minimise the effects of diurnal hormone 
variation (Bremner et al. 1983, Dorn et al. 2006). Serum and urine were stored at -80 °C. 
Post-menarcheal girls provided urine and blood specimens in the mid-follicular phase (Day 7-
10) of their menstrual cycle. Serum and urine steroids were measured by LC-MS/MS assay 
(Chapter 2). Blood and urine samples with hormone values less than the LLOQ for E2 and T 
were taken as half the LLOQ. 
Serum and urine LH were measured by Immulite 1000 LH (Chapter 2). The within-assay 
coefficients of variation were <10%. Serum and urine LH values below the detection limit 
(0.1 IU/L) were set at zero. Urine FSH assays (Immulite, Delfia) did not pass validity tests 
(dilutional linearity, quantitative spike recovery) and were not used in this study. All urine 
hormone concentrations were adjusted for urine SG measured by reagent strip (Chapter 2) to 
a standard SG of 1.020.  
The study has ethical approval from the Human Research Ethics Committee, University of 
Sydney (HREC 13094) within the NHMRC, which are consistent with the Declaration of 
Helsinki. All participants assented, and a parent provided written informed consent prior to 
commencing the study. 
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6.3 Data analysis 
Two-way ANOVA was used to determine effects of gender and scheduled sampling time and 
their interaction on anthropometric and hormone outcomes. ANCOVA was used to assess the 
relationship between serum hormones with changes in anthropometric variables. Mixed 
models linear regression was used to assess the relationship between longitudinal changes in 
urinary hormones and changes in anthropometric values. Baseline hormone values and 
baseline anthropometric measurements were covariates. All statistical analyses were 
conducted using Stata 12.1 (StataCorp, Texas, USA). Statistical significance was set at the 
0.05 level. 
6.4 Results 
6.4.1 Cohort characteristics 
One hundred and four participants were recruited. The mean ages (SD) for the study 
participants at baseline were 12.5 (0.93) years for males and 11.8 (0.98) years for females. At 
follow-up, the ages were 13.5 (0.94) years for males and 12.9 (0.97) years for females. For 
the females, 22 (39%) had menarche prior to the study and one additional girl experienced 
menarche during the follow-up year. Post-menarcheal girls were significantly older than their 
pre-menarcheal counterparts (12.9 years vs. 11.9 years, p<0.001). A high proportion of 
scheduled samples were collected for urine (484, 92%) and serum (194, 93%). There was a 
low loss to follow-up (7, 6.7%). 
Mean anthropometric measurements, other than BMI, increased significantly over 12 months 
(Table 6.1) whereas age- and gender-standardized z-scores did not change over the 12 months 
follow-up (Table 6.2). Pre-menarcheal girls significantly increased their age-standardized 
weight (p<0.001) and height z-scores (p = 0.002), whereas these z-scores did not change for 
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post-menarcheal girls. Rate of change in anthropometric measurements were similar between 
genders (interaction p>0.05).  
Self-rated Tanner staging increased with fewer in stage 1 and more in stage 5 at 12-month 
follow-up. During the year, 14 participants (13.5%) progressed two Tanner stages, 43 
(41.3%) progressed one stage and 41 (39.4%) did not change in their self-rated Tanner stage 
(Table 6.3). Six (5.8%) participants (three boys) provided a lower self-rated Tanner stage at 
follow-up than baseline. One participant (1%, 1 boy) did not provide baseline Tanner staging 
and seven (6.7%, 1 boy, 6 girls) did not provide follow-up Tanner staging. 
Table 6.1 Baseline and 12-month follow-up anthropometry measurements. 
 
 
 
 
Table 6.2 Baseline and 12 month follow-up WHO and CDC z-scores (for age). 
 
 
 
 
 
 
 
 Baseline 12 Months ANOVA F-statistic (p-value) 
Mean  
(SD) 
M 
(n=47) 
F  
(n=57) 
M  
(n=47) 
F  
(n=57) 
Gender Time Gender x 
Time 
Height 
(cm) 
156.8 
(9.9) 
150.8 
(8.5) 
163.8 
(10.1) 
157.1 
(7.9) 
25.7 
(<0.001) 
27.6 
(<0.001) 
0.08 
(0.78) 
Weight 
(kg) 
49.3 
(12.0) 
44.1 
(10.9) 
55.2 
(13.2) 
50.1 
(11.4) 
9.7  
(0.002) 
13.2 
(<0.001) 
0.00 
(0.99) 
BMI 
(kg/m
2
) 
19.7  
(3.5) 
20.4 
(3.8) 
19.3  
(3.7) 
20.3  
(4.0) 
0.29  
(0.59) 
2.84 
(0.09) 
0.08 
(0.77) 
 
Mean 
(SD) 
Baseline 12 months 
Two-Way ANOVA  
F-statistic (p-value) 
Gender Time 
Gender x 
Time M F M F 
Height z 
(CDC) 
0.50 
(1.05) 
0.16 
(0.87) 
0.50 
(1.08) 
0.25 
(0.91) 
4.81 
(0.03) 
0.13 
(0.72) 
0.12 
(0.73) 
Weight z 
(CDC) 
0.43 
(1.12) 
0.19 
(0.96) 
0.46 
(1.11) 
0.35 
(0.91) 
1.46 
(0.23) 
0.44 
(0.51) 
0.19 
(0.67) 
BMI z 
(CDC) 
0.28 
(1.03) 
0.18 
(1.00) 
0.27 
(1.04) 
0.27 
(0.98) 
0.12 
(0.73) 
0.09 
(0.76) 
0.12 
(0.72) 
Height z 
(WHO) 
0.56 
(1.11) 
0.14 
(0.92) 
0.58 
(1.12) 
0.30 
(0.93) 
6.18 
(0.02) 
0.40 
(0.53) 
0.25 
(0.62) 
BMI z 
(WHO) 
0.51 
(1.24) 
0.29 
(1.18) 
0.42 
(1.21) 
0.32 
(1.18) 
0.91 
(0.34) 
0.03 
(0.87) 
0.14 
(0.71) 
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Table 6.3 Self-Rated Tanner staging at baseline and 12 month follow-up. 
 
 
 
6.4.2 Hormone measurements 
Serum: Of the 194 serum collections, nine (5%) LH assays and two (1%) T (all in separate 
individuals) were below the LLOQ. No E2 samples were below LLOQ. Those with LH 
samples below the limits of detection were significantly younger than their peers (mean 
difference = 1.47 years 95% CI 0.81-2.14 p<0.001). No difference in age was observed for 
those with serum T or E2 samples below LLOQ. Hormone values all significantly increased 
over the 12-month period and were significantly different between genders, but rate of 
change was not statistically significant between gender (interaction p>0.05) (Table 6.4). 
Table 6.4 Baseline and 12-month follow-up serum LH, E2 and T. 
 
 
 
 
 
 
N Baseline 12 Months 
Tanner M F M F 
1 6 14 0 3 
2 8 17 7 13 
3 9 16 6 15 
4 18 7 18 12 
5 5 3 14 8 
Total 46 57 45 51 
 
 
Baseline 12 months ANOVA F-statistic (p-value) 
Mean (SD) 
 M 
(n=47) 
F  
(n=57) 
M 
(n=47) 
F 
(n=57) 
Gender Time Gender x 
Time  
LH  
(IU/L) 
1.7 
(1.3) 
2.3 
(2.4) 
2.5  
(1.8) 
3.6 
(2.7) 
9.4 
(0.002) 
11.2 
(0.001) 
0.70 
(0.402) 
E2  
(pg/mL) 
19.1 
(8.5) 
43.4  
(29) 
24.9  
(9) 
54.7 
(30) 
73.5 
(<0.001) 
6.4 
(0.012) 
0.74 
(0.390) 
T  
(ng/mL) 
2.4 
(2.3) 
0.16 
(0.10) 
3.4  
(2.55) 
0.2 
(0.12) 
130.1 
(<0.001) 
 5.0 
(0.027) 
3.80  
(0.052) 
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Figure 6.1 shows serum LH, E2 and T at baseline and follow-up, stratified by Tanner stages. 
Data stratified by chronological age were similar. Hormone concentrations increased through 
each Tanner stage and each year of age, although ordinal groupings overlap. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Cross-sectional plots of serum LH (top), E2 (centre) and T (bottom) at 
baseline and 12-month follow-up, by self-rated Tanner stage. 
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Urine: For the 484 urine collections, five (1%) LH assays, 14 (3%) E2 and nine (2%) T assays 
were below the LLOQ. For LH, these participants were younger than the rest of the cohort 
(mean difference 1.35 years; 95% CI 0.41-2.30; p=0.005), but there was no age difference 
between those with urine E2 or T samples below or above the LLOQ. In five such cases (one 
urine and serum LH, one urine E2, one urine E2 and T, one urine T, one serum LH) the 
participant provided a Tanner stage 1 at baseline. 
Figure 6.2 shows within-person changes from baseline over the 12-month collection period 
and Table 6.5 shows the mean three monthly values for urinary LH, E2 and T over 12 months. 
There is a significant increase from baseline to follow-up in E2, T and LH. The same pattern 
is seen in females when stratified by menarcheal status (Table 6.6). Urine hormone levels 
were not strictly progressive and in some instances decreased over time, though there was an 
overall increase in mean levels for all three hormones for males and females overall. For 
serum hormones, a decline from baseline to follow-up was observed in 26 adolescents (18 
female) for LH, 22 adolescents (11 female) for E2 and 19 (13 female) for T. Overall declines 
in urinary LH were observed in 48 adolescents (30 female), 23 (9 female) for urinary E2, and 
24 (14 female) for urinary T. 
Urinary LH, E2 and T all positively correlated with Tanner staging at baseline and 12-month 
follow-up (p<0.001 for all). Urinary LH, E and T all increased across Tanner stages. 
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Figure 6.2 Plots of mean and SEM of individual changes from baseline (0) in urine LH, 
E2 and T concentrations in female (left panels) and male (right panels) at 3, 6, 9 and 12 
months. 
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Table 6.5 Mean urine LH, E2 and T. 
Mean 
(SD) 
Baseline 3 Months 6 Months 9 Months 
12 Months 
(Follow-Up) 
Two Way ANOVA 
F-statistic (p-value) 
 M F M F M F M F M F Gender Time 
Gender x 
Time 
LH  
(IU/L) 
8.7 
(7.4) 
9.6 
(10.0) 
8.4 
(5.9) 
10.2 
(10.1) 
9.6 
(7.4) 
11.5 
(11.4) 
9.8 
(6.1) 
13.3 
(16.6) 
10.1 
(7.9) 
10.1 
(9.9) 
3.2 
(0.074) 
0.9 
(0.438) 
0.4 (0.802) 
E2 
(ng/mL) 
0.7 
(0.9) 
1.8 
(2.0) 
0.7 
(0.9) 
2.1 
(2.8) 
1.1 
(1.6) 
2.5 
(3.1) 
0.9 
(1.1) 
3.5 
(4.8) 
1.0 
(1.0) 
2.7 
(2.8) 
52.4 
(<0.001) 
2.3 
(0.059) 
1.3 (0.255) 
T (ng/mL) 
23.3 
(35) 
3.9 
(3.8) 
19.9 
(26.1) 
5.0 
(6.2) 
35.1 
(80) 
5.0 
(4.1) 
26.4 
(34) 
6.0 
(4.1) 
26.2 
(28) 
5.4 
(5.1) 
57.9 
(<0.001) 
0.9 
(0.4870) 
0.8 (0.548) 
 
          Table 6.6 Mean urine hormone measurements for girls by menarcheal status. 
Mean 
(SD) 
Baseline 3 Months 6 Months 9 Months 
12 Months 
(Follow-Up) 
Two-way ANOVA F-statistic (p-
value) 
Menarcheal 
Status 
Time  
Menarcheal 
Status x 
Time 
Pre Post Pre Post Pre Post Pre Post Pre Post 
LH 
(IU/L) 
6.5 
(7.48) 
14.6 
(11.53) 
6.8 
(7.55) 
16.1 
(11.25) 
7.6 
(7.21) 
17.4 
(14.10) 
9.0 
(8.48) 
19.2 
(22.69) 
9.5 
(8.90)  
11.0 
(11.34) 
30.34 
(<0.001) 
1.05 
(0.384) 
1.34 
(0.255) 
E2 
(pg/mL) 
0.7 
(0.67) 
3.4 
(2.19) 
0.9 
(0.84) 
4.1 
(3.70) 
1.1 
(0.80) 
4.7 
(4.03) 
1.5 
(1.39) 
6.4 
(6.32) 
1.7 
(1.90) 
4.3 
(3.16) 
95.54 
(<0.001) 
3.20 
(0.014) 
1.50 
(0.201) 
T 
(ng/mL) 
2.4 
(2.00) 
6.3 
(4.70) 
2.7 
(2.03) 
8.9 
(8.70) 
3.2 
(2.72) 
7.7 
(4.48) 
4.5 
(2.99) 
8.0 
(4.53) 
4.3 
(3.16) 
6.9 
(4.38) 
57.21 
(<0.001) 
1.41 
(0.232) 
1.33 
(0.258) 
 
                                                                                                                                                                   Chapter 6 
 
   160 
 
6.4.3 Association between Serum and Urine Hormone Measurements and 
Anthropometry 
 
Change in serum LH was significantly positively associated with change in height and weight 
for females, but with neither in males (Table 6.7). Serum T was significantly positively 
associated with height changes in both sexes. Change in height was positively associated with 
urinary E2 and T in females and urinary E2 in males. No other significant associations were 
observed between urinary hormones and anthropometry over 12 months (Table 6.7). 
Table 6.7 Regression results for serum (left) and urine (right) hormones and 
anthropometric markers of puberty. 
 
 
 
 
 
 
 
 
 
 
 
Serum β 95% CI F-statistic p-value  Urine β 95% CI p-value 
Change in Height 
Female 
LH 0.53 0.21, 0.84 11.50 0.001  LH 0.01 -0.47, 0.48 0.979 
E2 -0.001 -0.04, 0.03 0.01 0.943  E2 -0.25 -0.38, -0.12 <0.001 
T 10.19 0.77, 19.61 4.73 0.035  T -0.25 -0.44, -0.06 0.011 
Male 
LH -0.16 -0.92, 0.61 0.17 0.681  LH 0.31 -0.11, 0.72 0.149 
E2 0.09 -0.02, 0.21 2.61 0.115  E2 -0.10 -0.16, -0.03 0.004 
T 0.89 0.48, 1.31 19.26 <0.001  T -1.05 -3.74, 1.64 0.446 
Change in Weight 
Female 
LH 0.45 0.10, 0.81 6.67 0.013  LH -0.13 -0.55, 0.28 0.535 
E2 -0.01 -0.05, 0.03 0.20 0.656  E2 -0.02 -0.14, 0.09 0.695 
T 11.81 1.15, 22.48 4.96 0.031  T -0.14 -0.30, 0.03 0.110 
Male 
LH -0.10 -1.74, 1.54 0.02 0.900  LH 0.07 -0.13, 0.27 0.492 
E2 0.07 -0.18, 0.31 0.31 0.583  E2 0.01 -0.02, 0.04 0.505 
T 0.21 -0.86, 1.28 0.16 0.688  T 0.81 -0.48, 2.10 0.218 
Change in BMI 
Female 
LH 0.03 -0.10, 0.16 0.24 0.625  LH -0.79 -2.03, 0.45 0.214 
E2 0.001 -0.01, 0.01 0.01 0.921  E2 0.03 -0.31, 0.37 0.858 
T 2.18 -1.73, 6.09 1.25 0.269  T -0.47 -0.97, 0.02 0.062 
Male 
LH -0.10 -0.46, 0.26 0.31 0.580  LH -0.03 -0.89, 0.82 0.940 
E2 -0.02 -0.07, 0.03 0.69 0.412  E2 -0.02 -0.16, 0.11 0.737 
T -0.01 -0.24, 0.23 0.00 0.963  T 1.33 -4.19, 6.86 0.636 
Change in Self-Rated Tanner Stage 
Female 
LH 0.07 -0.04, 0.17 1.51 0.225  LH 0.46 -1.19, 2.11 0.583 
E2 0.002 -0.01, 0.01 0.12 0.730  E2 -0.24 -0.70, 0.22 0.310 
T 1.59 -1.25, 4.44 1.28 0.265  T 0.11 -0.56, 0.78 0.757 
Male 
LH -0.08 -0.33, 0.17 0.44 0.510  LH -0.10 -1.23, 1.03 0.863 
E2 0.03 -0.003, 0.07 3.38 0.075  E2 -0.15 -0.33, 0.03 0.100 
T 0.16 0.02, 0.29 5.40 0.026  T -0.27 -7.64, 7.09 0.942 
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6.5 Discussion 
The two major findings of this study are the validation of a MS assay for pubertal urine 
steroids in a young adolescent population and the demonstration that it is feasible to collect 
urine samples from a community-based adolescent cohort at three-monthly intervals, with 
high compliance (93% serum and 92% urine collections completed) and low follow-up 
attrition rate.  
In order to demonstrate the specific effects of puberty hormones on any biological aspect of 
adolescent development and health, a methodology that allows more frequent biological 
sampling than has been previously reported for epidemiological studies is essential. Urine 
samples have the advantage over blood samples that these are more acceptable both ethically 
and practically by adolescents, and each overnight sample provides a more time-integrated 
hormone measure. This is particularly true in early puberty when pubertal hormones 
commence pulsatile secretion nocturnally (Dorn et al. 2006), so that a morning overnight 
urine sample may be more informative than a serum sample at any single time point. Urine 
collections also allow for more frequent collection than repeated venepuncture would be 
tolerated (Aksglaede et al. 2009). Salivary samples are potentially easier to collect, but blood 
contamination and influence of flow-rate on measurements seriously limits validity and 
accuracy.  
Anthropometric and serum hormone changes in our study revealed the anticipated increases 
over the course of one year in a cohort of young adolescents. The urine data also revealed 
anticipated hormone increases over the 12-months of observation. However, mean and 
individual urinary hormone changes were not strictly progressive; suggesting within-subject 
variability in early and mid-pubertal hormone levels may contain hitherto unexploited 
information on determinants of biological aspects of pubertal progression. This finding also 
                                                                                                                                                                   Chapter 6 
 
   162 
 
suggests that three monthly urine collections over an extended period have the capacity to 
provide new insights into the biology of puberty.  
The cross-sectional associations between chronological age and self-reported Tanner stage 
and both serum and urinary hormones reveal considerable overlap between hormone levels at 
each age or stage, and emphasise the need to have better descriptors of puberty hormone 
change. Both Tanner stage and anthropometric change lag behind hormonal change. Using 
the former as surrogates for puberty hormone change will less accurately describe the 
relationship between hormone changes and the resultant physical changes, as well as any 
other adolescent health or developmental change of interest, such as mood or behaviour. 
Previous work has questioned the validity of self-rated Tanner staging (Bonat et al. 2002, 
Desmangles et al. 2006, Dorn et al. 2006, Hergenroeder et al. 1999, Morris and Udry 1980); 
however, our data support the validity of self-rated Tanner staging as a high proportion of 
adolescents completed the scales with findings of consistent or advanced Tanner stage at 12 
months follow-up in all but 6% of adolescents and with the self-rated Tanner staging 
corresponding well with conventional anthropometric measures of puberty.  
In conclusion, our work has used a robust methodology of urine sex steroid hormone 
measurement, using LC tandem mass spectrometry measurements for urine sex steroids 
(Handelsman and Wartofsky 2013), which display the high sensitivity and specificity to 
detect the lower levels of sex hormones, a particular challenge to the study of pubertal 
progression (Courant et al. 2010, Rosner et al. 2013). Based on previously recorded 
longitudinal growth data (Marceau et al. 2011, Steinbeck et al. 2012), it is anticipated that 
frequently measured urine samples over the two to three year window of puberty will not 
only provide a firmer biological basis for clinically observed patterns of puberty, such as 
early or late onset and rapid or slow tempo, but also allow determination of the true 
biological effects of puberty hormones on adolescent health and development.
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Chapter 7  Conclusions 
In this thesis, we successfully developed suitable sample preparation techniques and LC-
MS/MS assays to measure steroids in various biological samples. The methods were further 
applied for clinical research studies including remote sampling and field studies. We also 
demonstrated that previously validated LH immunoassays for human blood samples are also 
suitable with qualifications for urine samples. This thesis consists of four research chapters as 
summarized in the sections below. 
7.1 Blood spot sampling after sc steroid injection 
This study was to assess the feasibility and pharmacology of sc injection of androgen ester in 
healthy men using DBS for frequent sampling. A sensitive and specific LC-MS/MS assay 
was developed and validated to measure steroids from DBS samples. To avoid common 
problems of using DBS samples such as non-homogenous distribution of blood on the filter 
card and hematocrit effect, we developed a novel sampling method which used the whole 
blood spotted onto the filter card instead of using a subsample (e.g. by a punch). The DBS 
technology provided intensive and simplified blood collection by the study participants at 
home without the need of clinic visit. This study provided a detailed pharmacological 
analysis of sc injection of ND in oil vehicle. We found a sustained release of this androgen 
ester which suggests that sc injections of T esters may prove to be safe and tolerable. This 
would make self-injection of long-acting depot form of T delivery more feasible with the 
potential benefits of reducing medical care costs demand on medical personnel time. 
Additionally this delivery method may also reduce injection site pain or bruising as well as 
allowing freer use among those with bleeding disorders or on anticoagulants. Further studies 
using T esters in men with differing body weight and after repeated injections are required to 
evaluate duration of action and usefulness in clinical practice of sc relative to im injections. 
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7.2 Urinary LH immunoassays in stored samples 
This study was to assess whether commercially available LH immunoassays (ICL and IF) 
previously validated for human blood samples is suitable for urine samples kept at prolonged 
frozen storage (4 years) without addition of any preservative. Urinary LH may be dissociated 
into its subunits due to high urinary concentrations of urea that may cause loss in 
immunoreactivity after prolonged frozen storage. Using samples from a clinical study 
completed in 2008 and aliquots of the same samples stored frozen at -20 °C without added 
preservatives, this study describes the deviations in performance of ICL and IF 
immunoassays and their ultimate applicability for reliability clinical research and for anti-
doping purposes. The study demonstrated that the two LH immunoassays optimized for blood 
samples can also be used for urinary LH measurement but the performance of both the assay 
differed markedly. The ICL immunoassay showed quantitatively reproducible LH 
measurement even after prolonged storage at -20 °C for 4 years without addition of 
preservatives. By contrast, the IF immunoassay demonstrated consistently but proportionately 
lower LH measurements relative to the ICL assay both initially (2008) and then exhibited a 
further decrease after 4 years of frozen storage (2012). Yet, both the assays displayed similar 
patterns of the time-course of urine LH measurement both before and after 4 years of frozen 
storage. In conclusion, we found that both immunoassays are suitable for urinary LH 
measurements with ICL assay being more robust for quantitative urinary LH measurement 
such as for anti-doping purpose whereas the IF could be applicable for research studies where 
urine LH levels are compared within-study but not in absolute terms. 
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7.3 SG and creatinine adjustments for urinary hormones 
The study aimed to determine whether first morning void hormonal assessments carried out 
in growing young adolescents require adjustments to correct for variation due to hydration, 
and if so, to determine the best adjustment method based either on urinary creatinine or SG. 
While previous studies have examined broadly the issue of how to adjust urinary hormonal 
measurements none have focused on the specific situation where creatinine is changing 
systematically due to growth, hence this study contains novel information on whether urinary 
hormonal concentration adjustments are required in the setting of repeated serial sampling of 
a large adolescent population at various stages of pubertal progression. The present study 
demonstrated that unadjusted urinary steroids and LH concentration corresponded well with 
the concentration adjusted either with creatinine or SG when using first morning void urine 
samples, reflecting an overnight fast, even in growing adolescents. Based on these findings 
we suggest the possibility that the first morning void urine samples are not heavily influenced 
by the hydration status of study participants and may not require adjustments compared with 
randomly collected spot or timed urine collection methods. However, if the dilution 
adjustment is desired for the urine specimen, both the creatinine and SG appear equally 
suitable using first morning void urine samples. We also show that reagent strip SG 
measurements are simpler alternative to a refractometer and sufficiently reliable, economical 
and time-saving for large numbers of urine sampling in long-term field studies. 
7.4 Urinary puberty hormones 
The aim of this study was to develop and validate LC-MS/MS assay to measure urinary T and 
E2 in adolescents and subsequently to relate the changes in the urinary sex hormones over 12 
months to the standard anthropometric markers of puberty (height, weight, BMI, self-rate 
Tanner stage). Longitudinal relationships of within-individual hormone and anthropometric 
changes during puberty have not been fully described previous. Urine provides a more time-
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integrated hormone measure compared to blood samples and is particularly important as 
pulsatile secretion during early progression of puberty occurs nocturnally. The study 
demonstrated feasibility of urine samples collection from a community based-adolescent 
cohort at three-monthly intervals with high compliance and low follow-up attrition rate. Both 
urine and serum hormone data showed anticipated increase over 12 months. This study 
successfully developed a robust LC-MS/MS method to measure urinary steroids that display 
high sensitivity and specificity. The study preliminary findings demonstrate the feasibility of 
intensive collection of urine samples together with validated urine assays for sex steroids and 
LH. These will allow a more accurate and sensitive, individual assessment of puberty timing 
and tempo. Currently, three monthly urine and a yearly blood collection for the ARCHER 
longitudinal study over three years is being carried out to better understand the role of 
puberty hormones on adolescent events. This longitudinal study aims to determine how 
temporal changes in T and E2 independently affect physical status, social and emotional well-
being, education, sleep, risk behaviours, and mental health in adolescents. 
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sample collection and editing the manuscript. Reena Desai was involved in the assay 
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and was involve in the editing of the manuscript. David J Handelsman was responsible for 
study design, assay development, statistical analyses, writing and editing the manuscript. 
Chapter 4: 
Gurmeet KS Singh was responsible for the statistical analyses and involved in writing the 
first draft and editing the manuscript. Mark Jimenez conducted the LH assays and was 
involved in the editing of the manuscript. Ron Newman was involved in the editing of the 
manuscript. David J Handelsman was responsible for study design, statistical analyses, 
writing and editing the manuscript. 
Chapter 5: 
Gurmeet KS Singh was responsible for assay development and conducting the assays, as well 
as statistical analyses, writing the first draft and editing the manuscript. Ben WR Belzer, 
Reena Desai and Mark Jimenez were involved in the writing and editing of the manuscript. 
Reena Desai was also involved in the assay development. Katharine S Steinbeck was 
involved in study design, study oversight, writing, and editing this manuscript. David J 
                                                                                                                                                                 References 
 
   208 
 
Handelsman was responsible for study design, assay development, statistical analyses, 
writing and editing the manuscript. 
Chapter 6: 
Gurmeet KS Singh and Ben WR Balzer share equal authorship of this paper. Gurmeet KS 
Singh was responsible for assay development and conducting the assays, as well as 
authorship and editing the manuscript. Ben WR Balzer performed statistical analyses, wrote 
the first draft and contributed to the editing of the manuscript. Patrick J Kelly performed 
statistical analyses and contributed to editing the manuscript. Karen Paxton was involved in 
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